

ESULT 8
S-10-124-557-52
Sequence 52, Application US/10124557
Patent No. US20020137894A1
GENERAL INFORMATION:
APPLICANT: Turner, Katherine
Clark, Stephen C.
Jacobs, Kenneth
Hewick, Rodney M.
Gesner, Thomas G.
TITLE OF INVENTION: Megakaryocyte Stimulating Factors
NUMBER OF SEQUENCES: 143
CORRESPONDENCE ADDRESS
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 CambridgePark Drive
CITY: Cambridge
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA
; APPLICATION NUMBER: US/10/124,557
; FILING DATE: 16-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/643,502
; FILING DATE: 18-JAN-1991
; APPLICATION NUMBER: US 07/546,114
; FILING DATE: 29-JUN-1990
; APPLICATION NUMBER: US 07/457,196
; FILING DATE: 29-DEC-1989
; APPLICATION NUMBER: US 07/390,901
; FILING DATE: 08-AUG-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Cserr, Luann
; REGISTRATION NUMBER: 31,922
; REFERENCE/DOCKET NUMBER: GI 5190
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)876-1170
; TELEFAX: (617)876-5851
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1363 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 52:
US-10-124-557-52

Query Match 3.8%; Score 267.5; DB 12; Length 1363;
Best Local Similarity 21.6%; Pred. No. 1.2e-06;
Matches 183; Conservative 79; Mismatches 356; Indels 231; Gaps 37;





RESULT 9
US-10-124-557-2
; Sequence 2, Application US/10124557
; Patent No. US20020137894A1
; GENERAL INFORMATION:
; APPLICANT: Turner, Katherine
; Clark, Stephen C.
; Jacobs, Kenneth
; Hewick, Rodney M.
; Gesner, Thomas G.
; TITLE OF INVENTION: Megakaryocyte Stimulating Factors
; NUMBER OF SEQUENCES: 143
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/124,557
; FILING DATE: 16-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/643,502
; FILING DATE: 18-JAN-1991
; APPLICATION NUMBER: US 07/546,114
; FILING DATE: 29-JUN-1990
; APPLICATION NUMBER: US 07/457,196
; FILING DATE: 28-DEC-1989
; APPLICATION NUMBER: US 07/390,901
; FILING DATE: 08-AUG-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Cserr, Luann
; REGISTRATION NUMBER: 31,822
; REFERENCE/DOCKET NUMBER: GI 5130
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)876-1170
; TELEFAX: (617)876-5851
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1404 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-124-557-2



RESULT 10
US-10-124-557-62
; Sequence 62, Application US/10124557
; Patent No. US20020137894A1
; GENERAL INFORMATION:
; APPLICANT: Turner, Katherine
; Clark, Stephen C.
; Jacobs, Kenneth

Hewick, Rodney M
Gesner, Thomas G.
TITLE OF INVENTION: Megakaryocyte Stimulating Factors
NUMBER OF SEQUENCES: 143
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 CambridgePark Drive
CITY: Cambridge
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/124,557
FILING DATE: 16-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/644,602
FILING DATE: 18-JAN-1991
APPLICATION NUMBER: US 07/546,114
FILING DATE: 29-JUN-1990
APPLICATION NUMBER: US 07/457,196
FILING DATE: 29-DEC-1989
APPLICATION NUMBER: US 07/390,901
FILING DATE: 08-AUG-1989
ATTORNEY/AGENT INFORMATION:
NAME: Cserr, Luann
REGISTRATION NUMBER: 31,922
REFERENCE/DOCKET NUMBER: GI 5190
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)876-1170
TELEFAX: (617)876-5851
INFORMATION FOR SEQ ID NO: 62:
SEQUENCE CHARACTERISTICS:
LENGTH: 1404 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 62:
-10-124-557-62





RESULT 11
US-09-735-367B-3
; Sequence 3, Application US/09735367B
; Patent No. US20020151477A1
; GENERAL INFORMATION:
; APPLICANT: Gustafsson, Jan-Ake
; APPLICANT: Caira, Francoise
; APPLICANT: Antonsson, Per
; TITLE OF INVENTION: NUCLEAR RECEPTOR COACTIVATOR
; FILE REFERENCE: 102093-100
; CURRENT APPLICATION NUMBER: US/09/735,367B
; CURRENT FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: US 60/174,544
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 2005
; TYPE: PRT
; ORGANISM: mammal
US-09-735-367B-3

Query Match 3.8%; Score 267; DB 10; Length 2005;
Best Local Similarity 19.1%; Pred No. 1.9e-06;
Matches 247; Conservative 122; Mismatches 430; Indels 492; Gaps 58;







```
SULT 13
-10-124-557-58
Sequence 58, Application US/10124557
Patent No. US20020137894A1
  GENERAL INFORMATION
       APPLICANT: Turner, Katherine
                  Clark, Stephen C
                  Jacobs, Kenneth
                  Hewick, Rodney M
                  Gesner, Thomas G.
       TITLE OF INVENTION: Megakaryocyte Stimulating Factors
       NUMBER OF SEQUENCES: 143
       CORRESPONDENCE ADDRESS
            ADDRESSEE: Genetics Institute, Inc
            STREET: 87 CambridgePark Drive
            CITY: Cambridge
            STATE: Massachusetts
            COUNTRY: U.S.A.
            ZIP: 02140
       COMPUTER READABLE FORM:
            MEDIUM TYPE: Floppy disk
            COMPUTER: IBM PC Compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: PatentIn Release #1.0, Version #1.25
       CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/10/124,557
;              FILING DATE: 16-Apr-2002
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: US 07/643,502
;              FILING DATE: 18-JAN-1991
;              APPLICATION NUMBER: US 07/546,114
;              FILING DATE: 29-JUN-1990
;              APPLICATION NUMBER: US 07/457,196
;              FILING DATE: 29-DEC-1989
;              APPLICATION NUMBER: US 07/390,901
;              FILING DATE: 08-AUG-1989
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Cserr, Luann
;              REGISTRATION NUMBER: 31,822
;              REFERENCE/DOCKET NUMBER: GI 5190
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: (617)876-1170
;              TELEFAX: (617)876-5851
;    INFORMATION FOR SEQ ID NO: 58:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 1049 amino acids
;              TYPE: amino acid
;              TOPOLOGY: linear
;         MOLECULE TYPE: protein
;         SEQUENCE DESCRIPTION: SEQ ID NO: 58:
US-10-124-557-58

  Query Match             3.8%;  Score 264.5;  DB 12;  Length 1049;
  Best Local Similarity   21.8%;  Pred. No. 1.2e-06;
  Matches  172;  Conservative   68;  Mismatches  326;  Indels  223;  Gaps   34;

Qy      340 EGSLQSWQFQTMGTFLVQQAQFPPHLPDELESQLVAQIWRNFIELIHQRGWALMVILLSS 399
Db       74 ESSSSSSSSSSSSTIWKIKSSPNSAANPELQKFLKVK     DKKDE----------TK 118

Qy      400 FAPTPALEKPLLKFVSDQAPSGM----------AALCQH-KLLGALEQTPLAPMASR-S 446
Db      119 KKPTP---KPP---VVPEAGSGLDNGDFKVTTPDTSTTQHNKVSTSPKITTAKPINPPPS 172

Qy      447 HPPTQLEWKAGLRRGRMALDVFTFNEESYSAEVESWTTGEQFAGWILQGRGLEAPPKGWS 506
Db      173 LPPNSDTSKP---------TSLTVMKETTVETKETTTTNKQ-  - TSTPGKEKTTSAKE 218

Qy      507 VSLHSGDAWRDLPGCDFVL-------DLIGQTEDLGDPAGPHNYPIFPLGLAESIPPAPG 559
Db      219 TQSIFKTSAKDLAPTSKVLAKPTPKAETTTKGPALTTPKEP  TPTTPKEPASTTPKEPT 276

Qy      560 VQAPSLPPGLPPGPAPILASSPPPGPASKPENLDGFVDHLPEPALAPGPSDLEQGWALSR 619
Db      277 PTTIKSAPTTPKEPAPTTTKSAP----TTPK----------EPA-------------  306

Qy      620 PMPGGSVGPTQGYPMVYPGMVQAPSYQPAMIPAP---- MPVMPAMGA  VPTMPAMM 675
Db      307 --      PTTTKEPA- PTTPKEPAPTTTKEPAPTTTKSAPTTPKEPAPTTTPKTAPT 355

Qy      676 VPPQPQPLMPSLDSPGTAMGQGNPINQGAMTLAGGVTTQAMSLSFPLQPGPHLQPGAQTG- 732
Db      356 TPKEPAPTTPK-------------------------------EPTPTTPKEPAPT-- 379

Qy      733 ATSQPPPST----- TAPPAPPPAPQP-PPESNLEPSDVGLPEDTPEEAESKPQPPKGP 785
Db      380 TKEPAPTTPKEPAPTAPKKPAPTTPKEPAPTTPKEPAPTITKEPSP----TTPKEPAPT 434

Qy      786 QQKPDYPQKMGQDPPVKTVKPPAKVQIPQEEMEETEEEEDETAELSPPPPPPVVKKPL 845
Db      435 TTK  ----SAPTTTKEPAPTTTKSAPTTPKEPSPTTTKEPAPTTPKEPAPTTPKKPA 486

Qy      846 ----KASRPKAVKEDEAEPAQREVPIQGEDP-PVHSSNSAPQHP---------------- 884
Db      487 PTTPKEPAPTTPKEPAPTTTKKPAPTAPKEPAPTTPKETAPTTPKKLTPTTPEKLAPTTP 546

Qy      885 -KPSPVPPVQSSNSAPPPQPSPKPIPNIISMYQSPPSP    VAVPVQLPPIPTPLPP  938
```



RESULT 14
US 10/124,557-142
; Sequence 142, Application US/10124557
; Patent No. US20020137894A1
; GENERAL INFORMATION:
; APPLICANT: Turner, Katherine
; Clark, Stephen C.
; Jacobs, Kenneth
; Hewick, Rodney M.
; Gesner, Thomas G.
; TITLE OF INVENTION: Megakaryocyte Stimulating Factors
; NUMBER OF SEQUENCES: 143
; CORRESPONDENCE ADDRESS.
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/124,557
; FILING DATE: 16-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/643,502
; FILING DATE: 18-JAN-1991
; APPLICATION NUMBER: US 07/540,114
; FILING DATE: 20-JUN-1990
; APPLICATION NUMBER: US 07/457,196
; FILING DATE: 29-DEC-1989
; APPLICATION NUMBER: US 07/390,901
; FILING DATE: 08-AUG-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Cserr, Luann
; REGISTRATION NUMBER: 31,822
; REFERENCE/DOCKET NUMBER: GI 5190
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)876-1170
; TELEFAX: (617)876-5851
; INFORMATION FOR SEQ ID NO: 142:
; SEQUENCE CHARACTERISTICS
; LENGTH: 1313 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 142.
US 10/124,557-142

Query Match 3.8%; Score 264.5; DB 12; Length 1313;
Best Local Similarity 21.8%; Pred. No. 1.6e-06;
Matches 172; Conservative 68; Mismatches 320; Indels 223; Gaps 34;



RESULT 15
US-10-124 557-50
; Sequence 50, Application US/10124557
; Patent No. US20020137894A1
; GENERAL INFORMATION:
; APPLICANT: Turner, Katherine
; Clark, Stephen C.
; Jacobs, Kenneth
; Hewick, Rodney M.
; Gesner, Thomas G.
; TITLE OF INVENTION: Megakaryocyte Stimulating Factors
; NUMBER OF SEQUENCES: 143
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge

```
          STATE: Massachusetts
          COUNTRY: U.S.A.
          ZIP: 02142
       COMPUTER READABLE FORM:
          MEDIUM TYPE: Floppy disk
          COMPUTER: IBM PC compatible
          OPERATING SYSTEM: PC-DOS/MS-DOS
          SOFTWARE: PatentIn Release #1.0, Version #1.25
       CURRENT APPLICATION DATA
          APPLICATION NUMBER: US/10/124,557
          FILING DATE: 16-Apr-2002
          CLASSIFICATION: <Unknown>
       PRIOR APPLICATION DATA
          APPLICATION NUMBER: US 07/643,502
          FILING DATE: 18-JAN-1991
          APPLICATION NUMBER: US 07/546,114
          FILING DATE: 29-JUN-1990
          APPLICATION NUMBER: US 07/457,196
          FILING DATE: 28-DEC-1989
          APPLICATION NUMBER: US 07/390,901
          FILING DATE: 08-AUG-1989
       ATTORNEY/AGENT INFORMATION:
          NAME: Cserr, Luann
          REGISTRATION NUMBER: 31,822
          REFERENCE/DOCKET NUMBER: GI 5190
       TELECOMMUNICATION INFORMATION
          TELEPHONE: (617)876-1170
          TELEFAX: (617)876-5851
    INFORMATION FOR SEQ ID NO: 50:
       SEQUENCE CHARACTERISTICS:
          LENGTH: 1314 amino acids
          TYPE: amino acid
          TOPOLOGY: linear
       MOLECULE TYPE: protein
       SEQUENCE DESCRIPTION: SEQ ID NO: 50:
S-10-124-557-50

 Query Match             3.8%,  Score 264.5,  DB 12,  Length 1314,
 Best Local Similarity   21.8%,  Pred. No. 1.6e-06,
 Matches  170;  Conservative   68;  Mismatches  326;  Indels  223;  Gaps   34;

Qy    340 EGSLQSWQEQTMGTFLVQQAQRRPGLRDELFSQLVAQLWRNPDEQQNQRGWALMVILLSS 399
Db     75 EGSSQSSSQSSQTTIWKTKGSKNSAANRELQKKLKVK- ---DNKKNR----------TK 119

Qy    400 EAPTPALEKFLIKFVSDQAPSGM----------AALCQH-KLLGALEQTPLAPMASR-S 446
Db    120 KKPTP---KPP---VVDEAGSGLDNGDFKVTTPDTSTTQHNKVSTSPKITTAKPINPPPS 173

Qy    447 HPPTQLEWKAGLRRGRMALDVFTFNEECYGAEVESWTTGEQFAGWILQSRGLEAPPRGWS 506
Db    174 LPPNSDTGKE   ------TSLTVNKETTVETKETTTTNKQ     TSTDGKEKTTSAKE 219

Qy    507 VSLHSGDAWFDLPGCDFVL-------DLIGQTEDLGDPAGPHNYPITPLGLAESIPPAPG 559
Db    220 EQSIPFTSAPDLAPTSKVLAKPTPKAETTTVGPALTTPKEP- TPTTPKEPASTTPKEPT 277

Qy    560 VQAPSLPMGLPMGPAPILASSKPMGEASKPENLDGFVDHLFEPALAPGFSDLEQGWALSR 619
Db    278 PTTIKSAPTTPKEPAPTTTKSAP----TTPK----------EPA--------------- 307

Qy    620 EMKGGGSVGFTQQGYEMVYPGMVQAPSYQPAMIPAP-----MPVMPAMGA--VPTMPAMM 672
Db    308 ---------PTTTKEPA--PTTPKEPAPTTTKEPAPTTTKSAPTTPKEPAPTTPKKPAPT 356

Qy    673 VPFIPQFIVEDIGAQGLAGLQNFINIQAMILAQMTTQAMSLSLPQQNQPHQHQAQTSG 732
Db    357 TPKEPAPTTPK---------------------------------EPTPTTPKEPAPT-- 380

Qy    733 ATSQPPPST-- ---TAPKAKPPPAPQF-KPPSNLPPSGVGLPEDTPEEAESKPQPPKSF 785
Db    381 -TKEPAPTTPKEPAPTAPKKPAPTTPKEPAPTTPKEPAPTTTKEPSP----TTPKEPAPT 435

Qy    786 QQKPDVPQFMGQDPIPVKTVKPPAKVQIPQEEMEETEEFEDETAELSPPPPPPPVVKKPL 845
Db    436 TTK---------SAPTTTKEPAPTTTKSAPTTPKEPSPTTTKEPAPTTPKEPAPTTPKKPA 487

Qy    846 ----KASRPKAVKEDEAEPAQEEVPTQGEDP-PVHSSNSAPQHP---------------- 884
Db    488 PTTIKEPAPTTPKEPAPTITKKPAPTAPKEPAPTTPKETAPTTPKKLIPTTPEKLAPTTP 547

Qy    885 -KPSRVPPVQSSNSAPPRPQISREIPNIIRMYQSRPGF    VAVTVQETPPDIKTFQPV 938
Db    548 EKPAPTTPEELAPTTPEEPTPTT- - -    PEEPAPTTPKAAAPNTPKEPAPTTPKEP 598

Qy    939 --NDPKDEALAKLGIDGVHLFLSTSPNQGPSSPPAVVIEI--    PAPIPLEPILIQI 990
Db    599 APTTPKEPAPT- - - -TPKETAPTTPKGTAPTTLKEPAPTTPKPAPKELAPTTTPK 650

Qy    991 KQGPLPDLPGPCSPNPPTAPAPPPPPALPPPLSGEPKTP------SVESHALTPPMPDKN 1044
Db    651 PTSITSDKPAPTTPK-GTAPTTPKEPAPTTPKEPAPTTPKGTAPTTDKEPAPTTP--KK 706

Qy   1045 ISTKLLVPS 1053
Db    707 PAPKELAPT 715


Search completed: January 10, 2003, 02:29:03
Job time : 113.409 secs
```

GenCore version 5.1.3

M nucleic - nucleic search, using sw model

un on: January 9, 2003, 03:03:27 ; Search time 15302 Seconds
(without alignments)
11988.650 Million cell updates/sec

itle: US-09-803-126-2
erfect score: 6293
equen... 1 cgatgggatgtcaccttcc ... aaaaaaaaaaaaaaaaaaa 6293

coring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

earched: 2004640 seqs, 14551402878 residues

otal number of hits satisfying chosen parameters: 4009280

inimum DB seq length: 0
aximum DB seq length: 2000000000

ost processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

atabase: GenEmbl *
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_ov:*
22: em_pl:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rod:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	6293	100.0	6293	6	AX253079	AX253079 Sequence
2	4451	69.7	4479	6	AX253080	AX253080 Sequence
3	2384.2	37.9	6004	9	AB058686	AB058686 Homo sapi
4	2246	35.7	4602	9	AF418292	AF418292 Homo sapi
5	2055.4	32.7	7923	9	AF418290	AF418290 Homo sapi
6	1954.4	31.1	7515	9	AF418286	AF418286 Homo sapi
7	1949.6	31.0	4208	9	AF418293	AF418293 Homo sapi
8	1787.6	28.4	4174	6	AX253082	AX253082 Sequence
9	1496.6	23.8	1547	10	BC024506	BC024506 Mus muscu
10	1490	23.7	3780	6	AX253084	AX253084 Sequence
11	1119.4	17.8	5709	9	AF418289	AF418289 Homo sapi
12	1110.6	17.6	2372	9	AK097896	AK097896 Homo sapi
13	936.8	14.9	2347	9	BC027875	BC027875 Homo sapi
14	872.6	13.9	1891	9	AK026339	AK026339 Homo sapi
15	861	13.7	5424	9	AF418288	AF418288 Homo sapi
16	822.6	13.1	1767	9	HSM803107	AL713730 Homo sapi
17	721	11.5	147804	10	AL645647	AL645647 Mouse DNA
c 18	721	11.5	260210	2	AL645852	AL645852 Mus muscu
19	612.2	9.7	1098	9	AK096869	AK096869 Homo sapi
20	577	9.2	4802	9	AF418291	AF418291 Homo sapi
21	544.2	8.6	2099	9	AK025259	AK025259 Homo sapi
c 22	474.6	7.5	180356	2	AC123410	AC123410 Rattus no
23	474.6	7.5	200832	2	AC130970	AC130970 Rattus no
24	371.6	5.9	4462	9	AF418287	AF418287 Homo sapi
25	311.2	4.9	11876	9	AF144094	AF144094 Homo sapi
26	291.4	4.6	11769	10	AF144095	AF144095 Mus muscu
27	286.6	4.6	5351	10	AF053130	AF053130 Mus muscu
28	263.2	4.2	180956	2	AC123410	AC123410 Rattus no
c 29	262.2	4.2	200832	2	AC130970	AC130970 Rattus no
30	195.6	3.1	170056	2	AC087643	AC087643 Homo sapi
31	195.6	3.1	178515	2	AC015551	AC015551 Homo sapi
32	184.2	2.9	217584	2	AC087740	AC087740 Homo sapi
c 33	166.2	2.6	215434	2	AC019214	AC019214 Homo sapi
c 34	111.6	1.8	170056	2	AC087643	AC087643 Homo sapi
c 35	102	1.6	178515	2	AC015551	AC015551 Homo sapi
36	96.2	1.4	191184	2	AC120627	AC120627 Rattus no
37	96.2	1.4	195469	2	AC129460	AC129460 Rattus no
38	84.6	1.3	88406	10	AF144093	AF144093 Mus muscu
39	84.6	1.3	261189	2	AL596296	AL596296 Mus muscu
40	81.6	1.3	125020	9	AF420215	AF420215 Homo sapi
41	76.6	1.2	95255	9	AF051976	AF051976 Homo sapi
c 42	76.6	1.2	144448	9	AC109615	AC109615 Homo sapi
c 43	76.6	1.2	164429	9	AC087164	AC087164 Homo sapi
c 44	76.6	1.2	173749	2	AC026467	AC026467 Homo sapi
45	76.4	1.2	3110	9	HSM803101	AL713794 Homo sapi

ALIGNMENTS

RESULT 1
AX253079
LOCUS AX253079 6293 bp DNA linear PAT 05-OCT-2001
DEFINITION Sequence 2 from Patent WO0168866.
ACCESSION AX253079
VERSION AX253079.1 GI:15986277
KEYWORDS .
SOURCE Mus sp.
ORGANISM Mus sp.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia, Eutheria; Rodentia, Sciurognathi, Muridae, Murinae, Mus.
REFERENCE 1 (bases 1 to 6293)
AUTHORS Brooks,A.R., Deng,G.G. and Rubanyi,G.M.
TITLE Estrogen regulated unconventional myosin-related protein: compositions and methods of use

```
  JOURNAL   Patent: WO 0168866-A 2 20-SEP-2001;
            SCHERING AKTIENGESELLSCHAFT (DE)
FEATURES             Location/Qualifiers
     source          1..6293
                     /organism="Mus sp."
                     /db_xref="taxon:10095"
                     /note="Mouse myosin related protein (MRP) variant 1 cDNA"
BASE COUNT     1413 a   1917 c   1733 g   1210 t
ORIGIN

  Query Match             100.0%;  Score 6293;  DB 6;  Length 6293;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 6293;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 CCTTGGCACTTGTCACCTACCAGGTGCAGAAGTTCATAAACAGAAACAGGGGCCACCTGGA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 CCTTGGCACTTGTCACCTACCAGGTGCAGAAGTTCATAAACAGAAACAGGGGCCACCTGGA 60

Qy      61 CCCTGGCTGGAGATGCTCAGGCAGAGCCAGCTGCAGGTGACCTAGCCTTCCTTTCA 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CCCTGGCTGTGCTGGAGATGCTCAGGCAGAGCCAGCTGCAGGTGACCTAGCCTTCCTTTCA 120

Qy     121 GCTCATAGGGCAGCCTGTTCCAAGAAGCAGAGCCCCAGGCTGGGACTGACAAAAACAAACCC 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 GCTCATAGGGCAGCCTGTTCCAAGAAGCAGAGCCCCAGGCTGGGACTGACAAAAACAAACCC 180

Qy     181 CAGATTGGCCCTCCAATTCCAGCAGACCCTGGGTGACTTGCTAGCTCGGCTAGGCAGCAG 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 CAGATTGGCCCTCCAATTCCAGCAGACCCTGGGTGACTTGCTAGCTCGGCTAGGCAGCAG 240

Qy     241 GGGCCATGTCTACGTCATCCAGTGTCTCAATCCCACCCCTGGAAAGATCCCAGGCCTCTT 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 GGGCCATGTCTACGTCATCCAGTGTCTCAATCCCACCCCTGGAAAGATCCCAGGCCTCTT 300

Qy     301 GGAGCTGAGGGCAGCAGCTGGCAGAGCAGCTGCGTCAGGCTGGCATCCTGGAGATCATAGGCAC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 GGAGCTGAGGGCAGCAGCTGGCAGAGCAGCTGCGTCAGGCTGGCATCCTGGAGATCATAGGCAC 360

Qy     361 CCGGACTACCCACTTCCCCGTGCGAGTGTCCTTCCAAGTCTTTCTGGCAAGGTTCCATGC 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 CCGGACTACCCACTTCCCCGTGCGAGTGTCCTTCCAAGTCTTTCTGGCAAGGTTCCATGC 420

Qy     421 GCTGGGGTCAGGGAGACAGAAAGCTGCCTCTGACCAGGAGAGGTGTGGTGCCATCCTCAG 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 GCTGGGGTCAGGGAGACAGAAAGCTGCCTCTGACCAGGAGAGGTGTGGTGCCATCCTCAG 480

Qy     481 TGAAGTGCCTGGGGGCAGAGTCACCGCTGTATCACATCTTGGAGTCACCCAGGTCCTGCTGCA 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 TGAAGTGCCTGGGGGCAGAGTCACCGCTGTATCACATCTTGGAGTCACCCAGGTCCTGCTGCA 540

Qy     541 GGAAAAGGGCTGGCAGCAGCTAGAACAGCTGTGGGCTCAGCGGGCTCACAGGCCTGCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 GGAAAAGGGCTGGCAGCAGCTAGAACAGCTGTGGGCTCAGCGGGCTCACAGGCCTGCT 600

Qy     601 CACTCTGCACCCTGGGCCTCCGAGCCCGTATCACCCGGCAGGGCCTCCGTCCTCCTGCCCCG 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 CACTCTGCACCCTGGGCCTCCGAGCCCGTATCACCCGGCAGGGCCTCCGTCCTCCTGCCCCG 660

Qy     661 GATGTACAGCTCCTGTGCGTGGGCTCCAGGCCAGGAAGCGATATCTCCAGCGGAGGTCAGC 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 GATGTACAGCTCCTGTGCGTGGGCTCCAGGCCAGGAAGCGATATCTCCAGCGGAGGTCAGC 720

Qy     721 TCTTGGACAGGTGAACACCATTCTCCTAGTGGCCCGGCCCCTGCTCCGGAGACGACAGAA 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 TCTTGGACAGGTGAACACCATTCTCCTAGTGGCCCGGCCCCTGCTCCGGAGACGACAGAA 780

Qy     781 GCTACGGTGTGCCCCTGGCCCGCACAGCGGGGGAGCCCTGGGGGAAAAGTGTCAAATATGGA 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 GCTACGGTGTGCCCCTGGCCCGCACAGCGGGGGAGCCCTGGGGGAAAAGTGTCAAATATGGA 840

Qy     841 CCTGGGTCGCTTAGAGATCCCCGCCCAGCTGGCTACTCTGCTGGAGAGGGCGGAAGGCCA 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 CCTGGGTCGCTTAGAGATCCCCGCCCAGCTGGCTACTCTGCTGGAGAGGGCGGAAGGCCA 900

Qy     901 CCAGGCCTTGCTGACGGGGAGCATCACAGAGTCCCTGCTACTGACTTCCCCGCCGCCC 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 CCAGGCCTTGCTGACGGGGAGCATCACAGAGTCCCTGCTACTGACTTCCCCGCCGCCC 960

Qy     961 CAGCCTGACTCTCCCTCCAGACATTGACCAGTTTCCCTTCCTCAGTTTTGTATCCACTAT 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 CAGCCTGACTCTCCCTCCAGACATTGACCAGTTTCCCTTCCTCAGTTTTGTATCCACTAT 1020

Qy    1021 CTTTCAGAAGCCATTCTGCCTCGACCAGGGCAGCCACGACGAGCCCTGAGCCGTT 1080
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 CTTTCAGAAGCCATTCTGCCTCGACCAGGGCAGCCACGACGAGCCCTGAGCCGTT 1080

Qy    1081 AGATGGCGAGAACCCTCAGCAGGCTCTGGAGATCAACAGGGTGATGCTGCGGCTCCGGG 1140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1081 AGATGGCGAGAACCCTCAGCAGGCTCTGGAGATCAACAGGGTGATGCTGCGGCTCCGGG 1140

Qy    1141 GGAAGGATCTCTGCAGTCCTGGCAAGAGGAGAACATGGCAGTTCTGCTGCAGAAGT 1200
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1141 GGAAGGATCTCTGCAGTCCTGGCAAGAGGAGAACATGGCAGTTCTGCTGCAGAAGT 1200

Qy    1201 CCAGCGACGGCCGGGACTCGAGATGAGCTCTTCAGCAAGTTTGTTGTTTAGCTTCTGGG 1260
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1201 CCAGCGACGGCCGGGACTCGAGATGAGCTCTTCAGCAAGTTTGTTGTTTAGCTTCTGGG 1260

Qy    1261 CAACCCAGATGAGCAACAGAATCAGCGTGGCTGCCTCCTAAGTCGAGTCTTGTTCATTT 1320
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1261 CAACCCAGATGAGCAACAGAATCAGCGTGGCTGCCTCCTAAGTCGAGTCTTGTTCATTT 1320

Qy    1321 CTTTGCTCCCACACTGCCCTGGAGAAGCCACTGCTCAAACTTGACTGACCAGTTTCT 1380
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1321 CTTTGCTCCCACACTGCCCTGGAGAAGCCACTGCTCAAACTTGACTGACCAGTTTCT 1380

Qy    1381 CAGTGGCATGGCAGCCCTGTGCCAGCACAAGTTGTTAGTTCTTCTGAGCAGACAGTCTT 1440
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1381 CAGTGGCATGGCAGCCCTGTGCCAGCACAAGTTGTTAGTTCTTCTGAGCAGACAGTCTT 1440

Qy    1441 GGCTCCCATGGCTTCGAGGTCCCACCCACCCACAAGTTCACTCGAAGTCTCTTTTTA 1500
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1441 GGCTCCCATGGCTTCGAGGTCCCACCCACCCACAAGTTCACTCGAAGTCTCTTTTTA 1500

Qy    1501 TCGGGGCCGCATGGCGCTGGATGTGTTCACATTCAACAGAGAAAATTACTCCTCGAAGTT 1560
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1501 TCGGGGCCGCATGGCGCTGGATGTGTTCACATTCAACAGAGAAAATTACTCCTCGAAGTT 1560

Qy    1561 GGAATCCTGGACCACGGGAGAGCAGTTTGCAGGGTGATCTACAGAGTCAGAGTCTTGA 1620
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1561 GGAATCCTGGACCACGGGAGAGCAGTTTGCAGGGTGATCTACAGAGTCAGAGTCTTGA 1620

Qy    1621 GGCGCCCCCTGGTGGCTGGTCTGTGTCACTGCATTCTCCCGAACTTCTCT 1680
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1621 GGCGCCCCCTGGTGGCTGGTCTGTGTCACTGCATTCTCCCGAACTTCTCT 1680

Qy    1681 TGGCTGTGACTTTGTGTTGGACCTAAATAGGCAGACTCAAGACTTTGAGACACTCAATTCT 1740
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1681 TGGCTGTGACTTTGTGTTGGACCTAAATAGGCAGACTCAAGACTTTGAGACACTCAATTCT 1740

Qy    1741 TCCCCACAACTACCCCATCACTCCTCTTGGTTTAGTCAAGATCATCCCTAACTTCTCT 1800
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1741 TCCCCACAACTACCCCATCACTCCTCTTGGTTTAGTCAAGATCATCCCTAACTTCTCT 1800

Qy    1801 TGTCCAGGCTCCTTCCCTGCCCCCAGGACTCCTTCAAGTCAATACTCCTGAGTCAA 1860
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1801 TGTCCAGGCTCCTTCCCTGCCCCCAGGACTCCTTCAAGTCAATACTCCTGAGTCAA 1860

Qy    1861 CAGCCGCCCTCCGGGCGAGGCCAGTAAGCCTGAGAACCTTGATTTTTGTGAACCAACTT 1920
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1861 CAGCCGCCCTCCGGGCGAGGCCAGTAAGCCTGAGAACCTTGATTTTTGTGAACCAACTT 1920

Qy    1921 CTTTGAACCAGCGCTCGCTCCGGGTTTCAGTGATCTGTGAATCTGTTCCCCCTTAATATCT 1980
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1921 CTTTGAACCAGCGCTCGCTCCGGGTTTCAGTGATCTGTGAATCTGTTCCCCCTTAATATCT 1980
```

```
Qy     1981 ACGCATGAAGGGAGGGGGCTCTGTTGGGCCCACCCAGCAGGGCTACCCCATGGTGTACCC 2040
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     1981 ACGCATGAAGGGAGGGGGCTCTGTTGGGCCCACCCAGCAGGGCTACCCCATGGTGTACCC 2040

Qy     2041 AGGTATGGTGCAGGCACCTAGCTACCAGCCAGCTATGATACCCGCACCGATGCCCGTCAT 2100
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2041 AGGTATGGTGCAGGCACCTAGCTACCAGCCAGCTATGATACCCGCACCGATGCCCGTCAT 2100

Qy     2101 GCCAGCCATGGGCGCAGTCCCAACCATGCCAGCCATGATGGTGCCACCCCAGCCACAGCC 2160
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2101 GCCAGCCATGGGCGCAGTCCCAACCATGCCAGCCATGATGGTGCCACCCCAGCCACAGCC 2160

Qy     2161 TCTGGTGCCCAGTTTGGACTCAAGGCAGCTGGCACTACAGCAGCAAAACTTCATCAACCA 2220
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2161 TCTGGTGCCCAGTTTGGACTCAAGGCAGCTGGCACTACAGCAGCAAAACTTCATCAACCA 2220

Qy     2221 GCAGGCGATGATTCTGGCGCAGCAGATGACCACCCAGGCCATGAGCCTGTCCCTGGAGCA 2280
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2221 GCAGGCGATGATTCTGGCGCAGCAGATGACCACCCAGGCCATGAGCCTGTCCCTGGAGCA 2280

Qy     2281 GCAGAATCAGAGATACCAGCACTAAGCTCAGACCTCTGGGGCCACCTCCCAGCCTCCACC 2340
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2281 GCAGAATCAGAGATACCAGCACTAAGCTCAGACCTCTGGGGCCACCTCCCAGCCTCCACC 2340

Qy     2341 CTCAACCACTGCTCCCAAGGCCAAGAAGCCTCCTGCCCCCCAAGAGAAGCCAGAGAGTAA 2400
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2341 CTCAACCACTGCTCCCAAGGCCAAGAAGCCTCCTGCCCCCCAAGAGAAGCCAGAGAGTAA 2400

Qy     2401 CCTAGAGCCTTCGGGTGTTGGCTTGAGAGAGGACACCCCAGAGGAAGCTGAAAGCAAGCC 2460
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2401 CCTAGAGCCTTCGGGTGTTGGCTTGAGAGAGGACACCCCAGAGGAAGCTGAAAGCAAGCC 2460

Qy     2461 TCAGCGCCCCAAGAGCTTCCAACAGAAACGGGACTATTTCCAGAAGATGGGGCAAGATCC 2520
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2461 TCAGCGCCCCAAGAGCTTCCAACAGAAACGGGACTATTTCCAGAAGATGGGGCAAGATCC 2520

Qy     2521 GATCAGAGTGAAGACGGTGAAACCTCCAGCCAAGGTTCAGATCCCCCAAGAGGAGATGGA 2580
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2521 GATCAGAGTGAAGACGGTGAAACCTCCAGCCAAGGTTCAGATCCCCCAAGAGGAGATGGA 2580

Qy     2581 GGAGACGGAGGAGGAGGAGGATGAGACCGCCGAGTTGTCCCCTCCTCCTCCCCCTCCCCC 2640
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2581 GGAGACGGAGGAGGAGGAGGATGAGACCGCCGAGTTGTCCCCTCCTCCTCCCCCTCCCCC 2640

Qy     2641 GGTTGTGAAGAAGCCGCTGAAGGCAAGCAGGCCCAAAGCCGTAAAGGAAGATGAGGCAGA 2700
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2641 GGTTGTGAAGAAGCCGCTGAAGGCAAGCAGGCCCAAAGCCGTAAAGGAAGATGAGGCAGA 2700

Qy     2701 GCCCGCCCAGGAGGAAGTACCGACCCAGGGCGAGGATCCCCCGGTGCACAGCTCCAACTC 2760
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2701 GCCCGCCCAGGAGGAAGTACCGACCCAGGGCGAGGATCCCCCGGTGCACAGCTCCAACTC 2760

Qy     2761 CGCACCTCAGCACCCAAACCCAGCAGGGTACCCCCAGTGCAGAGCTCCAACTCCGCACC 2820
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2761 CGCACCTCAGCACCCAAACCCAGCAGGGTACCCCCAGTGCAGAGCTCCAACTCCGCACC 2820

Qy     2821 TCCACGCCCGCAACCCAGCAGGGAAATCCGAAACATCATCCGAATGTACCAGAGCCGTCC 2880
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2821 TCCACGCCCGCAACCCAGCAGGGAAATCCGAAACATCATCCGAATGTACCAGAGCCGTCC 2880

Qy     2881 AGGGCCTGTGGCTGTGCCCGTACAACCCACCAGGCCCATCAAAACTTTTCAGAAGAAAAA 2940
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2881 AGGGCCTGTGGCTGTGCCCGTACAACCCACCAGGCCCATCAAAACTTTTCAGAAGAAAAA 2940

Qy     2941 TGACCCTAAGGATGAGGCTTTGGCTAAGTTAGGGATAAATGGCGTCCACTTGCCCCTATC 3000
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     2941 TGACCCTAAGGATGAGGCTTTGGCTAAGTTAGGGATAAATGGCGTCCACTTGCCCCTATC 3000

Qy     3001 GACATCGCCTAACCAAGGGAAGAGCTCTCCACCGGCTGTAGTTCCTCGACCTAAGGCTCG 3060
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3001 GACATCGCCTAACCAAGGGAAGAGCTCTCCACCGGCTGTAGTTCCTCGACCTAAGGCTCG 3060

Qy     3061 ACCTCGTCTTGAGCCTTCCCTATCCATCCAGGAAAAGCAGGGACCCCTTCGGGACTTGTT 3120
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3061 ACCTCGTCTTGAGCCTTCCCTATCCATCCAGGAAAAGCAGGGACCCCTTCGGGACTTGTT 3120

Qy     3121 TGGCCCATGTAGTCCAAACCCACCTACAGCTCCAGCACCCCCGCCTCCACCAGCACTCCC 3180
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3121 TGGCCCATGTAGTCCAAACCCACCTACAGCTCCAGCACCCCCGCCTCCACCAGCACTCCC 3180

Qy     3181 ACCGCCTCTGTCTGGGGAGCCCAAGACCCCTTCAGTGGAGTCTCATGCCTTGACAGAGCC 3240
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3181 ACCGCCTCTGTCTGGGGAGCCCAAGACCCCTTCAGTGGAGTCTCATGCCTTGACAGAGCC 3240

Qy     3241 CATGGAGGACAAGAACATCTCCACAAAGCTCCTTGTGCCCTCTGGAAGTGTGTGCTTCTC 3300
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3241 CATGGAGGACAAGAACATCTCCACAAAGCTCCTTGTGCCCTCTGGAAGTGTGTGCTTCTC 3300

Qy     3301 CTATGCCAATGCACCCTGGAAGTTGTTCTTACGCAAGGAGGTGTTCTACCCCCGGGAGAA 3360
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3301 CTATGCCAATGCACCCTGGAAGTTGTTCTTACGCAAGGAGGTGTTCTACCCCCGGGAGAA 3360

Qy     3361 CTTCAGTCATCCATACTGCCTCAGTCTCCTCTGCCAGCAGATCCTGCGGGACACCTTCAC 3420
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3361 CTTCAGTCATCCATACTGCCTCAGTCTCCTCTGCCAGCAGATCCTGCGGGACACCTTCAC 3420

Qy     3421 AGAGTCCTGCACCCGGATCTCACAGGATGAGCGGCACAAAATGAAAGGCCTTCTGGGAGA 3480
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3421 AGAGTCCTGCACCCGGATCTCACAGGATGAGCGGCACAAAATGAAAGGCCTTCTGGGAGA 3480

Qy     3481 CTTGGAGGTGAGTCTGGAGACCCTTGACATTGTTGAAGACAGCATCAAAAAACGCATCGT 3540
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3481 CTTGGAGGTGAGTCTGGAGACCCTTGACATTGTTGAAGACAGCATCAAAAAACGCATCGT 3540

Qy     3541 GGTCGCTGCTGGGACAACTGGGCCAATTACTTCTCCCGCATCTTCCCAGTCTCGGGTGA 3600
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3541 GGTCGCTGCTGGGACAACTGGGCCAATTACTTCTCCCGCATCTTCCCAGTCTCGGGTGA 3600

Qy     3601 GAGTGGCAGCGATGTACAGCTGCTGGGTGTGTCTCACCGGGGACTGCGGCTGCTGAAGGT 3660
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3601 GAGTGGCAGCGATGTACAGCTGCTGGGTGTGTCTCACCGGGGACTGCGGCTGCTGAAGGT 3660

Qy     3661 GACCCAAAGCCCGAGCTTCCACCTGGACCAGCTGAAGACACTCTGTTCCTACAGCTATGC 3720
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3661 GACCCAAAGCCCGAGCTTCCACCTGGACCAGCTGAAGACACTCTGTTCCTACAGCTATGC 3720

Qy     3721 TGAAGTCCTGACCGTGCAGTGCAGGGCAGATCCACCCTGGAGCTGTCCTTGAAGAATGA 3780
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3721 TGAAGTCCTGACCGTGCAGTGCAGGGCAGATCCACCCTGGAGCTGTCCTTGAAGAATGA 3780

Qy     3781 GCAGCTGATACTGCACACAGCCTGGGCGAGGGCCATCAAGGCCATGGTGGATCTATTTCT 3840
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3781 GCAGCTGATACTGCACACAGCCTGGGCGAGGGCCATCAAGGCCATGGTGGATCTATTTCT 3840

Qy     3841 GAGTGAACTCAGGAAGGACTCCGGCTATGTCATCGCCCTGCGCAGCTACATCACCGATGA 3900
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3841 GAGTGAACTCAGGAAGGACTCCGGCTATGTCATCGCCCTGCGCAGCTACATCACCGATGA 3900

Qy     3901 CAATAGCCTCCTCAGTTTCCACCGTGGGGACCTCATTAGGTTACTGCCAGTGACCGCTCT 3960
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3901 CAATAGCCTCCTCAGTTTCCACCGTGGGGACCTCATTAGGTTACTGCCAGTGACCGCTCT 3960

Qy     3961 GGAACCAGGCTGGCAGTTCGGTTCTGCCGGGGCCGCTCCGGACTCTTTCCCGATGACGT 4020
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     3961 GGAACCAGGCTGGCAGTTCGGTTCTGCCGGGGCCGCTCCGGACTCTTTCCCGATGACGT 4020

Qy     4021 GGTGCAGCCAGCTGCTGCCCCCGACCTCTCCTTTTCCCTGGGAAAGAGAAACAGCTGGCA 4080
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     4021 GGTGCAGCCAGCTGCTGCCCCCGACCTCTCCTTTTCCCTGGGAAAGAGAAACAGCTGGCA 4080

Qy     4081 ACGCAAGAGTAAGCTGGGGCCAGCTCAGGAGGTGAGGAAGACAGAAGAGGTGAAGTGATA 4140
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     4081 ACGCAAGAGTAAGCTGGGGCCAGCTCAGGAGGTGAGGAAGACAGAAGAGGTGAAGTGATA 4140

Qy     4141 CAGGCCTAACTTGGAGACTGAGAAGGAAAGAGCAGGGTTGCTTCGGGTGTTGTCCACTTC 4200
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```



RESULT 2
AX253080
LOCUS AX253080 4475 bp DNA

```
EFINITION  Sequence 3 from Patent WO0168866.
CCESSION   AX253080
ERSION     AX253080.1  GI:15986276
EYWORDS    .
OURCE      Mus sp.
 ORGANISM  Mus sp.
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
EFERENCE   1  (bases 1 to 4375)
 AUTHORS   Brooks,A.R., Deng,G.G. and Pubanyi,G.M.
 TITLE     Estrogen-regulated unconventional myosin related protein:
           compositions and methods of use
 JOURNAL   Patent: WO 0168866-A 3 20-SEP-2001;
           SCHERING AKTIENGESELLSCHAFT (DE)
EATURES             Location/qualifiers
     source         1..4375
                    /organism="Mus sp."
                    /db_xref="taxon:10095"
                    /note="Mouse myosin related protein (MRP) variant 2 cDNA"
ASE COUNT       966 a    1368 c    1216 g     825 t
IGIN

Query Match:             [illegible]%;  Score 4351;  DB 6;  Length 4375;
Best Local Similarity   100.0%;  Pred. No. 0,
Matches 4352;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 CGCTGGGACTGTCACTTACCAGGTGCACAAGTTCATAAACAGAAACAGGGGCCACCTGGA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 CGCTGGGACTGTCACTTACCAGGTGCACAAGTTCATAAACAGAAACAGGGGCCACCTGGA 60

Qy      61 [illegible] 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 [illegible] 120

Qy     121 [illegible] 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 GCTCATGGGCAGTTTGTTCAAGAAGTAGAGCGGCTAGGCTGGGACTGAGCAAAACAAACC 180

Qy     181 [illegible] 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 CACATTGGCTTCTTAATTCAATAGACCTTGGGTGACTTGCTAGCTCGGCTAGGCAGCAG 240

Qy     241 [illegible] 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 GGGTCATGTTTATTTCATTAACTCTTTAATCCCACCCCTGGAAAGATCCCAGGCCTCTT 300

Qy     301 [illegible] 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 TGATGTTGGGTATGTTTGATGATTATTGTTGTCAGGCTGGCATCCTGGAGATCATAGGCAC 360

Qy     361 [illegible] 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 CCTGATGTATTCATTTTTTTTTGTGATTGTCCTTCAAGTCTTTCTGGCAAGGTTCCATGC 420

Qy     421 [illegible] 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 [illegible] 480

Qy     481 TGAAGTGCTTGGGTTATAGTTTATCCGTTGTATCATCTTGGAGTCACCCAGGTCCTGCTGCA 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 TGAAGTGCTTGGGTTATAGTTCATCCGTTGTATCATCTTGGAGTCACCCAGGTCCTGCTGCA 540

Qy     541 GGAATAGGGTTTGTCATAGTTATAAACAATTTGTGGGCTCAGCGGCGCTCACAGGCCCTGCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 GGAATAGGGTTTGTCATAGTTATAAACAATTTGTGGGCTCAGCGGCGCTCACAGGCCCTGCT 600

Qy     601 [illegible] 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 [illegible] 660

Qy     661 GATGTAGTTTTTGTTGTTTTTGGTGCAGGCCAGGAAGCGATATCTCCAGCGGAGGTCAGC 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 GATGTAGTTTTTGTTGTTTTTGGTGCAGGCCAGGAAGCGATATCTCCAGCGGAGGTCAGC 720

Qy     721 TCTGGGACAGCTGAACACCATTCTCCTAGTGGCCCGGCTCCTGCTCCGGAGACGACAGAA 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 TCTGGGACAGCTGAACACCATTCTCCTAGTGGCCCGGCTCCTGCTCCGGAGACGACAGAA 780

Qy     781 GCTACGGTGTGCCCCTGGCCCGCACAGTGGGAGCCTGGGGAAAGTTTCAAATATGGA 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 GCTACGGTGTGCCCCTGGCCCGCACAGTGGGAGCCTGGGGAAAGTTTCAAATATGGA 840

Qy     841 CCTGGGTCGCTTAGAGATCCCCGCCCAGCTGGCTACTCTGCTGGAGAGGGGGGAAGGCCA 900
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 CCTGGGTCGCTTAGAGATCCCCGCCCAGCTGGCTACTCTGCTGGAGAGGGGGGAAGGCCA 900

Qy     901 CCAGGCCTTGCTGACGGGGAGCATCACAGAGTCCCTGCCA[illegible] 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 CCAGGCCTTGCTGACGGGGAGCATCACAGAGTCCCTGCCA[illegible] 960

Qy     961 CAGCCTGACTCTCCCTCCAGACATTGACCAGTTTCCCTTCTCCAGTTTTGTATCCACCAG 1020
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 CAGCCTGACTCTCCCTCCAGACATTGACCAGTTTCCCTTCTCCAGTTTTGTATCCACCAG 1020

Qy    1021 CTTTCAGAAGCCATTTCTGCCTCGACCAGGGCAGCCACTGGAGGAGCCCTTACCGGGTT 1080
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 CTTTCAGAAGCCATTTCTGCCTCGACCAGGGCAGCCACTGGAGGAGCCCTTACCGGGTT 1080

Qy    1081 AGATGGCGAGAACCCTCAGCAGGCTCTGGAGATCAACAGGGTGATGCTGCGGGCTCTTGGG 1140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1081 AGATGGCGAGAACCCTCAGCAGGCTCTGGAGATCAACAGGGTGATGCTGCGGGCTCTTGGG 1140

Qy    1141 GGAAGGATCTCTGCAGTCCTGGCAAGAGCAGACCATGGGCA[illegible] 1200
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1141 GGAAGGATCTCTGCAGTCCTGGCAAGAGCAGACCATGGGCA[illegible] 1200

Qy    1201 CCAGCGACGGCCGGGAGTCCGAGATCAGCTTTCAGCCACTTCCCGGTCAGTTCTTCCC 1260
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1201 CCAGCGACGGCCGGGAGTCCGAGATCAGCTTTCAGCCACTTCCCGGTCAGTTCTTCCC 1260

Qy    1261 CAAGCCAGATGAGCAACAGAATCAGGTGGTGGTGGGCCTAATGGTGATC[illegible] 1320
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1261 CAAGCCAGATGAGCAACAGAATCAGGTGGTGGTGGGCCTAATGGTGATC[illegible] 1320

Qy    1321 CTTTGCTCCCACACCTGCCCTGGAGAAGCCACTGCTCAAATTTGTATCGACAGGTTCC 1380
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1321 CTTTGCTCCCACACCTGCCCTGGAGAAGCCACTGCTCAAATTTGTATCGACAGGCTCC 1380

Qy    1381 CAGTGGCATGGCAGCCCTGTGCCAGCACAAGCTGTTAGGTG[illegible] 1440
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1381 CAGTGGCATGGCAGCCCTGTGCCAGCACAAGCTGTTAGGTG[illegible] 1440

Qy    1441 GGCTCCCATGGCTTCGAGGTCCCAGCCACCCACAACTTGACTGGAAGGTTGGTTTACG 1500
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1441 GGCTCCCATGGCTTCGAGGTCCCAGCCACCCACAACTTGACTGGAAGGTTGGTTTACG 1500

Qy    1501 TCGGGGCCGCATGGCGCTGGATGTGTTCACATTCAACGAGGAAAGCTACTCCCCGGAACT 1560
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1501 TCGGGGCCGCATGGCGCTGGATGTGTTCACATTCAACGAGGAAAGCTACTCCCCGGAACT 1560

Qy    1561 GGAATCCTGGACCACGGGAGAGCAGTTTGCAGGGTGGATCCTACAGAGCAGAGGCCTGA 1620
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1561 GGAATCCTGGACCACGGGAGAGCAGTTTGCAGGGTGGATCCTACAGAGCAGAGGCCTGA 1620

Qy    1621 GGCGCCCCCTGGTGGCTGGTCTGTGTCAGTGCATTCTGGGATGTTTGTGATTGATT 1680
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1621 GGCGCCCCCTGGTGGCTGGTCTGTGTCAGTGCATTCTGGGATGTTTGTGATTGATT 1680

Qy    1681 TGGCTGTGACTTTGTGTTGGACCTAATAGGCCAGACTGAGGACTTTGGAGACTCAGTT 1740
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1681 TGGCTGTGACTTTGTGTTGGACCTAATAGGCCAGACTGAGGACTTTGGAGACTCAGTT 1740

Qy    1741 TCCCCACAACTACCCCATCACTCCTCTTGGTTTAGTTAGAGCATCTTTCAACCCTTGC 1800
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1741 TCCCCACAACTACCCCATCACTCCTCTTGGTTTAGTTAGAGCATCTTTCAACCCTTGC 1800
```



























ESULT 3
8058686
OCUS AB0[illegible] 6004 bp mRNA linear PRI 06 JUN 2001
EFINITION Homo sapiens mRNA for KIAA1783 protein, partial cds.
CCESSION AB058686
ERSION AB058686.1 GI:14017782
EYWORDS
URCE Homo sapiens brain cDNA to mRNA, clone:fg01285.
RGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
EFERENCE 1 (sites)
AUTHORS Nagase,T., Nakayama,M., Nakajima,D., Kikuno,R. and Ohara,O.
TITLE Prediction of the coding sequences of unidentified human genes. XX.
The complete sequences of 100 new cDNA clones from brain which code
for large proteins in vitro
OURNAL DNA Res. 8 (2), 85-95 (2001)
MEDLINE 21245130
EFERENCE 2 (bases 1 to 6004)
AUTHORS Ohara,O., Nagase,T. and Kikuno,R.
TITLE Direct Submission
OURNAL Submitted (27-MAR-2001) Osamu Ohara, Kazusa DNA Research Institute,
Department of Human Gene Research; 1532-3, Yana, Kisarazu, Chiba
292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp,
URL:http://www.kazusa.or.jp/huge, Tel:+81-438-52-3913,
Fax:81 438-52-3914)
EATURES Location/Qualifiers
source 1..6004
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="fg01285"
/tissue_type="brain"
/note="vector:pBluescriptII SK plus"
gene 1..6004
/gene="KIAA1783"
CDS <1081..5763
/gene="KIAA1783"
/note="Start codon is not identified."
/codon_start=1
/product="KIAA1783 protein"
/protein_id="BAB47417.1"
/db_xref="GI:14017783"
/translation="PVCCAGSFPIDPVGYTASADGITHPCALARMKEASGVGRGHSPM
CPPHCHMPPGPAGEWPGATVQQPPQPAPTALLQPDAAGPGGGGVSAGVAVLGACPSAS
EGVLPRPPGRSAPQPPEYPGPPLMAVPGWSAMVPSPLTATSTSQATDHTHIQPSHYHH
GDHPSYAKPPLPLPVFTVPHYAGTVTYQVHPFLNPNPDQLDPAVVEMLGQSQLQLVGS
LPLEAEPQSPGGPGPPTLASPLQALEDLIAPLGPSHVYPTQCLTPNPGPLPGLMVG
HVTEQLHQAAILEAVGTPSANFPVPVPFFAFLASFQAIGSPPQFDLLSIPLPGGAVSNQ
VLGAESPLYHLGATKVILQFLQWLPLFLPDQQPSQALVDLHPSFHTCLSQPVLPRM
QARMPGFQAPKPYLPPPAAIGQLNTILLVAQPLLQPPQPLQLQSFWQGWHSSPPALPPV
PSMPLGPLEIPAELAVMLHTAFSHPDAIAGSTTPCLPPEVPAPEPGLTLPADILPLPPS
SPVAIGPQEPSLPPPPQPLAPPLTQLPGPNPQPALPDINKVMLPLLGPGSLPSWQPQTM
GAYLVPQGQCWPGLRNELPSQLVAQLWQNPDEQQSPGWALMAVLLSAPPLLFVLQKP
LLKFVSDQAPPGMAALCQHKLLGALEQSQLASGATEAHPPTIQLEWLAGWPPGRMALDV
PTPSEECYSAEVESWTTGEQIAGWILQSPGLPAPPPGWSVSLHSPDAWQDVAGSNVL
DLISQTEDLGDPAPPRSYPITPLGSAEAIPLAPGIQAPSLPPGPPPGPAITLPSSDHT
GRVQPSGSLDGSHIQLPQPVISSGLSDLPQSWAISSPMGGGAIGPTQLCYDMVYPGM
IQMPAYQPGMVPAPMPMMPAMGTVPAMPAMVVPPQPPLPSLDAGQLAVQQNPLQQCA
LLLAQQMIAQAMSLSLPQQMQQMQQQAPASPAASQASPSAVISKSPRSLTDPEKPQNP
LGSEGGCLPETSEEAFPPPYQPPSPQQYPNYFQPMGQPQLTVETMKPDAKVHLPQGNA
QPEEEEEEEEEEPLEPLSVETPAVPSPPPPPIVPFPLPQGSAFALKPAAPAAPAAPAAK
GHGQGPAQGRGTVVKSSLSKPPRPQPSPEIQNLLPMVQSFPGPVVSVPVLPSPPPKAPL
PKIDPKPDEALAKLGINDAHCSFPMLSFSPGPSFPAVAFPPPAPLQLGHSSSIKPKQS
PLLDLFGQKLPIAHTPPPPPAPPLPLPEDPGTLSAEPRCLTQPVEDQGVSTQLLAPSG
SVLFSYTGTPWFLFLPKEVFYSPENFSHSYYLFLLSPQTLAQGPFFSTAPQQPPPPK
MKDLLGGLEVDLDSLTTTFDSVKFPIVVAAPDNWANVPSPPPPVSGPAQNDVQLLAVS
HPGLPLPVTVQGPGLAPPQLPLLQSYSFAPVLSVPVPQQRSTLPLSLKPPQLVMPPAPA
PAIEALVELFLNELKKDSGYVIALPSYITPNCSLLGFPPGPLIKLLPVATLPPGWQPG
SAGGPSGLPPADIVQPAAAPDPSPSKEQPSGWHPGQLSNGPGQLAAWTPAASPMKPMGE
GQAEARPA"
BASE COUNT 1134 a 1942 c 1870 g 1058 t
ORIGIN

Query Match 27.9%; Score 2394.2; DB 9; Length 6004;
Best Local Similarity 75.7%; Pred. No. 0;
Matches 3027, Conservative 0; Mismatches 928, Indels 47; Gaps 9;











RESULT 4
AF418292
LOCUS AF418292 4602 bp cDNA linear PRI 16-JUN-2002
DEFINITION Homo sapiens clone cDNA1 myosin XVBP (MYO15B) pseudogene, partial sequence.
ACCESSION AF418292
VERSION AF418292.1 GI:16303815
KEYWORDS .
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 4602)
AUTHORS Boger,E.T., Sellers,J.R. and Friedman,T.B.
TITLE Human myosin XVBP is a transcribed pseudogene
JOURNAL J. Muscle Res. Cell. Motil. 22 (5), 477-483 (2001)
MEDLINE 21960014
PUBMED 11964073
REFERENCE 2 (bases 1 to 4602)
AUTHORS Boger,E.T., Sellers,J.R. and Friedman,T.B.
TITLE Direct Submission
JOURNAL Submitted (13-SEP-2001) Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, 5 Research Court, Rockville, MD 20850, USA
FEATURES Location/Qualifiers
source 1..4602
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="17"
/map="17q24-q25"
/clone="cDNA1"
/tissue_type="kidney; stomach"
gene <1..>4602
/gene="MYO15B"
/note="myosin XVBP"
/pseudo
BASE COUNT 927 a 1495 c 1405 g 775 t
ORIGIN

Query Match 35.7%; Score 2246; DB 9; Length 4602;
Best Local Similarity 71.0%; Pred. No. 0;
Matches 3293; Conservative 0; Mismatches 1175; Indels 172; Gaps 17;







```
Db    4522 TGTTTTTTCAACGGCCAGCATCTCATCCTCATGGACCCCAGCTCCCAGAGCCTGTACTGCC 4581

Qy    5843 TTTTTATGCTAAAAGACCTG 5851
           |  |  |  |  |  |  |||
Db    4582 GCATTGCCCTGAAGAGCCTG 4601


RESULT 6
AF418290
LOCUS       AF418290               7925 bp    mRNA    linear   PRI 06-JUN-2001
DEFINITION  Homo sapiens clone 15 myosin XVBP (MYO15B) pseudogene, partial
            sequence.
ACCESSION   AF418290
VERSION     AF418290.1  GI:16303815
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 7925)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Human myosin XVBP is a truncated pseudogene
  JOURNAL   J. Muscle Res. Cell. Motil. 22 (5), 477-483 (2001)
  MEDLINE   21960014
   PUBMED   11964073
REFERENCE   2  (bases 1 to 7925)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Direct Submission
  JOURNAL   Submitted (13-SEP-2001) Laboratory of Molecular Genetics, National
            Institute on Deafness and Other Communication Disorders, 5 Research
            Court, Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..7925
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /map="17q24-q25"
                     /clone="15"
                     /tissue_type="stomach"
     gene            <1..>7925
                     /gene="MYO15B"
                     /note="myosin XVBP"
                     /pseudo
BASE COUNT     1454 a   2543 c   2691 g   1237 t
ORIGIN

  Query Match          82.7%;  Score 2055.4;  DB 9;  Length 7925;
  Best Local Similarity   73.4%;  Pred. No. 0;
  Matches 2483;  Conservative    0;  Mismatches  871;  Indels  155;  Gaps   10;

Qy     238 GCCAATTGGCCTTCCATTCCAGCAGACCCTGGGTGACTTGCTAGCTCGGCTAGGCAGC 238
           ||.|   | |||||||| ||||||||| ||||||  ||| |  |||| |||||  | |||
Db    4270 TTGGACTGGGCCTCTGGCTTCCAGCAGGCCCTGGAGGACCTCATAGCCCGGCTGGCCAGG 4269

Qy     298 AGGGGCATGTCTACGTCATCCACTGTCTCAATCCCACCCCTGGAAAGATCCCAGGCCTC 298
           |||||||||  |||||| || |||  || | ||||||||| | |||||||||
Db    4211 A   TCATGTCTATTTCATCCAGTGCCTCACCCCTAACCCTGGAAAGCTTCCAGGCCTC 4326

Qy     358 TTTCAGGTGGGGGCATGTGGCAGAGCAGCTGTGTCAGGCTGGCATCCTGGAGATCATAGGC 358
           || |||||| |||||| |||||| ||||  |||||  | ||| ||||||  | | |||
Db    4327 TTTGACGTGGGACATGTGACAGAGCAACTGCACCAGGCAGCCATACTGGAGGCGTGGGC 4386

Qy     418 AAGTGAGTACCCACTTCCCCGTGCGAGTGTCCTTCCAAGTCTTTCTGGCAAGGTTCCAT 418
           ||  |||| |||| | |||||||||||| ||| ||||  | | ||| ||||| || ||||||
Db    4387 AAGCGAGTGCCAACTTCCCCGTGCGTGTGGCCTTTGAGGCCTTCCTGGCCAGCTTCCAG 4446

Qy     478 GTCTTGGGGTCAGGGAGACAGAAAGCTGCCTCTGACCAGGAGAGGTGTGGTGCCATCCTC 478
           |||||||||||   | |||  |||    |||||||| ||||| ||||||||| ||||
Db    4447 GTCTGGGGTCAGAAGGGCAGGAAGACCTCTCTGACCGGGAGAAGTGTGGTGCCGTCCTG 4506

Qy     538 AAGAAAGGTGTGGGGGCAGAGTCACCGCTGTATCATCTTGGAGTCACCCAGGTCCTGCTG 538
           ||||| | | | ||||||| | | |||| |||||||||| ||||| ||||||||||||
Db    4507 AAGAAGTGTCTGGGGGCCGAATCACCTCCTCTACCACCTTGGAGCCACCAAGGTCCTGCTG 4566

Qy     598 CAGGAACAGGGCTGGCAGCAGTAGAACAGCTCTGGGTTCAATTTTTTACAATGTCCT 653
           |||| ||||||||||| || || |||| ||| |  |||  |||||||||||||||||
Db    4567 CAGGAGCAGGGCTGGCAGCGGTTGGAACAGCTCCGGGACTTCATAGTCCTCATGTCCT 4626

Qy     654 CTCACTCTGCACCGTGGCCTCCGAGCCTGTATCAGCCCCAGCCTCTCCTGTTCT 708
           ||  |||||||| || |||  |||| ||| |||| |.|||  |||||| |
Db    4627 CTCGACCTGCACCGCAGCTTCCACACCTGCATCTCCCCCAGCCC  CCTCTGCCT 4680

Qy     709 CCGATCCAGCCTCCTCTGCCCCCCCCCCCCAGCCCAGCAACCCCCCCAGCCCCCCCCCCA 768
           |||||||||||   |||||||| ||||||||||||||||||||  |||||||||||| |
Db    4681 CGGATGCAGGCTCACATGCTGCGGTTCCAGGCCAGGAAC  CCACCC  CCCCCCCCA 4736

Qy     769 GCTCTGGGACAGCTGAACACCATTCTCCTACTGCCCCCCCCCCCCCCCCCCCCCCCCCA 828
           ||| |||||||||||||||||| || |||||||  |||||||||||||||||||||||
Db    4741 GCTTTGGGACAGCTGAACACCATCCTGCTGTGGCCCCCCCCCCCCCCCCCCCCCCCCCA 4800

Qy     829 AACCTACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA 888
           | || | | || | | | | |                                      |
Db    4801 AGACTGCCAGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA 4860

Qy     889 TCAAACTATGGACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA 948
           ||| |||| ||||| |||| ||||||||||||||||||||||||||||||||||||||
Db    4861 CCAAGCATGGAGCTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGA 4920

Qy     949 GCGGAAGGGCACCAGGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA 1008
           ||||
Db    4921 GCGGA-------------------------------------------------------- 4926

Qy    1009 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA 1068
                                                                      |
Db    4926 ---------- ---------- ---------- ---------- ----------AACTTCC 4961

Qy    1069 GTAGCCAGCAGCTTTCAGAAGCCATTCCTGCCTGGAGCAGGGAGCAGCAGGCAGCCCC 1128
           ||  ||| | |||||||| | || |  |||||  | ||||| ||||||| ||| |||||
Db    4962 GTCGCCATCGGCTTTCAGGAACCGTTCCTGCCCAGCAGGGAGCAGTGGCAAGCCCC 5021

Qy    1129 CTGACGCGGTTAGATGGCGAGAACCCTCAGCAGGTTCTGGAGATTAAAAGTGGATGTCG 1188
           || || | | | | |||||| ||  |||  |||||||||||||||||||||||||||||
Db    5022 CTAACCCAGCTGGATGGAGACAACCCTCAGCGTGCCCTGGAGATTAAAAGTGGATGTCG 5081

Qy    1189 CGGCTCCTGGGGGGAAGGATCTCTGCAGTCCTGCAAGAGCAGACAGTGGGCACGTTCCTC 1248
           |||||||||||||| ||||| ||| |||||||||  |||| | ||||||| | ||||
Db    5082 CGGCTCCTGGGGGACGGATCCCTGGAGTCCTGCAGAGCCAGACAGTGGGCACATACCTG 5141

Qy    1249 GTGCAGCAGGCCCAGGAGCAGGCCGGAGTCCGAGAAGAGAG  AG AG AGGAGAGGCC 1308
           ||| |||||  ||| | |||| || || ||  ||| | | | | | |  |||| | |
Db    5142 GTGCTGCAGGGCTAGTGCGGCCTGGGAAACAGCCCCAGCAGCTGTTGGTCTTCC 5201

Qy    1309 CAGCTGTGGGGCAACCCAGATGAGCAGCAGAGCCAGCCCCCCCCCCCCCTAATGCTGACC 1368
           ||||| ||||  |||||||||| || |||  |||||||||||||||||| |||
Db    5202 CAGCTATGGCAGAACCCAGATGAACAGCAGAGCCAGCCTGTGGTTGGGCTTATGGCTGTT 5261

Qy    1369 CTGCTCAGCTCCTTTGCTCCCACACCTGCCTCCAGAAGAGCAAGCCTAAATTCTATTT 1428
           |||||||| |||| | ||  |||| |||| |||||||||| | | | |||| | | |
Db    5262 CTGCTCAGCGCCTTTCCCCCACTGCCTGTCCCAGAAGCCAGCCTGCTAAGTTCTTTTT 5321

Qy    1429 GACCAGGCTCCCAGTGGCATGGCAGCCCTGTGCCAGTACAAGTCCTTAAGTGCCCTGGAG 1488
           |||||||| |||| |||||||||||| |||||||||||||||||||||||||||||||
Db    5322 GACCAGGCCCCCAGGGGCATGGCAGCGTCTGTGCCAGCACAAGCCCTTTGGAGCCCTGG 5381

Qy    1489 CAGACACCGCCTGGCTCCCATGCCCTTGAGGTCCTACCCACCCCCCCCCCCCCCCCCCAG 1548
           ||| | | |||||| | |||| | || |||||||| |  | | | | | |||| | |
Db    5382 CAGTCGCAGCTGGCCTCGGGGGCCATCGGGGCCCACCCCCCCCCCCCCCCCCCCCCCAG 5441

Qy    1549 GCTGGTTTACGTCGGGGGCGCCTATGGTGCTGGATGTGTTCTACATCTTAAGCTAAATCTAC 1608
           || || |  || ||||||||||||||||||||||||||||||||||| | | | |||| |
Db    5442 GCCGGGTGGCGGCGGGGCCGCATGCGCTGGATGTGTACTACTTCAGCAGCAGTCTTACT 5501

Qy    1609 TCCCCGCAAGTGCAATCCTGGAGCCAGCGGGAGCAGCAGCCCCCCCCCCCCCCCCCCCCC 1668
           || || || |||| | |||||| | |||||||||||||||||||||||||||||||||||
Db    5502 TCGGCCGAGGTGGAGTCCTGGACCAGCGGGAGCAGCAGCCCCCCCCCCCCCCCCCCCCC 5561
```

























```
RESULT 6
AF418286
LOCUS       AF418286               7515 bp    mRNA    linear   PRI 06-JUN 2002
DEFINITION  Homo sapiens clone 1 myosin XVBP (MYO15B) pseudogene, partial
            sequence.
ACCESSION   AF418286
VERSION     AF418286.1  GI:16303809
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 7515)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Human myosin XVBP is a transcribed pseudogene
  JOURNAL   J. Muscle Res. Cell. Motil. 22 (5), 477-483 (2001)
  MEDLINE   21960014
    PUBMED  11964073
REFERENCE   2  (bases 1 to 7515)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Direct Submission
  JOURNAL   Submitted (13-SEP-2001) Laboratory of Molecular Genetics, National
            Institute on Deafness and Other Communication Disorders, 5 Research
            Court, Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..7515
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /map="17q24-q25"
                     /clone="1"
                     /tissue_type="kidney"
     gene            <1..>7515
                     /gene="MYO15B"
                     /note "myosin XVBP"
                     /pseudo
BASE COUNT     1350 a   2469 c   2540 g   1156 t
ORIGIN

  Query Match             31.1%;  Score 1954.4;  DB 9;  Length 7515;
  Best Local Similarity   71.1%;  Pred. No. 0;
  Matches 2249;  Conservative    0;  Mismatches  886;  Indels  282;  Gaps   10;
```




























```
RESULT 2
AF418293
LOCUS       AF418293               4208 bp    mRNA    linear   PRI 07-JUN-2002
DEFINITION  Homo sapiens clone cDNA2 myosin XVBP (MYO15B) pseudogene, partial
            sequence.
ACCESSION   AF418293
VERSION     AF418293.1  GI:16303816
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 4208)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Human myosin XVBP is a truncated pseudogene
  JOURNAL   J. Muscle Res. Cell. Motil. 22 (5), 477-483 (2001)
  MEDLINE   21760014
   PUBMED   11964073
REFERENCE   2  (bases 1 to 4208)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Direct Submission
  JOURNAL   Submitted (13-SEP-2001) Laboratory of Molecular Genetics, National
            Institute on Deafness and Other Communication Disorders, 5 Research
            Court, Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..4208
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /map="17q24-q25"
                     /clone="cDNA2"
                     /tissue_type="kidney; stomach"
     gene            <1..>4208
                     /gene="MYO15B"
                     /note="myosin XVBP"
                     /pseudo
BASE COUNT      862 a   1386 c   1275 g    685 t
ORIGIN
```















RESULT 9
BC024506
LOCUS BC024506 1547 bp mRNA linear EST 07-MAY-2002
DEFINITION Mus musculus, clone IMAGE:4983596, mRNA, partial cds.
ACCESSION BC024506
VERSION BC024506.1 GI:19353981
KEYWORDS .
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 1547)
AUTHORS Strausberg,R.
TITLE Direct Submission
JOURNAL Submitted (01-MAR-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Rm 11A52, Bethesda, MD 20892-2590, USA
REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www.shgc.stanford.edu
Contact: (Dickson, Mark) med-pax11.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found at the I.M.A.G.E. Consortium/LLNL web site: http://image.llnl.gov
Series: IRAK Plate: 59 Row: o Column: 9
This clone was selected for full length sequencing because it passed the following selection criteria. Hexamer frequency OFF analysis.
FEATURES Location/Qualifiers
source 1..1547
/organism="Mus musculus"
/db_xref="taxon:10090"
/map="FVB/N"
/clone="IMAGE:4983596"
/tissue_type="Colon, normal, 5 month old male mouse."
/clone_lib="NCI_CGAP_Co24"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"
CDS <1..1256

```
                     /codon_start=3
                     /product="Unknown (protein for IMAGE:4983596)"
                     /protein_id="AAH24506.1"
                     /db_xref="GI:19353982"
                     /translation="PPPPGPDELSLIYELLPLCQDDLPDEMYCQVIPQVTGHEPPHC
                     ALGWSVLSLFTGFFAPSTTLMPYVIKFLQDSSPSPEELARRSQENLQRTVKYGGRQQLP
                     LPGEMNAFLKGQAVRLLLTHLPGGVDYPRTNSQTPTVAGEVLEELCGQMGITDLEEVQE
                     FALFLIKGEGELVRPLSPHEYINNVVTDQDMSLLHSRRLGWETPLHFDHSTYTETHYGQ
                     VLPDYLQCWIIVSTQAFALLAQLAAFQHFDKTGTSSPPSEQELLSYIPFFLQWQVNTA
                     NIKSLVTQEIPQMQGYSKQPAQIGFIESTAQLPLPGYTVYVVLRVSKLALPGPGLLGL
                     NRQHLVLMDPSSQFLCCSVMLKDIKQLHLLSPLQFDGPPGLELNYGSVDNPQTIWLEL
                     PQAQEIAQHTIIFLLGSMSTQWPGLL"
ASE COUNT      407 a    429 c    414 g    297 t
RIGIN

 Query Match           23.8%;  Score 1495.6;  DB 10;  Length 1547;
 Best Local Similarity   99.1%;  Pred. No.: 0;
 Matches 1504;  Conservative    0;  Mismatches   14,  Indels    0,  Gaps    0;

Qy    477 AGCTGAAGGCTGTGCC 4855
          ||||||||||||||||
Db      1 AGCCTAAGGCTGTGCC 60

Qy   4836 AAGATGAGCTTTAGGAGGAGATATGTACTGCAGGTCATCAAGCAAGTCACAGGACACCCCC 4895
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 AAGATGAGCTTTAGGAGGAGATATGTACTGCAGGTCATCAAGCAAGTCACAGGACACCCCC 120

Qy   4896 AGCCAAAGGTACTGTGCTCTGGGCTGGAGGGTCCTCAGCCTCTTCACAGGCTTCTTTGCAC 4955
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 AGCCAAAGGTACTGTGCTCTGGGCTGGAGGGTCCTCAGCCTCTTCACAGGCTTCTTTGCAC 180

Qy   4956 CATCAACTACTCTGATGTCCTATGTGACCAAGTTCCTGCAGGATTCCAGCCCCAGTGAAG 5015
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 CATCAACTACTCTGATGTCCTATGTGACCAAGTTCCTGCAGGATTCCAGCCCCAGTGAAG 240

Qy   5016 AGTTGTGTAAGAAGAGTTCAAAGAAGTTCCAGCGCAACAGTTAAATATGGGGGACGCCAGC 5075
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 AGTTGTGTAAGAAGAGTTCAAAGAAGTTCCAGCGCACAGTTAAATATGGGGGACGCCAGC 300

Qy   5076 AGTTGCTGTTAGTTGTGAAATGAATGCTTTTCTGAAAGGGCAAGCAGTTCGTTTGCTTC 5135
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 AGTTGCTGTTAGTTGTGAAATGAATGCTTTTCTGAAAGGGCAAGCAGTTCGTTTGCTTC 360

Qy   5136 TAATTCAGCTGCTGTGGGGTGTGGACTACAGGACGAATTCACAGACATTCACAGTGGCAG 5195
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 TAATTCAGCTGCTGTGGGGTGTGGACTACAGGACGAATTCACAGACATTCACAGTGGCAG 420

Qy   5196 TTTAATTGAGTTAAGAAGATCTGTGGACAGATGCGCATCAGAGACTTGGAAGAAGTGCAGG 5255
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 TTTAATTGAGTTAAGAAGATCTGTGGACAGATGCGCATCAGAGACTTGGAAGAAGTGCAGG 480

Qy   5256 AATTTGCCGTCTTTCTCATCAAAGGAGAAGGTGAGCTGGTTCGGCGCTGTCACCCCATG 5315
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 AATTTGCCGTCTTTCTCATCAAAGGAGAAGGTGAGCTGGTTCGGCGCTGTCACCCCATG 540

Qy   5316 AGTACATCAACAATGTGGTGACGGACCAGGACATGAGGCTTCAGAGCGGACGGCTTGGTT 5375
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 AGTACATCAACAATGTGGTGACGGACCAGGACATGAGGCTTCAGAGCGGACGGCTTGGTT 600

Qy   5376 GGGAGACTCCAGTTCATTTTTATCACTTCGACTTACAGGAAACCCACTATGGCCAGGTGC 5435
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 GGGAGACTCCAGTTCATTTTTATCACTTCGACTTACAGGAAACCCACTATGGCCAGGTGC 660

Qy   5436 TTCGGGACTACCTGCAAGGCAAGCTGATAGTCAGCATCCAGGCAGAGGCTCTACTTGCCC 5495
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 TTCGGGACTACCTGCAAGGCAAGCTGATAGTCAGCATCCAGGCAGAGGCTCTACTTGCCC 720

Qy   5496 AGTTTGATGCTTTCCAACAGTTTGACAAAACGGGAACTTCTAGTCCTCCATCAGAGCAAG 5555
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 AGTTTGCTGCTTTCCAACAGTTTGACAAAACGGGAACTTCTAGTCCTCCATCAGAGCAAG 780

Qy   5556 AGCTGCTGTCTTATATTCCCAAGCCACTGCAATGGCAGGTGAACACAGCCAACATAAAGA 5615
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db    781 AGCTGCTGTCTTATATTCCCAAGCCACTGCAATGGCAGGTGAACACAGCCAACATAAAGA 840

Qy   5616 GCTTGGTGACCCAGGAGCTGAGGCAGATGCAAGGGTACAGCAAGCAGAGAGCACAGATTG 5675
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    841 GCTTGGTGACCCAGGAGCTGAGGCAGATGCAAGGGTACAGCAAGCAGAGAGCACAGATTG 900

Qy   5676 GCTTTATAGAGAGCACAGCGCAGCTGCCCCTCTTGGCTACACTGTGTACGTAGTGCTGA 5735
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    901 GCTTTATAGAGAGCACAGCGCAGCTGCCCCTCTTGGCTACACTGTGTACGTAGTGCTGA 960

Qy   5736 GAGTGAGTAAGCTGGCCCTCCCTGGACCAGGCCTCCTGGGGCTGAACCGTCAGCACCTGG 5795
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    961 GAGTGAGTAAGCTGGCCCTCCCTGGACCAGGCCTCCTGGGGCTGAACCGTCAGCACCTGG 1020

Qy   5796 TCCTCATGGACCCCAGCTCTCAGGAACTCTGCTGCTCCTGTCATGCTAAAAGACCTGAAGC 5855
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1021 TCCTCATGGACCCCAGCTCTCAGGAACTCTGCTGCTCCTGTCATGCTAAAAGACCTGAAGC 1080

Qy   5856 AGTTCCACCTGCTGAGCCCACTGCAGGAGGACGGGCCCCCTGGCCTAGAACTCAACTATC 5915
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1081 AGTTCCACCTGCTGAGCCCACTGCAGGAGGACGGGCCCCCTGGCCTAGAACTCAACTATC 1140

Qy   5916 GCTCTGTTGACAACCCCCAGACCATCTGGTTGGAGTTGCCACAGGCCAGGAGCTGCAGC 5975
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1141 GCTCTGTTGACAACCCCCAGACCATCTGGTTGGAGTTGCCACAGGCCAGGAGCTGCAGC 1200

Qy   5976 ACACCATCATCTTCCTGCTGGGCAGCATGTCCACTCAGTGGCCAGGTCTCCTCTGAGGAG 6035
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1201 ACACCATCATCTTCCTGCTGGGCAGCATGTCCACTCAGTGGCCAGGTCTCCTCTGAGGAG 1260

Qy   6036 TGGAGATAAGGCAGCGGTCTCTCACTGGGCAGTCTGCCTTAGTCCTGCTCTGAATCCGCT 6095
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1261 TGGAGATAAGGCAGCGGTCTCTCACTGGGCAGTCTGCCTTAGTCCTGCTCTGAATCCGCT 1320

Qy   6096 GCACAACCCCCCACCCCACGTGGAGGCCAAAAGGCAAAGTTGTGTCACCTGGGAGAATAG 6155
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1321 GCACAACCCCCCACCCCACGTGGAGGCCAAAAGGCAAAGTTGTGTCACCTGGGAGAATAG 1380

Qy   6156 GCAGACACATCCCCTCTGGGGTGGACTGCAACAGGAGTTGGGGCATTTGCTGGCTAGCCC 6215
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1381 GCAGACACATCCCCTCTGGGGTGGACTGCAACAGGAGTTGGGGCATTTGCTGGCTAGCCC 1440

Qy   6216 CAGGGAAAATGCCCACCCAGCTCGAAAGCGGCACAAGTAAAACACCCAAGAAAAAAAAA 6275
          ||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| |
Db   1441 CAGGGAAAATGCCCACCCAGCTCGAAAGCGGCACAAGTAAAACACCCAAGAAAAAAATGT 1500

Qy   6276 AAAAAAAAAAAAAAAAAA 6293
               |||||||||||||
Db   1501 GTGTGAAAAAAAAAAAAA 1518


RESULT 10
AX253084
LOCUS       AX253084               3780 bp    DNA     linear   PAT 05-OCT-2001
DEFINITION  Sequence 7 from Patent WO0168866.
ACCESSION   AX253084
VERSION     AX253084.1  GI:15986280
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 3780)
  AUTHORS   Brooks,A.R., Deng,G.G. and Rubanyi,G.M.
  TITLE     Estrogen-regulated unconventional myosin-related protein:
            compositions and methods of use
  JOURNAL   Patent: WO 0168866-A 7 20-SEP 2001;
            SCHERING AKTIENGESELLSCHAFT (DE)
FEATURES             Location/Qualifiers
     source          1. .3780
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /note="Partial DNA sequence for human myosin related
```

protein variant 2 (hMRP2)"
BASE COUNT 838 a 1228 c 1107 g 607 t
ORIGIN

Query Match 23.7%; Score 1490; DB 6; Length 3780;
Best Local Similarity 67.1%; Pred. No. 0;
Matches 2719; Conservative 0; Mismatches 810; Indels 422; Gaps 12;









RESULT 11
AF418289
LOCUS AF418289 5709 bp mRNA linear PRI 06-JUN-2002
DEFINITION Homo sapiens clone 11 myosin XVBP (MYO15B) pseudogene, partial sequence.
ACCESSION AF418289
VERSION AF418289.1 GI:16303812
KEYWORDS .
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 5709)
AUTHORS Boger,E.T., Sellers,J.R. and Friedman,T.B.
TITLE Human myosin XVBP is a transcribed pseudogene
JOURNAL J. Muscle Res. Cell. Motil. 22 (5), 477-483 (2001)
MEDLINE 21960014
PUBMED 11964073
REFERENCE 2 (bases 1 to 5709)
AUTHORS Boger,E.T., Sellers,J.R. and Friedman,T.B.
TITLE Direct Submission
JOURNAL Submitted (13-SEP-2001) Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, 5 Research Court, Rockville, MD 20850, USA
FEATURES Location/Qualifiers
source 1..5709
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="17"
/map="17q24-q25"
/clone="11"

```
                     /tissue_type="stomach"
     gene            <1..>5709
                     /gene="MYO15B"
                     /note="myosin XVBP"
                     /pseudo
BASE COUNT     1041 a   1830 c   2017 g    821 t
ORIGIN

  Query Match             17.8%;  Score 1119.4;  DB 9;  Length 5709;
  Best Local Similarity   75.2%;  Pred. No. 5.8e-250;
  Matches 1490;  Conservative    0;  Mismatches  416;  Indels   71;  Gaps    4;

Qy      685 CCAAGCCCAGCAAGCCATATCTCCAGCGGAGGTCAGCTCTGGGACAGCTGAACACCATTCT 744
            |  ||  |||||||| || |||| |||| || ||||| ||||||||||||||||||||| ||
Db     5811 CCTCAAAGCAAGCGGTACCTCCGGGGGGGGGCAGCTTTGGGACAGCTGAACACCATCCT 5870

Qy      745 CCTAATGGCCCGGCCCCTGCTCCGGAGACGACAGAAGCTACGGTGTGCCCCTGGCCCG-- 802
            ||  |||||| |||||||| || ||| || |||| || | |  || | | | | | |
Db     5871 GCTTGTGGCCCAGCCCCTGCCCCAGAGGCGGCAGAGACTGCAGCTTGGGCGTTGGCAGGG 5930

Qy      803          CACAGCGGGGAGCCCTGGGGGAAAGTGTCAAATATGGAGCTGGGTCGCTTAGA 855
                     |||||  | ||| || || |||| |||  ||||| ||||| ||||| ||
Db     5931 TTGCTATAGCAGCGAAAGGGCCTTGGAGAGAGTGCCAAGCATGGAGCTGGGGGGCTTGGA 5990

Qy      856 GATCCTCAGCCCAGCTGGCTACTCTGCTGGAGAGGGGGGAAGGCCACCAGGCCTTGCTCAC 915
            |||||| ||  |||||||      ||||| ||| ||||||| |||| | || |  ||| |
Db     5991 GATCCCGGCCGAGCTGGCCTCATGCTGAAGACGGGGGAAAGCCATCTGGGACGCCCTGGC 6050

Qy      916 AGCAAGCATCACAGACTCCCTCCCACCTGAGGTCCCCGGCCCCCCCAGCCTGACTCTCCC 975
            |||||||||| |||| ||||| |||||||| || |||||||||||||||||||||||||
Db     6051 TTCGAGCATCTACCGAGTGCCTGCCGCCTGAGGTTCCTGCCCGGCCCCAGCCTGACTCTCCC 6110

Qy      976 TCTAAAACATTGACCAGTTTCCCTTCTCCAGCTTCGTCGCCATCGGCTTTCAGGAACCGTC 1035
            ||||||||||| ||| || |||||||| || ||  ||| | |||||||| | || |
Db     6111 AGCAACACATTGACCTGTTCCCTTTCTCCAGCTTCGTCGCCATCGGCTTTCAGGAACCGTC 6170

Qy     1036 TCTTCCTCGACCAGGGCAGCCACTGGACGAGCCCCTGACGCGGTTAGATGGCGAGAACCC 1095
            ||  | | ||||||||||||||||    ||||||| || | | | ||||| || |||||
Db     6171 CCTTCCCCAGGCCAGGGCAGCCACTGGGCGAAGCCCCTAACCCAGCTGGATGGAGACAACCC 6230

Qy     1096 TAAATAGCTCTGGAGATCAACAGGGTGATGCTGCGGCTCCTGGGGGAAGGATCTCTGCA 1155
            |||||  || ||||| |||||||  ||||||||||||||||||||||||| ||||| |
Db     6231 TAATTAGCTGCCTGGACATCAACAAAGTGATGCTGCGGCTCCTGGGGGACGGATCCCTGGA 6290

Qy     1156 ATTTGGCAAGAGCAGACCATGGGCACGTTCCTCGTGCAGLAGGCCCAGCGACGGCGGG 1215
            | | |||   ||||| ||||||| | | ||| |||| |||||  ||| |  |||| ||
Db     6291 GTTTTGCACACGCACATCATGGGGCATATTTGTGTGCGCAGGGGCAGTGCTGGCCAGG 6350

Qy     1216 AGTTTGAGATGAGCTCTTCAGCGACGCTGGTGGCCCACGTGTGCGCAACCCAGATGAGCA 1275
            |  ||  |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     6351 GCTTCGGAATGAGCTCTTTAGCCAGCTGGTGGCCCAGCTATGGCAGAACCCAGATGAACA 6410

Qy     1276 AAGAATCAGGGTGGCTGGGCCCTAATGGTGATCCTGCTCAGGTTCCTTTGCTCCCACACC 1335
            |||| |||||||||||||||| ||||    |  |||||||| ||||| | ||      ||
Db     6411 GCAGAGCCAGCGTGGCTGGGCCCCCATGGCTGTTTTGCTCAGCGCCTTTCCCCCACTGCC 6470

Qy     1336 TGCCTTGGAGAAGCCACTGCTCAAATTTGTATCTGACCAGGCTCCCAGTGGCATGGCAGC 1395
            ||  ||  |||||||||||||||| || ||  |||||||||||  ||||| ||||||||||
Db     6471 TTCCTAGAGAAGCCACTGCTCAAGTTCGTGTCTGACCAGGCCCCCAGGGCCATGGCAGCC 6530

Qy     1396 CCTCTGCCCAGCACAAGCTGTTAGGTGCCCTGGAGCAGACACCGCTGGCTCCCATGGCTTC 1455
            |||||||||||||||| | || ||| |||||||| | | ||||||    |||  |
Db     6531 CCTCTGCCCAGCACAAGCTGCTGGGGGCCTTGGAGCAGTCGCAGCTGGCCTCGGGGGCCAC 6590

Qy     1456 CAGCTGCCCACCACCACACAACTTGAGTGGAAGGCTGGTTTACGTCGGGGCCGCATGGC 1515
            ||  ||||||| || || || ||||||   ||| || |  || |||||||||||||||||
Db     6591 TTCGGCCCACCCCCCGACCCAGCTGGAGTGGCTGGCCGGATGGCGGCGGGGTCGCATGGC 6650

Qy     1516 GCTGCATCTCTCACATTCAAGGAGGAAAGCTACTCGGCGGAAGTGGAATCCTGGACCAC 1575
            ||  |||||||||| |||| ||||||   ||||||| || || ||||| || ||||||||
Db     6651 GCTGGATGTGTTCACCTTCAGCGAGGAGTGCTACTCGGCCGAGGTGGAGTCTTGGACCAC 6710

Qy     1576 GGGAGAGCAGTTTGCAGGTGGATTCTACAGAGC---------------------------- 1609

Db     6711 CCCCCGGCCAAGGTCCACATCCCCAGGGGGAAGCCTAGGAGAGTA 6755

RESULT 12
```

```
K097896
CUS        AK097896                 2372 bp    mRNA    linear   PRI 15-JUL-2003
EFINITION  Homo sapiens cDNA FLJ40577 fis, clone THYMU2007467, weakly similar
           to Mus musculus non-muscle myosin-15 mRNA
CCESSION   AK097896
ERSION     AK097896.1  GI:21757796
EYWORDS    oligo capping; fis (full insert sequence).
OURCE      Homo sapiens shymus cDNA to mRNA, clone_lib:THYMU
           clone:THYMU2007467.
 ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo
EFERENCE   1
 AUTHORS   Oshima,A., Takahashi-Fujii,A., Tanase,T., Inoue,N., Takeuchi,F.,
           Arita,M., Musashino,K., Yuuki,H., Hara,H., Sugiyama,T., Irie,R.,
           Otsuki,T., Sato,H., Ota,T., Wakamatsu,A., Ishii,S., Yamamoto,T.,
           Isono,Y., Kawai,Hir.Y., Saito,K., Nishikawa,T., Kimura,K.,
           Yamashita,H., Matsuo,K., Nakamura,Y., Sekine,M., Fukuchi,H.,
           Kanda,K., Wagatsuma,M., Murakawa,K., Kanehori,K., Sugiyama,A.,
           Kawakami,B., Suzuki,Y., Sugano,S., Nagahari,K., Masuho,Y., Nagai,K.
           and Isogai,T.
 TITLE     NEDO human cDNA sequencing project
 JOURNAL   Unpublished
EFERENCE   2  (bases 1 to 2372)
 AUTHORS   Isogai,T. and Yamamoto,J.
 TITLE     Direct Submission
 JOURNAL   Submitted (04-NOV-2002) Takao Isogai, FLJ Project(HRI Team); 2-6-7
           Kazusa-Kamatari, Kisarazu, Chiba 292-0812, Japan
           (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
MMENT      NEDO human cDNA sequencing project supported by Ministry of
           Economy, Trade and Industry of Japan; cDNA full insert sequencing:
           Research Association for Biotechnology (RAB), cDNA library
           construction: Helix Research Institute (HRI) (supported by Japan
           Key Technology Center etc.), 5'- & 3'-end one pass sequencing: RAB,
           HRI, and Biotechnology Center, National Institute of Technology and
           Evaluation; clone selection for full insert sequencing: HRI and
           RAB; annotation: HRI and RAB.
EATURES             Location/Qualifiers
     source         1..2372
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="THYMU2007467"
                    /tissue_type="shymus"
                    /clone_lib="THYMU2"
                    /note="cloning vector: pME18SFL3"
SE COUNT      486 a    780 c    715 g    391 t
IGIN

Query Match          17.6%;  Score 1110.6;  DB 9;  Length 2372;
Best Local Similarity   73.3%;  Pred. No. 6.5e-246;
Matches 1502;  Conservative    0;  Mismatches  524;  Indels   27;  Gaps    5;

    2031 TGGTGTACCCAGGTATGGTGCAGGCACCTAGTTACCAGCCAGCTATGATACCCGCACCGA 2090
         |||||||||||||| ||| | |||   |||   |||||||||| ||| | || ||||| |
       1 TGGTGTACCCAGGAATGATTCAGATGCCTGCATACCAGCCAGGCATGGTCCCTGCACCCA 60

    2091 TGCCCGTCATCTTCAGCCATGGGTGCAGTCCCAACCATGCCAGCCATGATGGTGCCACCCC 2150
         ||||| | ||||||| |||||| |||||||  |||||||||||||| ||||||| || |
      61 TGCCCATGATCCCAGCAATGGGCACATCCCTGCCATGCCAGCCATGATGGTGCCCCCGC 120

    2151 AGCCACAGCCTCTGGTGCCCAGTTTGGACTCAAGGCAGCTGGCACTACAGCAGCAAAACT 2210
         |||||| ||      | ||||| ||||  || |||||||||  | ||||||| ||||
     121 AGCCACCGC------TTCCAGCCTGGATGCAGGCAGCTGGCCGTCCAGCAGCAGAACT 174

    2211 TCATCAACTAGCAGGAGGATGATTCTGGGCGAGCAGATGACACCCAGGCCATGAGCCTGT 2270
         | ||| | ||||||||  | || ||||| ||||||||||  ||||||||||  |||||
     175 TTATCCAGCAGCAGGGCCTAATCCTGGCCCAGCAGATGACAGCCCAGGCCATGTCCCTGT 234

    2271 CCCTGGAGCAGCAGAATCAGAGACAGCAGCAGCAAGCTCAGACCTCTGGGGCCACCTCCC 2330
         |||||||||||||  |||   |  ||||| || |||| | |||  | ||||  | ||||
     235 CCCTGGAGCAGCAGACGCAGCAGCGGCAGCAGGGCTCGGGCCTCCGAGGCTGCGTCCC 294

    2331 AGCCTCCAGCCTCAACCACTGTTCCCAAGGCCAAGAAGCCTCCTGGCCCCCAAGAGAAGC 2390
```

```
Qy    2331 CAGAGAGTAACCTAGAGCCTTCCGGGTGTTGGCTTGAGAGAGACACCCAGAGGAAGA 2390
           || || || |||| |   |  |||||  || |||  ||| | |||| |||
Db     355 CACAGCGTGACCTGGGATCAGAGGGTGGTGCTGAG---GGAGACTCTGAGGAGGCTG 411

Qy    2391 AAAGCAAGCCTCAGCGCCCAAGAGCTTCCAACAGAAACCGGACCTATTCCAAGAGATGG 2450
           || || ||| | |  |||||||||||||| |||||||| ||||||||||| ||||
Db     412 AAGACAGGCCCTATCAGCCCAAGAGCTTCCAGCAGAAACGGAACTATTTCCAGAGGATGG 471

Qy    2451 GGCAAGATCCGATCAGAGTGAAGACGGTGAAACCTCCAGCCAAGGTTCAGATCCCCAAG 2510
           ||||    | ||||| |||| |||| ||| || || |||||||| || ||||||| |
Db     472 GGCAGCACAGATCACAGTGAGGAGCGATGAAGCCCCGGCCAAGGTCACATCCCCAG 531

Qy    2511 AGGAGATGGAGGAGAGGGAGGAGGAGGAGGATGAGAGCGGGAGTTGTCCTCTCTCTC 2570
           |||    | |||| |||||||||||||| |||    | |||  ,    |
Db     532 GGGAAGGGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGCAGGAGCAGCAAGAAG 591

Qy    2571 CCCCTCCCCCGGTTGTGAAGAAGCCGCTGAAGGTAAGTACCCCAAAGTCCTAAAGGAAG 2630
           |  | | ||| | ||| |  |||  |||| | |||| |  | | |  |
Db     592 TGGAAACAAGAGCAGTGCCTCCCTC---CTCCTCCCCCCATCGTGAAGAAGCCAT 646

Qy    2631 ATGAGGCAGAGCCCGCCCAGGAGGAAGTACGACCCAGGGCGAGGATCCCCCGGTGCATA 2690
           || ||  ||| | |  | | | |  ||| ||  ||  |
Db     647 TGAAGCAAGGTGGGGCCAAAGCTCCAAAAGAGGCTGAGGCTGAGCCAGCCAAGGAGACAG 705

Qy    2691 GCTCCAACTCCGCACCTCAGCACCCCAAACCCAGCAGGGTACCCCCAGTGCAGAGCTCCA 2750
           |||  |  ||  |  ||  |  |||||  |||  |  |  |||  |  |||  |||
Db     706 CGGCCAAGGGCCATGGCAAAGGCAGCCAAAGCAGAGGGACTGTGGTGCCCAGCTCAG 765

Qy    2751 ACTCCCACCCTCAGCCCCAAGCCAGCAGGAAATCCGAAATATCATCCGAATGTACC 2810
           |||||  ||  | ||  |||||||||||||||  | ||||||||| |||||
Db     766 ACTCCAAGCCCAAGCCGCAGAACCAGAAGGAAATCCGAAATATCATCCGAATGTACC 825

Qy    2811 AGAGCCGTCCAGGGCCTGTGGCTGTGCCCCATACAACCCACCAGCCCCATCAAAACCTTCC 2870
           |||||| || || || ||| |||||||||| || ||  |||||| |||| |||| |
Db     826 AGAGCCGCCCCGCCCCCGTGCCTGCCCCCGCAGCCACCCAGGCCCCCAAACCTTCC 885

Qy    2871 AGAAGAAAAATGAACCCTAAGGATGAGGCTTTGGCTAAGTTAGGGATAAATGCGCCCAC 2930
           || |||||  |||| |||| |||| | | || | || | |  | |  |||||
Db     886 TGAGGAAAATGGACCCCAAGGACGAGGCTCTGGCCAAGCTGGGTATCAACGGTGCCCACT 945

Qy    2931 TGCCCCTATGGA---CATGGCCTAACCAAGGGAAGAGCTCCTCCACCGGCTGAGTTCCTC 2987
           | |||   |||      || || | || ||| ||| || | || || |||| | ||||
Db     946 CGTCCCCGGCCGATGCTGTCCCCCAGCCCAGGAAAGGGCCCCCCCGCAGTTGTGGCTCCTC 1005

Qy    3048 GACCTAAGGCTCGACCTGGTCTGGAGCCTCCCCTATCCTACCAGAAAAGCAGGGACCCCT 3107
           |||| |||||  |  |  |||| ||| ||    |||||| ||||||||||||| ||||
Db    1006 GACCCAAGGCCCCGCTACAGCTTGGGCCCTCTAGCTCCACCAAGGAAAAGCCGGGGCCCC 1065

Qy    3108 TTCGGGACTTGTTTGGCCCATGTAGTCCAAACCCACCTACAGCTCCAGCACCCCCGCCTC 3167
           ||| |||| |||||||||           || |  |||| || |  |||||| ||||
Db    1066 TTCTGGACCTGTTTGGCCAG----------AAGCTGCCTATTGCCCACACACCCCCACCTC 1116

Qy    3168 CACCAGCACTCCCACCGCCTCTGTCTGGGGAGCCCAAGACCCCTCAGTGGAGTCTCATG 3227
           |||||| |  |||| |||||| | | ||| ||    |||| |||| '|| || | |
Db    1117 CACCAGTGCCACCACTGCCTCTGCCCGAGGAGCCCAGGACCCTTCAGAGAGGTCGTT 1176

Qy    3228 CCTTGACAGAGCCCATGGAGGACAAGAACATCTCCACAAAGCTCCTTGTGCCCTCTGAA 3287
           |||||| |||| |||||||| ||    ||||||  |||| || | |||||||||| |
Db    1177 GCTTGACACAGCCGTGGAGGAGCAGGGGGTCTCCACCAGATACTCGCGCCCTCTGGCA 1236

Qy    3288 GTGTGTGCTTCTCCTATGCCAATGCACCCTGGAAGTTGTTCTTACGCAAGGAGGTGTTCT 3347
           | |||||||||||||  ||    ||||||||||||||| ||||||||||||||||
Db    1237 GCGTGTGCTTCTCCTACACGGGCACACCCTGGAAGTTGTTCCTACGCAAGGAGGTGTTCT 1296

Qy    3348 ACCCCCGGGAGAACTTCAGCCATCCCTACTACCTGAGCCTCCTCTGTGAGCAGATCCTCC 3407
           |||| |||||||||||| ||||| |||| ||| || |||||| | ||||||||| |
Db    1297 ACCCACGGGAGAACTTCAGCCATCCCTACTACCTGAGCCTCCTCTGTGAGCAGATCCTAC 1356

Qy    3408 GGGACACCTTCACAGAGTCCTGCACCCCGATCTCACAGGATGAGCGGGACAAAATGAAAG 3467
           |||||||||| | |||||||| | |||||| || ||| ||| |||||  ||||||| |
Db    1357 GGGACAGCTTCACAGAGTCCTGCACCCCGATCTCACAGGATGAGCGGGACAAAATGAAAG 1416
```

```
Db   1357 GGGACACTTCTCCCAGCCCTGTATCCGGATTTCCCAGAATGAGCGGCGGAAAATGAAAG 1416

Qy   3468 [illegible]GGAGACTTCGAGGGAGTCTGGAGACCCTTGACATTGTTGAAGACAGTATTA 3527

Db   1417 ACCTGGTGGGAGGCTTGGAGGTGGACCTGGATTCTCTCACCACCACGGAAGACAGGGTCA 1476

Qy   3528 AAAAACGCATCGTGGTGCGCTGCTCAGGACAACTGGGCAATTACTTC[illegible] 3587

Db   1477 AACA[illegible]CATCGTGGT[illegible]GGGACAATGGGGCAATTACT[illegible] 1536

Qy   3588 CA[illegible]GGCTGAGAGT[illegible]AGCGATGTACAGCTGCTGGGTGTGTCTCACGGGGGACTGC 3647

Db   1537 CT[illegible]TCGGGCGGGAGTGGCAGCGACGTGCAGCTGTTAGCCGTGTCCCACGTGGGCTGC 1596

Qy   3648 [illegible]GAAG[illegible]GACCAAAGG[illegible]GGAC[illegible]AGCTGAAGACACTCTGTT 3707

Db   1597 GA[illegible]TCAAGGTGACCCAAGG[illegible]GACCAGCTGAAGATTCTCTGCT 1656

Qy   3708 CCTACAGCTATGCTGAAGTCCTGACCGTGCAGTGCAGGGGCAGATCCACCCTGGAGCTGT 3767

Db   1657 CATACAGCTTCGCGGAGGTGCTGGCTGTGGAATGCCGGGGCGGCTCCACCCTGGAGCTGT 1716

Qy   3768 CC[illegible]AAGAA[illegible]GATA[illegible]TAGTCT[illegible]AGG[illegible]TATTAAG[illegible]ATGG 3827

Db   1717 CA[illegible]TGAAGAGCCAGCAG[illegible]ACACAGCCCGGGCAAGGGCCATCGAGGCGCTGC 1776

Qy   3828 TGGATCTATTTCTGAGTGAACTCAGGAAGGACTCCGGCTATGTCATCGCCCTGCGCAGCT 3887

Db   1777 TTGAGCTATTCCTGAACGAGCTTAAGAAGGACTCCGGCTATGTCATCGCCCTGCGCAGCT 1836

Qy   3888 ACAT[illegible]ACGATGACAATAGCCTCCTCAGTTTCCACCCTGCCCACCTCATTAGGTTACTGC 3947

Db   1837 ACAT[illegible]ACTCAGAAC[illegible]TGC[illegible]ACCCTGGGACCTCATCAAGCTGCTGC 1896

Qy   3948 [illegible]GGAACTCAGG[illegible]AGT[illegible]GGACTTTT 4007

Db   1897 [illegible]GGAG[illegible]AGGCTGGTAGTTTT[illegible]GTT[illegible]GGAC[illegible] 1956

Qy   4008 TT[illegible]GATGACGTGGTGCAGCCAGCTGCTGCCCGGACC[illegible]GGGAAAGA 4067

Db   1957 TTCCTGCCGACATAGTGCAGCCGGCTGCCGCTCCCGACTTT[illegible]CAAGGAGCAGA 2016

Qy   4068 GAAACAGCTGGCA 4080

Db   2017 GGAGTGGCTGGCA 2029
```

RESULT 1[illegible]
BC027875
LOCUS BC027875 2347 bp mRNA linear PRI 01-MAY-2002
DEFINITION Homo sapiens, hypothetical protein FLJ22686, clone MGC:34148
IMAGE:5205535, mRNA, complete cds.
ACCESSION BC027875
VERSION BC027875.1 GI:20379900
KEYWORDS MGC.
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2347)
AUTHORS Strausberg,R.
TITLE Direct Submission
JOURNAL Submitted (08-APR-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: National Institutes of Health Intramural
Sequencing Center (NISC),
Gaithersburg, Maryland;
Web site: http://www.nisc.nih.gov/
Contact: nisc_mgc@nhgri.nih.gov
Akhter,N., Ayele,K., Beckstrom-Sternberg,S.M., Benjamin,B.,
Blakesley,R.W., Bouffard,G.G., Breen,K., Brinkley,C., Brooks,S.,
Dietrich,N.L., Granite,S., Guan,X., Gupta,J., Haghighi,P.,
Hansen,N., Ho,S.-L., Karlins,E., Laric,P., Legaspi,R., Maduro,Q.L.,
Masiello,C., Maskeri,B., Mastrian,S.D., McCloskey,J.C., McDowell,J.,
Pearson,R., Stantripop,S., Thomas,P.J., Touchman,J.W., Tsurgeon,C.,
Vogt,J.L., Walker,M.A., Wetherby,K.D., Wiggins,L., Young,A.,
Zhang,L.-H. and Green,E.D.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 49 Row: g Column: 24
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: [illegible].

```
FEATURES             Location/Qualifiers
     source          1..2347
                     /organism="Homo sapiens"
                     /db_xref="LocusID:80022"
                     /db_xref="taxon:9606"
                     /clone="MGC:34148 IMAGE:5205535"
                     /tissue_type="Lung, Spleen, fetal, pooled"
                     /clone_lib="NIH_MGC_122"
                     /lab_host="DH10B"
                     /note="Vector: pCMV SPORT6"
     CDS             418..1881
                     /codon_start=1
                     /product="hypothetical protein FLJ22686"
                     /protein_id="AAH27875.1"
                     /db_xref="GI:20379901"
                     /translation="MQEFARRYFRRS[illegible]
                     [illegible]
                     QVTGHPRPEHCTRGWSFLSLLTGFFPPSTFLMPYLTKFLQDSGPSQELARSQ[illegible]
                     [illegible]
                     MGITEPQEVQEFALFLIKEESQLVFIL[illegible]
                     [illegible]
                     KQLQRQVNIA[illegible]
                     ALSGF[illegible]
                     DNPQTIWFELPQAQELLYTTVFLIDSSAS[illegible]TEWRSIN"
BASE COUNT      574 a    719 c    654 g    400 t
ORIGIN

  Query Match             14.9%;  Score 936.8;  DB 5;  Length 2347;
  Best Local Similarity   74.0%;  Pred. No. 2.3e-[illegible];
  Matches 1275;  Conservative    0;  Mismatches  427;  Indels  [illegible];  Gaps  [illegible];

Qy       4294 TGGTACTTAGTTCAGTGTC[illegible]ATAGAGGATGCTTAATAAATAA[illegible] 4353

Db        146 TGGTACTTAGTTCAAGGCTGCCCCAGCAGATGCTTAATAAACA[illegible] 205

Qy       4353 TTTCTGGTGTCACTCCC[illegible]AAT[illegible]TGAGACTGACTA 4412

Db        206 CTTCTGGTCTTGCTCCTTGGTGTCTGGCTGGGGAGGGA[illegible] 256

Qy       4413 TT[illegible]TAGAT[illegible]AAA[illegible] 4472

Db        257 AGGACCCCTGGGACAGGGCACTGGACACT[illegible] 316

Qy       4473 GCCCCACCCATCCCAGGAAACAAGAACCCAGTGAAGACTGGAGG[illegible]TTTACAA 4532

Db        317 [illegible] 376

Qy       4533 CCTACAGCT---CTTTGTCTGCCCGACCCCCACAACTACACCATGCAGGAATTTCC[illegible] 4589

Db        377 CTGTGGCCTATGCCTTTCTGCCCGACTCC[illegible] 436

Qy       4590 G[illegible]ATTCCGGAAGCCTCATA[illegible] 4649

Db        437 GTTACTTCGGGAGGTC[illegible]AGGCCTTCCTG[illegible] 496
```



```
Db    1571 GGGTGCTGCGAGTGAGCATGCAGGCCTGTCCGGACCCACTCTCCTGGGGCTCAACCCCC 1630

Qy    5787 AGCACCTGGTCCTCATGGACCCCAGCTCTCAGGAACTCTGCTGCTCTGCATGCTAAAAG 5846

Db    1631 AGCATCTCATCCTCATGGACCCCAGCTCCCAGAGCCCTACTCCCATCTCCTGAATA 1690

Qy    5847 ACCTGAAGCAGTTCCACCTGCTGAGCCCACTGCAGGAGCAGCCCCTCCCTAGAAC 5906

Db    1691 GCCTGCAGCCCTCCACCTGCTAAGCCTCTTGAGCAACAAGCCCCTCCTTGAAG 1750

Qy    5907 TCAACTATGGCTCTGTTGACAACCCCCAGACCATCTGCTTGGAGTTGCCACAGCCCAGG 5966

Db    1751 TCAACTATGGCTCAGCTGACAACCCCCAGACCATCTGCTTTGAGTCGCCACAGCCCAGG 1810

Qy    5967 AGCTGCAGCACACCATCATCTTCCTGCTGGGCAGCATGTCCACT 6010

Db    1811 AGCTGCTATACACCACTGTCTTCCTGATAGACAGCAGTGCCTCT 1854
```

RESULT 14
AK026339
LOCUS AK026339 1891 bp mRNA linear PRI 27-JAN-2003
DEFINITION Homo sapiens cDNA: FLJ22686 fis, clone HSI10987.
ACCESSION AK026339
VERSION AK026339.1 GI:10439173
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens human small intestine cDNA to mRNA, clone_lib:HSI clone:HSI10987.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Watanabe,K., Kumagai,A., Itakura,S., Yamaraki,M., Tashiro,H., Ota,T., Suzuki,Y., Obayashi,M., Nishi,T., Shibahara,T., Tanaka,T., Nakamura,Y., Isogai,T. and Sugano,S.
TITLE NEDO human cDNA sequencing project
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1891)
AUTHORS Sugano,S., Suzuki,Y., Ota,T., Obayashi,M., Nishi,T., Isogai,T., Shibahara,T., Tanaka,T. and Nakamura,Y.
TITLE Direct Submission
JOURNAL Submitted (29-AUG-2000) Sumio Sugano, Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure Analysis, Human Genome Center, Shirokane dai, 4-6-1, Minato-ku, Tokyo 108-8639, Japan (E-mail:cdna1@ims.u-tokyo.ac.jp, Tel:81-3-5449-5286, Fax:81-3-5449-5416)
COMMENT NEDO human cDNA sequencing project supported by Ministry of International Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing: Department of Virology and Human Genome Center, Institute of Medical Science, University of Tokyo (partly supported by Science and Technology Agency).

```
FEATURES             Location/Qualifiers
     source          1..1891
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="HSI10987"
                     /tissue_type="human small intestine"
                     /clone_lib="HSI"
                     /note="cloning vector pME18SFL3"
     CDS             29..1492
                     /note="unnamed protein product"
                     /codon_start=1
                     /protein_id="BAB15453.1"
                     /db_xref="GI:10439174"
                     /translation="MQRFAPPYFPRSQALLGQTDGGAAGKDTDSLVQVTKAPIQESLL
                     SLSLDVSKLAVASFLALMKFMGDQSKPPGKDEMMELYELLELQQQEKLMEIYCQVIK
                     QVTGHPRPEHCTRGWSFLSLLTGFFPPSTPLMPYLTKFIQDSGPSQFIAPSSQEHLQR
                     TVFYGGEFFMDPPGEMFAFLPGQAIFLLLIHLPSGVCKRTNIQTFTVAAEYQHLLAQ
                     MGITEPQEVQEFALFLIKEKSQLVPPLQPAECLNSVVVPQDVSLHSPRILHWETPLHFD
                     NSTYISTHYSQVLWDYLQGFLPVSAKADAQLAPLAALQHLSKANRNTPSGQDLLAYVP
```



```
                     KQLQPQVNTASIPNLMQQH PPLPGHSPQPAQISPIPAMSQLPLPGYTVYGVLRVSMQ
                     ALGSPILLSLRNAQELLLM  PSQLVTPALPSLQPLHLLSPLLEPGIPSLSVVSGLA
                     DNPQTIWPELPQAQELLYTTVPLIDSSAGCTEWPGIN"
BASE COUNT      454 a    595 c    536 g    306 t
ORIGIN

  Query Match           13.9%;  Score 872.6;  DB 9;  Length 1891;
  Best Local Similarity   76.2%;  Pred. No. 2.1e-102;
  Matches 2115;  Conservative    0;  Mismatches  339;  Indels    9;  Gaps    3;
```



```
RESULT 15
AF418288
LOCUS       AF418288               5424 bp    mRNA    linear   PRI 
DEFINITION  Homo sapiens clone 9 myosin XVBP (MYO15B  pseudogene, partial
            sequence.
ACCESSION   AF418288
VERSION     AF418288.1  GI:16903811
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 5424)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Human myosin XVBP is a transcribed pseudogene
  JOURNAL   J. Muscle Res. Cell. Motil. 22 (5), 477-485 (2001)
  MEDLINE   21966014
   PUBMED   11964073
REFERENCE   2  (bases 1 to 5424)
  AUTHORS   Boger,E.T., Sellers,J.R. and Friedman,T.B.
  TITLE     Direct Submission
  JOURNAL   Submitted (13 SEP 2001) Laboratory of Molecular Genetics, National
            Institute on Deafness and Other Communication Disorders, National
            Court, Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..5424
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /map="17q24-q25"
                     /clone="9"
                     /tissue_type="kidney"
     gene            <1..>5424
                     /gene="MYO15B"
                     /note="myosin XVBP"
```


/pseudo
ASE COUNT 966 a 1732 c 1930 g 796 t
RIGIN
Query Match 13.7%; Score 861; DB 9; Length 5424;
Best Local Similarity 69.8%; Pred. No. 1 1e-189;
Matches 1421; Conservative 0; Mismatches 460; Indels 149; Gaps 12;


Search completed: January 9, 2003, 19.47.11

Job Time : 15088 Secs

GenCore version 5.1.3


```
OM nucleic - nucleic search, using sw model

Run on:            January 9, 2003, 02:40:16 ; Search time 1034.91 Seconds
                                          (without alignments)
                                          1294.449 Million cell updates/sec

Title:             US-09-803-126-2
Perfect score:     6293
Sequence:          1 [illegible] ..... aaaaaaaaaaaaaaaaaa 6293

Scoring table:     IDENTITY_NUC
                   Gapop 10.0 , Gapext 1.0

Searched:          2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters:      437478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing:   Minimum Match 0%
                   Maximum Match 100%
                   Listing first 45 summaries

Database :         N_Geneseq_101002.*
                   1:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
                   2:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
                   3:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
                   4:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
                   5:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
                   6:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
                   7:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
                   8:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
                   9:  /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
                   10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
                   11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
                   12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
                   13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
                   14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
                   15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
                   16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
                   17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
                   18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
                   19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
                   20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
                   21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
                   22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
                   23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
                   24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	6293	100.0	6293	22	AAS13819	cDNA #1 encoding m
	2	4352	69.2	4375	22	AAS13820	cDNA #2 encoding m
	3	1787.6	28.4	4174	22	AAS13821	DNA encoding human
	4	1490	23.7	3780	22	AAS13823	DNA encoding human
	5	913	14.5	1960	24	ABK35127	Human cDNA encodin
	6	707.2	11.2	1346	22	AAS33274	DNA encoding human
	7	[illegible]	11.[illegible]	[illegible]	[illegible]	AAZ[illegible]	Human transmembran
	8	628.8	10.0	1044	22	AAD07791	Human secreted pro
	9	626.4	10.0	1268	23	ABK43544	DNA encoding novel
	10	621.2	9.9	1247	22	AAC27110	cDNA encoding nove
	11	621.2	9.9	1247	23	ABK43853	DNA encoding novel
	12	470.2	7.5	926	22	AAD07777	Human secreted pro
c	13	166.2	2.6	24757	22	AAS[illegible]	DNA encoding novel
	14	166.2	2.6	24757	22	AAS33481	DNA encoding human
	15	97.6	1.6	[illegible]	22	AAS33[illegible]	DNA encoding human
c	16	94.4	1.5	566	22	ABA62139	Human foetal liver
c	17	94.4	1.5	566	22	ABA[illegible]	Probe #8013 for ge
c	18	94.4	1.5	566	22	AAK10458	Human brain expres
c	19	94.4	1.5	566	22	AAK[illegible]	Human bone marrow
c	20	94.4	1.5	566	22	AAI42087	Probe #10773 used
c	21	94.4	1.5	566	24	ABS10413	Human genome deriv
c	22	92.2	1.5	233	22	ABA74633	Human foetal liver
c	23	92.2	1.5	233	22	ABA[illegible]	Probe #[illegible] for g
c	24	92.2	1.5	233	22	AAK23104	Human brain expres
c	25	92.2	1.5	233	22	AAK49270	Human bone marrow
c	26	92.2	1.5	233	22	AAI55120	Probe #[illegible] used
c	27	92.2	1.5	233	24	ABS22813	Human genome deriv
c	28	89.4	1.4	526	22	ABA60390	Human foetal liver
c	29	89.4	1.4	526	22	ABA28621	Probe #7087 for ge
c	30	89.4	1.4	526	22	AAK[illegible]	Human brain expres
c	31	89.4	1.4	526	22	AAK34556	Human bone marrow
c	32	89.4	1.4	526	22	AAI40274	Probe #8960 used t
c	33	89.4	1.4	526	24	ABS09192	Human genome deriv
c	34	75.2	1.2	170	22	ABA72929	Human foetal liver
c	35	75.2	1.2	170	22	ABA[illegible]	Probe #16964 for g
c	36	75.2	1.2	170	22	AAK21359	Human brain expres
c	37	75.2	1.2	170	22	AAK47502	Human bone marrow
c	38	75.2	1.2	170	22	AAI53353	Probe #22039 used
c	39	75.2	1.2	170	24	ABS21624	Human genome-deriv
	40	[illegible]	[illegible]	[illegible]	[illegible]	AA[illegible]	DNA encoding novel
	41	64.6	1.0	[illegible]	24	ABN[illegible]	Novel human coding
	42	64.2	1.0	1951	23	ABL04085	Drosophila melanog
	43	64.2	1.0	4966	23	ABL[illegible]	Drosophila melanog
	44	61.4	1.0	1030	23	AAS[illegible]	DNA encoding novel
	45	[illegible]	1.0	6733	23	ABL[illegible]	Drosophila melanog

ALIGNMENTS

```
RESULT 1
AAS13819
ID   AAS13819 standard; cDNA; 6293 BP.
XX
AC   AAS13819;
XX
DT   19-DEC-2001  (first entry)
XX
DE   cDNA #1 encoding mouse myosin related protein, mMRP.
XX
KW   Mouse; oestrogen-regulated unconventional myosin related protein; MRP;
KW   infertility; antiatherosclerotic; osteopathic; neuroprotective; nootropic;
KW   antiparkinsonian; cytostatic; oestrogen receptor; atherosclerosis;
KW   osteoporosis; breast cancer; cardiovascular disease; deafness; ss;
KW   Alzheimer's disease; Parkinson's disease; chromosome 11; immunogenic.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   CDS             125..4138
FT                   /*tag=  a
FT                   /product= "mMRP"
FT                   /note= "Oestrogen-regulated unconventional myosin-
FT                          related protein"
XX
PN   WO200168866-A2.
XX
PD   20-SEP-2001.
XX
PF   12-MAR-2001; 2001WO-US08060.
XX
PR   10-MAR-2000; 2000US-188498P.
```

PR [illegible] MAR 2001; 2001US-0803126.
XX
PA [illegible] SCHERING AG.
XX
PI Brosius AP, Dunn GG, Rubanyi GM;
XX
DR WPI; 2001-402747/68.
DR P-PSDB; AAU07499.
XX
PT Novel oestrogen-regulated unconventional myosin-related protein and
PT polynucleotide for modulating effects of oestrogen in mammalian cells to
PT treat, prevent atherosclerosis, breast cancer and osteoporosis -
XX
PS Claim 4; Fig 2; 108pp; English.
XX
CC The invention relates to an isolated oestrogen-regulated unconventional
CC myosin-related protein (MRP). Modulating MRP is useful for modulating the
CC effects of oestrogen mediated by oestrogen receptor alpha or beta in a
CC mammalian cell. When the level of expression or activity of MRP is
CC increased, the development of atherosclerosis or osteoporosis is
CC inhibited and when the level is decreased the development of breast
CC cancer is inhibited in the mammal. Nucleic acid (I) encoding MRP is
CC useful for detecting the presence of oestrogen signaling in a mammalian
CC cell, by detecting the expression or activity of MRP or the level of MRP
CC mRNA in the cell. The presence of oestrogen signaling is used to
CC determine the responsiveness of the cell to the oestrogen or the tissue-
CC specific distribution of oestrogen signaling in a mammal. MRP is useful
CC as a marker gene for the investigation of tissue-specific and oestrogen
CC receptor specific ligands such as oestrogen receptor antagonists and
CC agonists. Modulators, recombinant forms, derivatives, variants or
CC fragments of MRP are useful for enhancing or inhibiting oestrogen
CC signaling in cells and for treatment of breast cancer or other cancers
CC and for preventing or treating wide variety of oestrogen-related
CC diseases, including osteoporosis, cardiovascular diseases, Alzheimer's
CC disease or Parkinson's disease. Modulation of MRP gene is also useful for
CC prevention and/or treating hearing loss and deafness. MRP polypeptides
CC are useful for generating monoclonal and polyclonal antibodies useful for
CC identifying oestrogen responsive cells, particularly cells responsive to
CC oestrogen through an oestrogen receptor alpha or beta, to identify
CC alleles, interspecies homologues and polymorphic variants and in
CC immunoassays to detect MRP. The present sequence represents the coding
CC sequence of mouse MRP variant #1 as described in the invention.
XX
SQ Sequence 6293 BP; 1433 A; 1917 C; 1733 G; 1210 T; 0 other;

Query Match 100.0%; Score 6293; DB 22; Length 6293;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 6293; Conservative 0; Mismatches 0; Indels 0; Gaps 0;











```
b   5871 ACTCTGCTGCTCTCTCATGCTAAAAGACCTGAAGCAGTTCCACCTGCTGAGCCCACTGCA 5930

y   5881 GGAGGACGGGCCCCCTGGCCTAGAACTCAACTATGGCTCTGTTGACAACCCCCAGACCAT 5940
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   5881 GGAGGACGGGCCCCCTGGCCTAGAACTCAACTATGGCTCTGTTGACAACCCCCAGACCAT 5940

y   5941 CTGGTTGGAGTTGCCACAGGCCCAGGAGCTGCAGCACACCATCATCTTCCTGCTGGGCAG 6000
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   5941 CTGGTTGGAGTTGCCACAGGCCCAGGAGCTGCAGCACACCATCATCTTCCTGCTGGGCAG 6000

y   6001 CATGTCCACTCAGTGGCCAGGTCTCTTCTGAGGAGTCTAGATAAGGCAGCGGTCTCTCAC 6060
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   6001 CATGTCCACTCAGTGGCCAGGTCTCTTCTGAGGAGTCTAGATAAGGCAGCGGTCTCTCAC 6060

y   6061 TGGGCAGTCTGGCTTTAGTCCTGCTCTGAAACCGCTGCACAACCCCCACCCCACGTGGAG 6120
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   6061 TGGGCAGTCTGGCTTTAGTCCTGCTCTGAAACCGCTGCACAACCCCCACCCCACGTGGAG 6120

y   6121 GCCAAAAGGCAAAGTTGTGTCACCTGGGAGAATAGGCAGACACATCCCCTCTGGGGTGGA 6180
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   6121 GCCAAAAGGCAAAGTTGTGTCACCTGGGAGAATAGGCAGACACATCCCCTCTGGGGTGGA 6180

y   6181 CTGCAACAGGAGTTGGGGCATTTGCTGGCTAGCCCCAGGGAAAATGCCCACCCAGCTCGA 6240
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   6181 CTGCAACAGGAGTTGGGGCATTTGCTGGCTAGCCCCAGGGAAAATGCCCACCCAGCTCGA 6240

y   6241 AAGCGGCACAAGTAAAACACCCAAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 6299
         ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
b   6241 AAGCGGCACAAGTAAAACACCCAAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 6293


ESULT 2
AS13820
D   AAS13820 standard; cDNA; 4375 BP.
X
C   AAS13820;
X
T   18-DEC-2001 (first entry)
X
E   cDNA #2 encoding mouse myosin related protein, mMRP.
X
W   Mouse; oestrogen regulated unconventional myosin-related protein, MRP,
W   auditory; antiatherosclerotic; osteopathic; neuroprotective; nootropic;
W   antiparkinsonian; cytostatic; oestrogen receptor; atherosclerosis;
W   osteoporosis, breast cancer; cardiovascular disease; deafness; ss;
W   Alzheimer's disease, Parkinson's disease, chromosome 11; immunogenic
X
S   Mus sp.
X
H   Key             Location/Qualifiers
T   CDS             125..4138
T                   /*tag= a
T                   /product= "mMRP"
T                   /note= "Oestrogen-regulated unconventional myosin-
T                         related protein"
X
N   WO200168866-A2.
X
D   20-SEP-2001.
X
F   12-MAR-2001; 2001WO-US08060.
X
R   10-MAR-2000; 2000US-188488P.
R   09-MAR-2001; 2001US-0803126.
X
A   (SCHD ) SCHERING AG.
X
I   Brooks AR, Peng CG, Elkhayl GM.
X
R   WPI; 2001-603747/69.
R   P-PSDB; AAU07399.
X
PT  Novel oestrogen-regulated unconventional myosin-related protein and
PT  polynucleotide for modulating effects of oestrogen in mammalian cells to
PT  treat, prevent atherosclerosis, breast cancer and osteoporosis
XX
PS  Claim 4; Fig 3; 108pp; English.
XX
CC  The invention relates to an isolated oestrogen-regulated unconventional
CC  myosin-related protein (MRP). Modulating MRP is useful for modulating the
CC  effects of oestrogen mediated by oestrogen receptor alpha or beta in a
CC  mammalian cell. When the level of expression or activity of MRP is
CC  increased, the development of atherosclerosis or osteoporosis is
CC  inhibited and when the level is decreased the development of breast
CC  cancer is inhibited in the mammal. Nucleic acid (I) encoding MRP is
CC  useful for detecting the presence of oestrogen signaling in a mammalian
CC  cell, by detecting the expression or activity of MRP or the level of MRP
CC  mRNA in the cell. The presence of oestrogen signaling is used to
CC  determine the responsiveness of the cell to the oestrogen or the tissue-
CC  specific distribution of oestrogen signaling in a mammal. MRP is useful
CC  as a marker gene for the investigation of tissue-specific and oestrogen
CC  receptor-specific ligands such as oestrogen receptor antagonists and
CC  agonists. Modulators, recombinant forms, derivatives, variants or
CC  fragments of MRP are useful for enhancing or inhibiting oestrogen
CC  signaling in cells and for treatment of breast cancer or other cancers
CC  and for preventing or treating wide variety of oestrogen related
CC  diseases, including osteoporosis, cardiovascular diseases, Alzheimer's
CC  disease or Parkinson's disease. Modulation of MRP gene is also useful for
CC  preventing and/or treating hearing loss and deafness. MRP polypeptides
CC  are useful for generating monoclonal and polyclonal antibodies useful for
CC  identifying oestrogen responsive cells, particularly cells responsive to
CC  oestrogen through an oestrogen receptor alpha or beta, to identify
CC  alleles, interspecies homologues and polymorphic variants and in
CC  immunoassays to detect MRP. The present sequence represents the coding
CC  sequence of mouse MRP variant #2 as described in the invention.
XX
SQ  Sequence 4375 BP; 966 A, 1368 C, 1116 G, 918 T, 7 other;

  Query Match             69.2%;  Score 4352;  DB 22;  Length 4375;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 4352;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 CGCTGGGACTGTCACCTACCAGGTGCACAAGTTCATAAACAGAAACAGAGGCCACCTGGA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CGCTGGGACTGTCACCTACCAGGTGCACAAGTTCATAAACAGAAACAGAGGCCACCTGGA 60

Qy     61 CCCCGCTGTGCTGGAGATGCTCAGGCAGAGCCAGCTGCAGGTGACCTAGCCTTCCTTTCA 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CCCCGCTGTGCTGGAGATGCTCAGGCAGAGCCAGCTGCAGGTGACCTAGCCTTCCTTTCA 120

Qy    121 GCTCATGGGCAGCCTGTTCCAAGAAGCAGAGCCCCAGCCTGGGACTGAGCAAAACAAACC 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 GCTCATGGGCAGCCTGTTCCAAGAAGCAGAGCCCCAGCCTGGGACTGAGCAAAACAAACC 180

Qy    181 CACATTGGCCTCTGGATTCCAGCAGACCCTGGGTGACTTGCTAGCTCGGCTAGGCAGCAG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 CACATTGGCCTCTGGATTCCAGCAGACCCTGGGTGACTTGCTAGCTCGGCTAGGCAGCAG 240

Qy    241 GGGCCATGTCTACGTCATCCACTGTCTCAATCCCACCCCTGGAAAGATCCCAGGCCTCTT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 GGGCCATGTCTACGTCATCCACTGTCTCAATCCCACCCCTGGAAAGATCCCAGGCCTCTT 300

Qy    301 GGAGTGGGGCATGTGGCAGAGCAGCTGGTCAGACTGGCATCCTGGAGATCATAGGCAC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 GGAGTGGGGCATGTGGCAGAGCAGCTGGTCAGACTGGCATCCTGGAGATCATAGGCAC 360

Qy    361 CGGGAGTACCCACTTCCCCGTGCGAGTGTCCTTCCAAGTCTTTCTGGCAAGGTTCCATGC 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 CGGGAGTACCCACTTCCCCGTGCGAGTGTCCTTCCAAGTCTTTCTGGCAAGGTTCCATGC 420

Qy    421 CCTGGGGTCAGGGAGACAGAAAGTGCCTCTGACCAGGAGAGGTGTGGTGCCAGCTCTCAG 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 CCTGGGGTCAGGGAGACAGAAAGTGCCTCTGACCAGGAGAGGTGTGGTGCCAGCTCTCAG 480

Qy    481 TGAAGTGCTGGGGGCAGAGTCACCGCTGTATCATCTTGGAGTCACCCAGGTCCTGCTGCA 540
```







Qy 3781 GCAGCTGATACTGCACACAGCCTGGGCGAGGGCCATCAAGGCCATGGTGGATCTATTTCT 3840
Db 3781 GCAGCTGATACTGCACACAGCCTGGGCGAGGGCCATCAAGGCCATGGTGGATCTATTTCT 3840

Qy 3841 GAGTGAACTCAGGAAGGACTCCGGCTATGTCATCGGCCCTGGCGAGCTACATCACCGATGA 3900
Db 3841 GAGTGAACTCAGGAAGGACTCCGGCTATGTCATCGGCCCTGGCGAGCTACATCACCGATGA 3900

Qy 3901 CAATAGCCTCCTCAGTTTCCACCGTGGGGACCTCATTAGGTTACTGCCAGTGACCGCTCT 3960
Db 3901 CAATAGCCTCCTCAGTTTCCACCGTGGGGACCTCATTAGGTTACTGCCAGTGACCGCTCT 3960

Qy 3961 GGAACCAGGCTGGCAGTTCGGTTCTGCCGGGGGCCGCTCCGGACTCTTTCCCGATGACGT 4020
Db 3961 GGAACCAGGCTGGCAGTTCGGTTCTGCCGGGGGCCGCTCCGGACTCTTTCCCGATGACGT 4020

Qy 4021 GGTGCAGCCAGCTGCTGCCCCCCGACCTCTCCTTTTCCCTGGGAAAGAGAAACAGCTGGCA 4080
Db 4021 GGTGCAGCCAGCTGCTGCCCCCGACCTCTCCTTTTCCCTGGGAAAGAGAAACAGCTGGCA 4080

Qy 4081 ACGCAAGAGTAAGCTGGGGCCAGCTCAGGAGGTGAGGAAGACAGAAGAGGTGAAGTGATA 4140
Db 4081 ACGCAAGAGTAAGCTGGGGCCAGCTCAGGAGGTGAGGAAGACAGAAGAGGTGAAGTGATA 4140

Qy 4141 CAGGCCTAACTTGGAGACTGAGAAGGAAAGAGCAGGGTTGCTTCGGGTGTTGTCCACTTC 4200
Db 4141 CAGGCCTAACTTGGAGACTGAGAAGGAAAGAGCAGGGTTGCTTCGGGTGTTGTCCACTTC 4200

Qy 4201 CTGTCCTGGTGGCCAGGGTCAATGTGTTCGTGTCCTTTACCATCTCCTGACTTTTTGCC 4260
Db 4201 CTGTCCTGGTGGCCAGGGTCAATGTGTTCGTGTCCTTTACCATCTCCTGACTTTTTGCC 4260

Qy 4261 ATTTGTGAGACTGTAAGTCACACCCTCTAACTCTGGTACTTAGTTCAGTGTCTCCATAGA 4320
Db 4261 ATTTGTGAGACTGTAAGTCACACCCTCTAACTCTGGTACTTAGTTCAGTGTCTCCATAGA 4320

Qy 4321 GGATGCTTAATAAATAACCTTGGTTTTCCTGG 4352
Db 4321 GGATGCTTAATAAATAACCTTGGTTTTCCTGG 4352

RESULT 3
AAS13821
ID AAS13821 standard, cDNA, 4174 BP.
XX
AC AAS13821;
XX
DT 18-DEC-2001 (first entry)
XX
DE DNA encoding human myosin-related protein, hMRP #1.
XX
KW Human; oestrogen regulated unconventional myosin-related protein; MRP;
KW auditory; antiatherosclerotic, osteopathic; neuroprotective, nootropic;
KW antiparkinsonian, cytostatic; oestrogen receptor, atherosclerosis;
KW osteoporosis; breast cancer; cardiovascular disease; deafness; ss;
KW Alzheimer's disease, Parkinson's disease; chromosome 17q25, immunogenic.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 561..1874
FT /*tag= a
FT /product= "hMRP"
FT /note= "Oestrogen regulated unconventional myosin
FT related protein"
XX
PN WO200168866-A2.
XX
PD 20-SEP-2001.
XX
PF 12-MAR-2001; 2001WO-US08060.
XX
PR 10-MAR-2000; 2000US-188488P.

PR 09-MAR-2001; 2001US-0803126.
XX
PA [redacted] SCHERING AG.
XX
PI Brooks AF, Deng GG, Rubanyi GM;
XX
DR WPI; 2001-602747/68.
DR P-PSDB; AAU07400.
XX
PT Novel oestrogen regulated unconventional myosin related protein and
PT polynucleotide for modulating effects of oestrogen in mammalian cells to
PT treat, prevent atherosclerosis, breast cancer and osteoporosis -
XX
PS Claim 4; Fig 5; 108pp; English.
XX
CC The invention relates to an isolated oestrogen-regulated unconventional
CC myosin related protein (MRP). Modulating MRP is useful for modulating the
CC effects of oestrogen mediated by oestrogen receptor alpha or beta in a
CC mammalian cell. When the level of expression or activity of MRP is
CC increased, the development of atherosclerosis or osteoporosis is
CC inhibited and when the level is decreased the development of breast
CC cancer is inhibited in the mammal. Nucleic acid (I) encoding MRP is
CC useful for detecting the presence of oestrogen signaling in a mammalian
CC cell, by detecting the expression or activity of MRP or the level of MRP
CC mRNA in the cell. The presence of oestrogen signaling is used to
CC determine the responsiveness of the cell to the oestrogen or the tissue-
CC specific distribution of oestrogen signaling in a mammal. MRP is useful
CC as a marker gene for the investigation of tissue-specific and oestrogen
CC receptor specific ligands such as oestrogen receptor antagonists and
CC agonists. Modulators, recombinant forms, derivatives, variants or
CC fragments of MRP are useful for enhancing or inhibiting oestrogen
CC signaling in cells and for treatment of breast cancer or other cancers
CC and for preventing or treating wide variety of oestrogen related
CC diseases, including osteoporosis, cardiovascular diseases, Alzheimer's
CC disease or Parkinson's disease. Modulation of MRP gene is also useful for
CC preventing and/or treating hearing loss and deafness. MRP polypeptides
CC are useful for generating monoclonal and polyclonal antibodies useful for
CC identifying oestrogen responsive cells, particularly cells responsive to
CC oestrogen through an oestrogen receptor alpha or beta, to identify
CC alleles, interspecies homologues and polymorphic variants and in
CC immunoassays to detect MRP. The present sequence represents the coding
CC sequence of human MRP variant #1 as described in the invention.
XX
SQ Sequence 4174 BP; 901 A; 1339 C; 1237 G; 697 T; 0 other;

Query Match 28.4%; Score 1787.6; DB 22; Length 4174;
Best Local Similarity 78.3%; Pred No. 0;
Matches 2[illegible]; Conservative 0; Mismatches 969; Indels 166; Gaps 15;









RESULT 4
AAS13823
ID AAS13823 standard; cDNA; 3780 BP.
XX
AC AAS13823;
XX
DT 18-DEC-2001 (first entry)
XX
DE DNA encoding human myosin related protein, hMRP #2
XX
KW Human; oestrogen regulated unconventional myosin-related protein; MRP;
KW auditory; antiatherosclerotic; osteopathic; neuroprotective; nootropic;
KW antiproliferative, cytostatic, oestrogen receptor, atherosclerosis,
KW osteoporosis; breast cancer; cardiovascular disease; deafness; ss;
KW Alzheimer's disease, Parkinson's disease, chromosome 17p11, immunogenic
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 561..2911
FT /*tag= a
FT /product= "hMRP"
FT /note= "Oestrogen regulated unconventional myosin-
FT related protein"
XX
PN WO200168866-A2.
XX
PD 20-SEP-2001.
XX
PF 12-MAR-2001; 2001WO-US08060.
XX
PR 16-MAR-2000; 2000US-188488P.
PR 09-MAR-2001; 2001US-0803126.
XX
PA (SCHE) SCHERING AG.
XX
PI Brueckner AM, Deng CG, Rubanyi GM;
XX
DR WPI; 2001-602747/68.
DR P-PSDB; AAU07406.
XX
PT Novel oestrogen regulated unconventional myosin related protein and
PT polynucleotide for modulating effects of oestrogen in mammalian cells to
PT treat, prevent atherosclerosis, breast cancer and osteoporosis -
XX
PS Claim 4; Fig 7; 108pp; English.
XX
CC The invention relates to an isolated oestrogen-regulated unconventional
CC myosin related protein (MRP). Modulating MRP is useful for modulating the
CC effects of oestrogen mediated by oestrogen receptor alpha or beta in a
CC mammalian cell. When the level of expression or activity of MRP is
CC increased, the development of atherosclerosis or osteoporosis is
CC inhibited and when the level is decreased the development of breast
CC cancer is inhibited in the mammal. Nucleic acid (I) encoding MRP is
CC useful for detecting the presence of oestrogen signaling in a mammalian
CC cell, by detecting the expression or activity of MRP or the level of MRP
CC mRNA in the cell. The presence of oestrogen signaling is used to
CC determine the responsiveness of the cell to the oestrogen or the tissue-
CC specific distribution of oestrogen signaling in a mamal. MRP is useful
CC as a marker gene for the investigation of tissue specific and receptor
CC receptor-specific ligands such as oestrogen receptor antagonists and
CC agonists. Modulators, recombinant forms, derivatives, variants or
CC fragments of MRP are useful for enhancing or inhibiting oestrogen
CC signaling in cells and for treatment of breast cancer or other cancers
CC and for preventing or treating a wide variety of oestrogen related
CC diseases, including osteoporosis, cardiovascular diseases, Alzheimer's
CC disease or Parkinson's disease. Modulation of MRP gene is also useful for
CC preventing and/or treating hearing loss and deafness. MRP polypeptides
CC are useful for generating monoclonal and polyclonal antibodies useful
CC identifying oestrogen responsive cells, particularly cells responsive to
CC oestrogen through an oestrogen receptor alpha or beta, to identify
CC alleles, interspecies homologues and polymorphic variants and in
CC immunoassays to detect MRP. The present sequence represents the nucleic
CC sequence of human MRP variant #2 as described in the invention.
XX
SQ Sequence 3780 BP; 838 A; 1228 C; 1107 G; 607 T; 0 other;



Query Match 23.7%; Score 1490; 18.2; Length 378;
Best Local Similarity 67.1%; Prod. No. 0;
Matches 2519; Conservative 0; Mismatches 811; Indels 422; Gaps 11;









RESULT 6
ABK34864
ID ABK34864 standard; cDNA; 1960 BP.
XX
AC ABK34864;
XX
DT 04-MAY-2002 (first entry)
XX
DE Human cDNA encoding secreted protein #265.
XX
KW Human; secreted protein; gene; sc; nutritional supplement; haemophilia;
KW viral infection; bacterial infection; fungal infection; diabetes; asthma;
KW autoimmune disorder; rheumatoid arthritis; multiple sclerosis; tumour;
KW autoimmune thyroiditis; allergic reaction; neurodegenerative disease;
KW Alzheimer's disease; Parkinson's disease; liver fibrosis; cancer; ulcer;
KW coagulation disorder; inflammatory disorder; Crohn's disease; incision;
KW tissue regeneration; wound healing; burn; haematopoiesis;
KW myeloid cell deficiency; lymphoid cell deficiency.
XX
OS Homo sapiens.
XX
PN WO200177288 A2.
XX
PD 18-OCT-2001.
XX
PF 29-MAR-2001; 2001WO-US10224.
XX
PR 06-APR-2000; 2000US-195582P.
XX
PA (GEMY) GENETICS INST INC.
XX
PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes JB, Kenney K;
PI Gutierrez F, Graham JR;
XX
DR WPI; 2002-179321/23.
XX
PT Five hundred and ninety two polynucleotides derived from a variety of
PT human tissue sources which encode secreted proteins, useful for
PT treating immune deficiencies and disorders such as autoimmune disorders
PT .
XX
PS Claim 1; Page 202-203; 372pp; English.
XX
CC The invention relates to 592 polynucleotides which have been derived from
CC a variety of human tissue sources and which encode novel secreted
CC proteins. The polynucleotides can be used as probes for the
CC identification and isolation of full length cDNA and genomic DNA. The
CC polynucleotides and proteins can also be used as nutritional supplements.
CC The proteins are useful in the treatment of various immune deficiencies
CC and disorders such as viral infections, bacterial infections, fungal
CC infections, autoimmune disorders (e.g. rheumatoid arthritis, multiple
CC sclerosis, autoimmune thyroiditis and diabetes), and allergic reactions
CC and conditions (e.g. asthma). They are also useful for treating
CC neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's
CC disease), liver fibrosis, coagulation disorders (e.g. haemophilia),
CC inflammatory disorders (e.g. Crohn's disease) and tumours. They are also
CC useful for tissue regeneration, for wound healing and in the treatment of
CC burns, incisions and ulcers. The proteins are also useful for regulating
CC haematopoiesis and for treating myeloid or lymphoid cell deficiencies.
CC Sequences ABK34861-ABK35454 represent polynucleotides of the invention.
XX
SQ Sequence 1960 BP; 433 A; 632 C; 567 G; 328 T; 0 other;



Query Match 14.5%; Score 914; DB 14; Length 1960;
Best Local Similarity 77.5%; Pred. No. 4.4e-192;
Matches 1190; Conservative 0; Mismatches 345; Indels 12; Gaps 4;



```
Qy   5874 CACTGCAGGAGGACGGGGCCCCTGGCCTAGAACTCAACTATGGCTCTGTTGACAACCCCC 5933
          ||| ||||| | ||||||||||||| ||| ||||||||||| | ||||||||||
Db   1435 CTCTGGAGGAGAAGGGGCCCCTGGCCTGGAAGTCAACTATGGCTCAGTTGACAACCCC 1494

Qy   5934 AGACCATTGGTTGGAGTTGCCACAGGCCCAGGAGCTGCAGCACACCATCATCTTCCTGC 5993
          |||||||||||| ||| ||||||||||||||||||||   ||||||   |||||||
Db   1495 AGACCATCTGGTTTGAGCTGCCACAGGCCCAGGAGCTGCTATACACCACTGTCTTCCTGA 1554

Qy   5994 TGGGCAGCATGTCCACT 6010
          | | |||||   || ||
Db   1555 TAGACAGCAGTGCCTCT 1571


RESULT 6
AAS33274
ID   AAS33274 standard; cDNA; 1346 BP.
XX
AC   AAS33274;
XX
DT   04-DEC-2001  (first entry)
XX
DE   DNA encoding human secreted protein, Seq ID No 233.
XX
KW   Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW   rheumatoid arthritis; antiarteriosclerotic; cardiant; vascular;
KW   cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW   cytostatic; Alzheimer's disease; Parkinson's disease; human; cancer;
KW   multiple sclerosis; cancer; hyperproliferative disorder; infection;
KW   Gaucher's disease; neurological disease; cerebrovascular disorder;
KW   thrombosis; wound healing; ss.
XX
OS   Homo sapiens.
XX
PN   WO200155326-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01347.
XX
PR   31 JAN 2000; 2000US-0176065.
XX
PA   (HUMA ) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-451931/48.
DR   P-PSDB; AAU20565.
XX
PT   New nucleic acids and polypeptides, useful for diagnosing, preventing
PT   or treating medical conditions -
XX
PS   Claim 1; SEQ ID NO 233; 753pp; English.
XX
CC   The invention relates to novel isolated nucleic acid molecules (I)
CC   encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC   treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC   goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC   the prevention, treatment and diagnosis of diseases associated with
CC   inappropriate expression of secreted proteins. (I) and complementary
CC   sequences may also be used as DNA probes in diagnostic assays (e.g.
CC   polymerase chain reactions (PCR)) to detect and quantitate the presence
CC   of similar nucleic acid sequences in samples, and so which patients may
CC   be in need of restorative therapy. (II) may also be used as antigens in
CC   the production of antibodies and in assays to identify related
CC   (agonists and antagonists) of the expression and activity of the secreted
CC   proteins. The anti-(II) antibodies and antagonists may also be used to
CC   down regulate expression and activity of (II). The anti-(II) antibodies
CC   may also be used as diagnostic agents for detecting the presence of (II)
CC   in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC   disorders include for example immuno/autoimmune diseases (e.g. HIV
CC   (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC   and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC   melanomas, neoplasms of the breast or liver, Sezary syndrome and
```





RESULT 7
AAZ56716
ID AAZ56716 standard; cDNA; 1476 BP.
XX
AC AAZ56716;
XX
DT 23-MAR-2000 (first entry)
XX
DE Human transmembrane protein HTMPN 13 [illegible] cDNA.
XX
KW Human; transmembrane protein; HTMPN; diagnosis; [illegible] specific;
KW antiproliferative; neuroprotective; immune disorder;
KW reproductive disorder; smooth muscle disorder; neurological disorder;
KW gastrointestinal disorder; developmental disorder;
KW cell proliferative disorder; ss.
XX
OS Homo sapiens.
XX
PN WO9961471 A2.
XX
PD 02-DEC-1999.
XX
PF 28-MAY-1999; 99WO-US011504.
XX
PR 29-MAY-1998; 98US-0087260.
PR 02-JUL-1998; 98US-0091674.
PR 02-OCT-1998; 98US-0102954.
PR 24-NOV-1998; 98US-0109869.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Tang YT, Lal P, Hillman JL, Yue H, Stoeckert KJ, Corley N;
PI Bandman O, Patterson C, Gorodon GA, Kaser MR, Bandman MR;
PI Au Young J;
XX
DR WPI; 2000-072605/06.
DR P-PSDB; AAY57895.
XX
PT Protein, polynucleotide, vectors, host cells and antibodies used to
PT diagnose, treat or prevent immune, reproductive, smooth muscle,
PT neurological, gastrointestinal, developmental and cell proliferative
PT disorders -

X
S Claim 9; Page 189; 229pp; English
X
C AAY56629 *:] AAY56776 [illegible] AAY57827 *:] AAY57955 which represent human
C transmembrane proteins designated HTMPN-1 to HTMPN-79, respectively.
C The transmembrane protein have immunospecific, antiproliferative and
C neuroprotective activities. The human transmembrane proteins,
C polynucleotides encoding them and other compositions and methods from
C the present invention, can be used for the diagnosis, treatment or
C prevention of immune, reproductive, smooth muscle, neurological,
C gastrointestinal, developmental and cell proliferative disorders. The
C HTMPN's can be used to treat or prevent disorders associated with a
C decreased expression or activity of HTMPN.
X
Q Sequence 1476 BP; 477 A; 479 C; 435 G; 285 T; 0 other;

Query Match 11.2%; Score 746.6; DB 21; Length 1476;
Best Local Similarity 79.9%; Pred. No. 2.8e-150;
Matches 880; Conservative 0; Mismatches 234; Indels 13; Gaps 3;

Qy 2946 AAGAATGAGGTTTGGCTAAGTTAGGGATAAATGGCGTCCACTTGCCCCTATCGA---CA 3004
Db 2 AAGGATGAGATTTGTGTCAAGTTGGTATCAAGGTGCCCACTCGTCCCCGCCGATGCTG 61

Qy 3005 TCGCCTAACTAAGGTAAGAGTTTTAGTGGTGTAGTTCCTCGACCTAAGGCTCGACCT 3064
Db 62 TCGCCCAGCCCAGGAAAGGGGCCCGTGAGCTTGGCTCCTCGACCCAAGGCCCCGCTA 121

Qy 3065 CCTCTTGAGCCTTCCCTATCCATCCAGCAAAAGCAGGGACCCCTTCGGGACTTGTTTGGC 3124
Db 122 CAGCTTGGGCCCTTAGCTCTAATAAGGAAAAGTAGGGGCCCTCTCTGGACCTGTTTGGC 181

Qy 3125 CCATGTAGTCCAAACCACCTACAGTTCCAGCAGCCCCGCCTCCACCAGCACTCCCACGG 3184
Db 182 CAGAAGTTGCCTATTGCCCACACACCCCACCTCCACCAGCCCCACCACTG 232

Qy 3185 CCTCCTCTCCGGGAGCCAAACACCTTCAGCAGAAGCTCCATGCCTTGACAGAGCCCATG 3244
Db 233 CCTCCCCCGAGGACCAGGGACCCTTCAGCAGAGCTGCTTGCCTGACACAGCCCGTG 292

Qy 3245 CAGGACAAGAACATTCCCACAAAGTCTTTGTCAGAAGTGCTTCAACCTCTCCTAT 3304
Db 293 CAGGACCAGCCGTCCCCACCAGTACTCCCCGCCAGTGTGCTTCTCCTAC 342

Qy 3305 CCTAACCACCCCTGGAAGTTCTTCCTACCTAAGGACGTCGTCTACCCACCGGGAGAACTTC 3364
Db 343 ACCCCCACCCCCTGGAAGTTCTTCCTACCTAAGGACGTCGTCTACCCACCGGGAGAACTTC 402

Qy 3365 AGTCATCCATACTCCCTCAGTCTCCTCCTCCAGCAGATCCTCGCGGGACACCTTCACAGAG 3424
Db 403 AGCCATCCCTACTACCTGAGTCTCCTCTTCGGACAGATCCTACGGGACACCTTCTCCGAG 462

Qy 3425 TCCTCTAACTACAGTGATGAAGAAGAGCCTGTACAAAATGAAAGGCCTTCTGGGAGACTTG 3484
Db 463 TCCTCTATCCCCGATTTCCCAGAATGAGCCCGGAAAATGAAAGACCTTCTCGGAGGCTTG 522

Qy 3485 GAGGTGAGTCTGGAGACCCTTGACATTGTTGAAGACAGCATCAAAAAATGCATCGTGGTC 3544
Db 523 GAGGTGGACCTGGACTTCTTCAACCACCAGAAGACAGCCTCAAGAAGCCCATCGTGGTG 582

Qy 3545 CCTCTCCCAGAAATGGGCAATTACTTCCCCGCATCTTCCTAGTCTGGGGTGAGAGT 3604
Db 583 CCCCCTCCGGACAATTGCCCAATTACTTCTTCCCCTTCTTTCCTGTCTCGGGCGAGAGT 642

Qy 3605 CCTACCAATGTACAGTTCCCCTCCTCACCGGGACTGCGGCTGCTGAAGGTGACC 3664
Db 643 CCCAGCCACTTCCACTTCTTACCCTCTCCCACCGTGGCTTCGGACTGCTCAAGGTGACC 702

Qy 3665 CAAAGCCCCAGCTTCCACTTGGACCAGCTGAAGAACACTCTGTTCCTACAGCTATGCTGAA 3724
Db 703 CAAGGCCCCCGCCTCCGCCCCAGCCAGCTGAAGATTCTCTGCTCATACAGCTTTGCCGAG 762

Qy 3725 CTCCTACCCCTACAGTCACAGCCACAGTCCACCTGGAGCTGTCCTTGAAGAATGAGCAG 3784
Db 763 CTCCTCCCCCTCCAGCCACAGCCACAGCCCACCTGGAGCTGTCCTTGAAGAGTGAGCAG 822

Qy 3785 CTGATACTGCACACAGCCTGGGCGAGGGCCATCAAGGCCATGGTGGATCTATTTCTGAGT 3844
Db 823 CTGGTGCTGCACACAGCCCGGGCAAGGGCCATCGAGGCCCTGGTGGAGCTATTCCTGAAT 882

Qy 3845 GAACTCAGGAAGGACTCCGGCTATGTCATCGCCCTGCCGCAGCTACATCACCGATGACAAT 3904
Db 883 GAGCTTAAGAAGGACTCCGGCTATGTCATCGCCCTGCCGCAGCTACATCACCTGACAACTGC 942

Qy 3905 AGCCTCCTCAGTTTCCACCGTGGGGACCTCATTAGGTTACTCCAGCCG ACCCCTCTGGA 3962
Db 943 AGCCTCCTCAGCTTCCACCGTGGGGACCTCATCAAGCTCCTCTCCCGCCTCCCA ACCCCTGGA 1002

Qy 3963 ACCAGGCTGGCAGTTCGGTTCTGCCGGGGCCCGCTCCGGACTCTTTCCCGATGACCTGGT 4022
Db 1003 GCCAGGCTGGCAGTTTGGCTCTGCCGGGGCCCGTTCCGGACTCTTTCCTGACGACATAGT 1062

Qy 4023 GCAGCCAGCTGCTGCCCCGACCTCTCCTTTCCCTGGGAAAGACAAACAGCTGGCA 4080
Db 1063 GCAGCCGGCTGCCGCTCCGACTTTTCCTTCTCCAAGGACAAGAGGAAGGGCTGGCA 1122

RESULT 8
AAD07791
ID AAD07791 standard; cDNA; 1044 BP.
XX
AC AAD07791;
XX
DT 16-AUG-2001 (first entry)
XX
DE Human secreted protein-encoding gene 8 cDNA clone HEENC85, SEQ ID NO:42.
XX
KW Human; secreted protein, proliferative disorder; cancer; tumour;
KW foetal abnormality; developmental abnormality, haematopoietic disorder;
KW immune system disorder, AIDS, autoimmune disease; rheumatoid arthritis;
KW inflammation; allergy; neurological disorder; Alzheimer's disease;
KW Parkinson's disease; cognitive disorder, schizophrenia, asthma;
KW skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW cardiovascular disorder, angiogenic disorder; kidney disorder;
KW gastrointestinal disorder; pregnancy-related disorder;
KW endocrine disorder; infection, wound healing; vulnerary;
KW cell culture; chemotaxis; food additive; gene therapy;
KW binding partner identification; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 616..657
FT /*tag= a
FT /product= "Human secreted protein precursor"
FT /note= "CDS does not include start codon"
FT /partial
XX
PN WO200132687-A1.
XX
PD 10-MAY-2001.
XX
PF 25-OCT-2000; 2000WO-US29364
XX
PR 29-OCT-1999; 99US-0162238.
PR 30-JUN-2000; 2000US-0215134.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Komatsoulis GA, Duan RD, Fiscella M, Ebner R;
XX
DR WPI; 2001-308740/32.
DR P-PSDB; AAE03399.
XX
PT Isolated nucleic acid molecule encoding a human secreted protein is
PT used in preventing, treating or ameliorating a medical condition

```
XX
PS   Claim 1; Page 862; 898pp; English.
XX
CC   AAD27795 AAD27794 represent cDNAs corresponding to 10 human secreted
CC   protein genes, and AAE03478 AAE03479 represent the proteins they encode.
CC   AAE03474 AAE03475 represent human secreted protein fragments or variants.
CC   The secreted proteins and their genes are useful for preventing,
CC   treating or ameliorating medical conditions, e.g., by protein or gene
CC   therapy. Pathological conditions can be diagnosed by determining the
CC   amount of the new protein in a sample or by determining the presence of
CC   mutations in the new genes. Specific uses are described for each of the
CC   10 genes, based on the tissues in which they are most highly expressed,
CC   and include developing products for the diagnosis or treatment of
CC   proliferative disorders, cancer, tumours, foetal and developmental
CC   abnormalities, haematopoietic disorders, diseases of the immune system,
CC   AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation,
CC   allergies, neurological disorders (e.g., Alzheimer's disease,
CC   Parkinson's disease), cognitive disorders, schizophrenia, asthma,
CC   skin disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis,
CC   cardiovascular disorders, angiogenic disorders, kidney disorders,
CC   gastrointestinal disorders, pregnancy related disorders, endocrine
CC   disorders, and infections. The proteins can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin ageing due to
CC   sunburn, to maintain organs before transplantation, for supporting cell
CC   culture of primary tissues, to regenerate tissues, to identify their
CC   cognate ligands or binding partners, and in chemotaxis, and can be used
CC   as a food additive or preservative to modify storage properties.
CC   Antibodies specific for a protein of the invention can be used in
CC   alleviating symptoms associated with the disorders mentioned above, and
CC   in diagnostic immunoassays e.g., radioimmunoassay or enzyme linked
CC   immunosorbent assay, (ELISA). The present sequence represents a human
CC   secreted protein encoding cDNA of the invention.
XX
SQ   Sequence 1044 BP; 217 A; 350 C; 326 G; 146 T; 5 other;

  Query Match          10.0%;  Score 628.8;  DB 22;  Length 1044;
  Best Local Similarity   76.4%;  Pred. No. 1.1e-132;
  Matches  [illegible];  Conservative    1;  Mismatches  236;  Indels    9;  Gaps    2;

Qy    1675 AGTGAAAGCAGCAGTTTGCAGGGTGGATGCTACAGAGCAGAGGGCTGGAGGGGCCCTTGGTG 1834
           ||  |  |  |||| ||| ||||||||||||||||||||||||| || || |
Db       7 CGTTGACGCANTTTGGNTGAATGGACCCTGTAGAGCAGAGGGCTGGAGGGCGCTCCCCGGG 66

Qy    1835 ATTTTTTTGTGTCACTGCATTCTGGGATGCTTGGGGTGACTTGCCTGGCTGTGACTTTG 1894
           ||  ||||||||||| | ||  ||| || |||  |||||| ||||||| |||||||
Db      67 GCTGGTCTGTGTCACTGTACTCCAGGGACGCATGGCAGGACTTGGCTGGCTGGGACTTTG 126

Qy    1895 TTTTGAACTAATATCTCAGAATTGAGAGTTCTCTGAGACTTAGTTGTTTTAGAACTTACC 1954
           ||  ||||  ||  |||||||||| |||| ||||||| | |||| || |||||
Db     127 TTTTGAACCTGATCAGCCAGATTGAGGAGCTGGGGGACCCTAGCTGGCCCTGGCAGCTACC 186

Qy    1955 CCAATCACTCCTCTTGGTTTAGTTGAGAGCATCCCTCCAGCCCCTGGTGTCCAGGCTCCTT 2014
           ||||||||||| | || |||  || || |  |||||||  | ||||| || |
Db     187 CAATCACTCCCTCTTGGTTCAGCCCAGGCCATTCCCCTTGCCCCCTGGCATTCAGGCCCCCT 246

Qy    2015 CCTCAGCCCAGGAGTCCCTCCAGGTCCAGCCCCAACCCTGCCCAGCAGGGACCACACAG 2074
           | |||||||||||| ||||||||||||||||||||  ||| |||||||   ||   | |
Db     247 CATGGCCCCAGGAGTCCCCTCCAGGTCCAGCCCCAACCCTGCCCAGCAGGGACCACACAG 306

Qy    2075 GTGAGGCAGTAAGCCTGAGAACCTGGATGGTTTCGTGGACCACCTCTTTGAACCAGCGC 2134
           |||||  | | | || ||||| || ||| |||||||  ||||  | |||| |
Db     307 GTGAGGCCCAGAAGTCCAGGGAGCCTGGATGGTTTCGTGGACCAGACTCTTCAGCCAGTGA 366

Qy    2135 TTCCTCCCGGGTTTCAGTGATCTGGAACAAGGCTGGGCCCTGAGCAGACGCATGAAGGGAG 2194
           |||  |||| |||||||||| ||||||| ||||||  |||||||||||||||||||||
Db     367 TATCCTCCGGGCTTCAGCGATTTGGAACAAAGCTGGGCTCTGAGCAGCGCCATGAAGGGAG 426

Qy    2195 GGGCCTCTGTTGGGCCCACCCAGCAGGGCTACCCCATGGTGTACCCAGGTATGGTGCCAGG 2254
           ||||  |  |||||||| |||||||||||||||||||||||||||||| ||| | |||
Db     427 GGGGGCCATGGGGCCCACACAGCAGGGCTACCCCATGGTGTACCCAGGAATGATTCCAGA 486

Qy    2255 TTCCTCTCCTACCAGCCACCTATGTATCCCCTACCCGATCCCCGTCATGCCTACCCATGCCC 2314
             ||   |||||||||| ||| | || ||||| |||||| | |||||||| ||||||
Db     487 TGCCTGCATACCTAGCCAGGCATGGTCCCTGCTACCCATCCCAGCCTACCCAATGCCCA 546

Qy    2315 CAGTCCCAACCCATGCCAGCCATGGATGGTCCTACCCCAGCCCATCCCTACCCTTACCCT 2374
           |||||||  |||||||||| | |||||| | |||  |  |  |  |  |  |  |||  |
Db     547 CAGTCCCTGCCCATCTACGCCATGGTGGTCCTACCCCAGCCCATCCCTACCCTTACCCT 606

Qy    2375 TGGACTCAAGGCAGCTGGCTACTACAGCAGCAAAACTTCTATTAACTACAGCAGGTATGATT 2434
           |||| || ||||||||| | |||||| ||||  |  ||||  |  |  |  |  |  |
Db     607 TGGATTCTAGTTCCTACCTGGCTCCCAGCAGCAAAACTTCTATTAACTACAGCAGGTATGAT 666

Qy    2435 GGGCCAGCAGAGATGACAGCCCAGGCCATGATGCCTGTCCCTGCAGCAGCAGCAGCAGCAT 2494
           |||| ||||||||||  |||||||||| |||||||||||||||||||||||||||||||
Db     667 TGGCCCAGCAGAGATGACAGCCCAGGCCATGATGCCTGTCCCTGCAGCAGCAGCAGCAGCAT 726

Qy    2495 AGCAGCAGCAGCAGCTCAGAGCTTTGGGCCCACTTCCTACTCTGCCTTAACTACTCTCT 2554
           ||||| || |||| | |||| | ||| | |||  | |||||||||||||||||||||||
Db     727 GGCAGCAGCAGGCTGGGGCCTCTGAGGCTGGTGCCCAGGGCTCATCCTTAGCCCTTACTCT 786

Qy    2555 CCAAGGCAAGAAAGCCTCCTGTGCCCCAAGAAAAGCAAGAAATTAACTTAGATCTTCCT 2614
           |||| ||| |||||  |  | ||||  |||||||| | | |||| | | |  |
Db     787 CCAAGCCCAGGAAGCCCCCATACCCCCTGAAAAGCCATCTTGACTTGGATCTAGAG 846

Qy    2615 GTGTTGGTTGAAGAGGACAGCCCAGAGAAAGTGAAAGAAACTTAGCCCCAAGA 2674
           |||  || ||||  ||| ||| | ||||| |||||  | ||| | | ||||||
Db     847 GTCCCTCTCCTACCCCCTAGCCCTCCTGAAGCCCTTCCTAGCCCCAAGA 897

Qy    2675 GTTTCTAACAGAAACCGGACTATTTCCAGAAGATCCCCAAGCTCAGATGAAGA 2734
           |||||||  |||||||| ||||||||||| ||||||||  |  |||| |||| |
Db     898 GCTTCCAGCAGAAACCGAACTATTCCAGAAGATCCCCAAGCTCAGATGAAGA 947

Qy    2735 CGTGAAACCTTTAGCTAAATTTCAAT[illegible]AAGAAAAAAAAAAAAAAAAAAAAA 2794
           || ||| || || |||||||| || |||||||  |  |  |  |  |  |  |  |
Db     948 CGATGAAGCCCCCGGCCAAGGTCACAT[illegible]AAAAAAAAAAAAAAAAAAAAAAAA 1007

Qy    2595 AGGAGGATGAGACCGCCGAGTTG 2617
           ||||||| |||  |  |||  |
Db    1018 AGGAGGAGGAGGACGAGGAGGAG 1040


RESULT 9
ABK43544
ID   ABK43544 standard; cDNA; 1068 BP.
XX
AC   ABK43544;
XX
DT   05-JUN-2002  (first entry)
XX
DE   DNA encoding novel central nervous system protein #114.
XX
KW   Central nervous system; CNS; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW   cardiac arrest; cerebrovascular disorder; ischaemia; angiogenesis;
KW   nervous system disorder; Alzheimer's disease; AIDS; ocular disorder;
KW   acquired immunodeficiency virus; dysphagia; gastrointestinal disorder;
KW   adenocarcinoma; reproductive system disorder; testicular [illegible];
KW   endocrine disorder; diabetes; cancer; leukaemia; neovascularisation;
KW   respiratory disorder; renal disorder; kidney failure; blood disorder;
KW   myocardial infarction; wound healing; cell proliferation; skin ageing;
KW   food additive; food preservative; gene therapy; sun; ss.
XX
OS   Homo sapiens.
XX
PN   WO200155318-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01332.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
```

17-MAR-2000; 2000US-0190776.
18-APR-2000; 2000US-0198103.
19-MAY-2000; 2000US-0205515.
07-JUN-2000; 2000US-0209467.
28-JUN-2000; 2000US-0214886.
30-JUN-2000; 2000US-0215135.
07-JUL-2000; 2000US-0216647.
07-JUL-2000; 2000US-0216880.
11-JUL-2000; 2000US-0217487.
11-JUL-2000; 2000US-0217496.
14-JUL-2000; 2000US-0218290.
26-JUL-2000; 2000US-0220053.
26-JUL-2000; 2000US-0220464.
14-AUG-2000; 2000US-0224518.
14-AUG-2000; 2000US-0224519.
14-AUG-2000; 2000US-0225019.
14-AUG-2000; 2000US-0225214.
14-AUG-2000; 2000US-0225266.
14-AUG-2000; 2000US-0225267.
14-AUG-2000; 2000US-0225268.
14-AUG-2000; 2000US-0225273.
14-AUG-2000; 2000US-0225447.
14-AUG-2000; 2000US-0225457.
14-AUG-2000; 2000US-0225758.
14-AUG-2000; 2000US-0225759.
18-AUG-2000; 2000US-0226279.
22-AUG-2000; 2000US-0226841.
22-AUG-2000; 2000US-0226868.
22-AUG-2000; 2000US-0227182.
23-AUG-2000; 2000US-0227366.
30-AUG-2000; 2000US-0228804.
01-SEP-2000; 2000US-0229267.
01-SEP-2000; 2000US-0229343.
01-SEP-2000; 2000US-0229344.
01-SEP-2000; 2000US-0229345.
05-SEP-2000; 2000US-0229859.
05-SEP-2000; 2000US-0229913.
06-SEP-2000; 2000US-0230437.
06-SEP-2000; 2000US-0230439.
08-SEP-2000; 2000US-0231043.
08-SEP-2000; 2000US-0231045.
08-SEP-2000; 2000US-0231244.
08-SEP-2000; 2000US-0231413.
08-SEP-2000; 2000US-0231414.
08-SEP-2000; 2000US-0231980.
08-SEP-2000; 2000US-0231981.
12-SEP-2000; 2000US-0231988.
14-SEP-2000; 2000US-0232447.
14-SEP-2000; 2000US-0232448.
14-SEP-2000; 2000US-0232389.
14-SEP-2000; 2000US-0232400.
14-SEP-2000; 2000US-0232401.
14-SEP-2000; 2000US-0232403.
14-SEP-2000; 2000US-0232404.
14-SEP-2000; 2000US-0232615.
21-SEP-2000; 2000US-0234273.
21-SEP-2000; 2000US-0234274.
25-SEP-2000; 2000US-0234997.
25-SEP-2000; 2000US-0234998.
26-SEP-2000; 2000US-0235494.
27-SEP-2000; 2000US-0235934.
27-SEP-2000; 2000US-0235936.
29-SEP-2000; 2000US-0236327.
29-SEP-2000; 2000US-0236367.
29-SEP-2000; 2000US-0236368.
29-SEP-2000; 2000US-0236369.
29-SEP-2000; 2000US-0236370.
02-OCT-2000; 2000US-0236802.
02-OCT-2000; 2000US-0237037.
02-OCT-2000; 2000US-0237038.
02-OCT-2000; 2000US-0237039.
02-OCT-2000; 2000US-0237040.
03-OCT-2000; 2000US-0239315.

PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 06-DEC-2000; 2000US-0251488.
PR 06-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251969.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 01-JAN-2001; 2001US-0259678.
XX
PA (HUMA) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-581833/65.
DR P-PSDB; AAU87214.
XX
PT New isolated nucleic acid encoding a protein for diagnosing,
PT preventing, treating or ameliorating medical conditions and used as
PT food additives or preservatives
XX
PS Claim 1; SEQ ID No 134; 837pp; English.
XX
CC The invention describes an isolated nucleic acid molecule (I) encoding a

CC novel central nervous system protein (I) and polypeptides (III) encoded
CC by it, are used to treat a medical conditions and in diagnosis of a
CC pathological condition. Disorders which are diagnosed or treated include
CC autoimmune diseases e.g. rheumatoid arthritic, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC analgesics, nervous system disorders e.g. Alzheimer's disease and
CC amyotrophic lateral sclerosis, infections caused by bacteria, viruses
CC e.g. Acquired immunodeficiency virus (AIDS) and fungi, ocular disorders
CC e.g. corneal infection, gastrointestinal disorders e.g. dysphagia,
CC adenocarcinomas and irritable bowel syndrome, reproductive system
CC disorders e.g. testicular feminisation, endocrine disorders e.g. diabetes
CC anti pituitary dwarfism, cancers and disorders at the cellular level e.g.
CC leukaemia, disorders involving neovascularisation e.g. malignancies,
CC respiratory disorders e.g. nonallergic rhinitis, renal disorders e.g.
CC acute kidney failure and blood related disorders e.g. myocardial
CC infarction. The polypeptides can also be used to aid wound healing and
CC epithelial cell proliferation, to prevent skin aging due to sunburn, to
CC maintain organs before transplantation, for supporting cell culture of
CC primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content, lipid, protein,

Query Match 10.0%; Score 626.4; DB 23; Length 1268;
Best Local Similarity 80.6%; Pred. No. 4.2e-132;
Matches 1760; Conservative 0; Mismatches 176; Indels 0; Gaps 0;

Qy 1 GCAGTCGCGAGCGCCTCTCTTCTGGGAGGCAAGAGCTCTTTAGTGAGTCTCATGCTTTG 3232
Db 5 GCTTCGGCACTGCCTCCTCCGGAGGACCCAGGGACCCTTTCAGCAGAGCGTCGTTGCTTG 64

Qy 3233 AGAGCGCTCAATCGAGCAACAACAACATCCCCAAAAGTGCTTTGTGCGCCTCTGAAGTGTG 3292
Db 65 AGAGCGCTCCTCAGGACCAAGTCCTCCTCCTCCTCCTCCTCCTCCAGCCTCTG 124

Qy 3293 TCTTTCTCTATGCGAATGCACGCGTGCAACTTGTTCTTACCGCAAGGAGTGTTCCTACCCC 3352
Db 125 TGCTTCTCTCTAGAGCCCCAGCCCCTGGAACTTGTTGCTACCGCAAGGAGGTCCTTCTACCCA 184

Qy 3353 CCCCAGAACTTCAGTCATCCATACTGCCTCAGTCTCCTCTGTGCAGCAGATCCTGCTTTAC 3412
Db 185 CCTCAGAACTTCAGCCATCCCTACTACCCTAGGCTGCTCTCTGTGAGCAGATCCTTACGGGAC 244

Qy 3413 AGCTTCTACAGACTCCTGCAGCCGGATCTCACAGCATCAGCGGGCACAAAATGAAAGGCCTT 3472
Db 245 AGCTTCTTCGAGTCCTGTATCCGGATTTCCCTAGAATGAGCGGGCGAAAATGAAAGACCTG 304

Qy 3473 CTGGAGAGTGAGTCTGCAGCAGCATGTGACATTGTTGAAGACAGCATCAAAAAA 3532
Db 305 CTGGAGGCTTGGAGGTGGACCTGGATTCTCTCACCACCACCGAAGACAGAGGTCAAGAAG 364

Qy 3533 CGTATCGTCGTCGTCTCTCTTCGACAAATCTCGTCGTCAATTACTTTCTCGTCGTATTTTCG 3592
Db 365 CGTTTTGTTGGCGTCGTCGGCGACAACTCGGGCCAATTACTTTTCCCCGTTCGTCTTTCCTCC 424

Qy 3593 TCGAGTGACAGTGGCAGCGATGTACAGTCGTCTCCCCTCGTCCACCGGAGACTCCTCTCG 3652
Db 425 TCAGGCGAGAGTGGCAGCGACGTGCAGCTGTTAGCCGTGTCCCACCGTGGGCTCGCACTTG 484

Qy 3653 CTAAGCGTCACCCAAAGCCCCAGCTTCCACTCGACCAGCTGAAGACACTCTCTCTACAC 3712
Db 485 CTAAGTGACCCAAGCCCCCGGCTCCCCCCCGACCACCTGAAGATTCTCTCGCTCATAC 544

Qy 3713 AATTATCTTGAAGTCCTCGACCGTGCTGATCCACCGCTAGATCCACCTTGGAGTCTGTCTTG 3772
Db 545 AGCTTTCCCGGAGCCTCCTCCGTCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCCTCC 604

Qy 3773 AAAAATGAAAAGTGCATACTGCACACAGCTTGGGCCGAGGGCCATCAAGCCTATGGTGGAT 3832
Db 605 AAAACCGAAGCAGTGCTCCTCCACACAGCCCGGCCAAGCCCATCAGAGCCTATGGTGGAT 664

Qy 3833 CTATTCTCAGTGAACTCAACTGAAGAACTTTCGTTATTCTACCTCGCCTCGCCAGCTCATCC 3892

Db 665 CTATTCTTGAATCAGCTTAACTAAGCACTCCCCCTATTCTACCTCGCCTCGCCAGCTCATCC 724

Qy 3893 ACCGATGACAATAGCTCCCTCATTTCTACCCCCCCCATCTCATCAGTTTACTCCCAGTTC 3952
Db 725 ACTGACTAACTTCCAGCTCCTCTTACTTCTACCCCCCCATCTCATCAGTTTACTCCCAGTTC 784

Qy 3953 AGCGCTCTGGAACCAGGCTGGCAGTCGGTTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 4012
Db 785 GCCACCCTGGAGCCAGGCTGGCAGTCGGTTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 844

Qy 4013 AAACACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 4072
Db 845 GCCCACACTAGCTCACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 904

Qy 4073 AGCTGGCA 4080
Db 905 GGCTGGCA 912

RESULT 10
AAS27110
ID AAS27110 standard; cDNA; 1247 BP.
XX
AC AAS27110;
XX
DT 07-NOV-2001 (first entry)
XX
DE DNA encoding novel signal transduction pathway protein, Seq ID 145.
XX
KW Neuroprotective; cytostatic; dermatological; immunosuppressive; anti-allergic;
KW antiinflammatory; anti-HIV; antibacterial; anti-inflammatory; cancer;
KW immune system disorder; rheumatoid arthritis; inflammatory bowel disease;
KW organ transplant rejection; infection; hepatitis C; blood disorder;
KW sickle cell anaemia; hyperproliferative disorder; Gaucher's disease;
KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW chromosomal abnormality; Down syndrome; ischaemia; renal disorder;
KW cardiovascular, respiratory; wound healing; endocrine; Addison's disease;
KW reproductive system, gastrointestinal, liver disorder; AIDS; HIV;
KW acquired immune deficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200154733-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01312.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 2-MAR-2000; 2000US-0186360.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205436.
PR 07-JUN-2000; 2000US-0209467.
PR 26-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.

R 14-AUG-2000; 2000US-0225270.
R 14-AUG-2000; 2000US-0225447.
R 14-AUG-2000; 2000US-0225757.
R 14-AUG-2000; 2000US-0225758.
R 14-AUG-2000; 2000US-0225759.
R 16-AUG-2000; 2000US-0226279.
R 22-AUG-2000; 2000US-0226681.
R 22-AUG-2000; 2000US-0226868.
R 22-AUG-2000; 2000US-0227182.
R 23-AUG-2000; 2000US-0227359.
R 30-AUG-2000; 2000US-0228924.
R 01-SEP-2000; 2000US-0229297.
R 01-SEP-2000; 2000US-0229343.
R 01-SEP-2000; 2000US-0229344.
R 01-SEP-2000; 2000US-0229345.
R 05-SEP-2000; 2000US-0229513.
R 06-SEP-2000; 2000US-0230457.
R 06-SEP-2000; 2000US-0230436.
R 07-SEP-2000; 2000US-0231242.
R 08-SEP-2000; 2000US-0231243.
R 08-SEP-2000; 2000US-0231244.
R 08-SEP-2000; 2000US-0231413.
R 08-SEP-2000; 2000US-0231414.
R 08-SEP-2000; 2000US-0232080.
R 08-SEP-2000; 2000US-0232081.
R 12-SEP-2000; 2000US-0231968.
R 14-SEP-2000; 2000US-0232397.
R 14-SEP-2000; 2000US-0232398.
R 14-SEP-2000; 2000US-0232399.
R 14-SEP-2000; 2000US-0232400.
R 14-SEP-2000; 2000US-0232401.
R 14-SEP-2000; 2000US-0233063.
R 14-SEP-2000; 2000US-0233064.
R 14-SEP-2000; 2000US-0233065.
R 21-SEP-2000; 2000US-0234223.
R 21-SEP-2000; 2000US-0234274.
R 25-SEP-2000; 2000US-0234997.
R 25-SEP-2000; 2000US-0234998.
R 26-SEP-2000; 2000US-0235484.
R 27-SEP-2000; 2000US-0235834.
R 27-SEP-2000; 2000US-0235836.
R 29-SEP-2000; 2000US-0236327.
R 29-SEP-2000; 2000US-0236367.
R 29-SEP-2000; 2000US-0236368.
R 29-SEP-2000; 2000US-0236369.
R 29-SEP-2000; 2000US-0236370.
R 02-OCT-2000; 2000US-0236802.
R 02-OCT-2000; 2000US-0237037.
R 02-OCT-2000; 2000US-0237038.
R 02-OCT-2000; 2000US-0237039.
R 02-OCT-2000; 2000US-0237040.
R 13-OCT-2000; 2000US-0239935.
R 13-OCT-2000; 2000US-0239937.
R 20-OCT-2000; 2000US-0241221.
R 20-OCT-2000; 2000US-0241785.
R 20-OCT-2000; 2000US-0241796.
R 20-OCT-2000; 2000US-0241797.
R 20-OCT-2000; 2000US-0241828.
R 20-OCT-2000; 2000US-0241829.
R 20-OCT-2000; 2000US-0241926.
R 01-NOV-2000; 2000US-0244617.
R 08-NOV-2000; 2000US-0246474.
R 08-NOV-2000; 2000US-0246475.
R 08-NOV-2000; 2000US-0246476.
R 08-NOV-2000; 2000US-0246477.
R 08-NOV-2000; 2000US-0246478.
R 08-NOV-2000; 2000US-0246523.
R 08-NOV-2000; 2000US-0246524.
R 08-NOV-2000; 2000US-0246526.
R 08-NOV-2000; 2000US-0246527.

PP 08-NOV-2000; 2000US-0246528.
PP 08-NOV-2000; 2000US-0246532.
PP 08-NOV-2000; 2000US-0246609.
PP 08-NOV-2000; 2000US-0246610.
PP 08-NOV-2000; 2000US-0246611.
PP 08-NOV-2000; 2000US-0246613.
PP 17-NOV-2000; 2000US-0249207.
PP 17-NOV-2000; 2000US-0249208.
PP 17-NOV-2000; 2000US-0249209.
PP 17-NOV-2000; 2000US-0249210.
PP 17-NOV-2000; 2000US-0249211.
PP 17-NOV-2000; 2000US-0249212.
PP 17-NOV-2000; 2000US-0249213.
PP 17-NOV-2000; 2000US-0249214.
PP 17-NOV-2000; 2000US-0249215.
PP 17-NOV-2000; 2000US-0249216.
PP 17-NOV-2000; 2000US-0249217.
PP 17-NOV-2000; 2000US-0249218.
PP 17-NOV-2000; 2000US-0249244.
PP 17-NOV-2000; 2000US-0249245.
PP 17-NOV-2000; 2000US-0249264.
PP 17-NOV-2000; 2000US-0249265.
PP 17-NOV-2000; 2000US-0249297.
PP 17-NOV-2000; 2000US-0249299.
PP 17-NOV-2000; 2000US-0249300.
PP 01-DEC-2000; 2000US-0250160.
PP 01-DEC-2000; 2000US-0250391.
PP 05-DEC-2000; 2000US-0251030.
PP 05-DEC-2000; 2000US-0251988.
PP 05-DEC-2000; 2000US-0256719.
PP 06-DEC-2000; 2000US-0251479.
PP 08-DEC-2000; 2000US-0251856.
PP 08-DEC-2000; 2000US-0251868.
PP 08-DEC-2000; 2000US-0251869.
PP 08-DEC-2000; 2000US-0251989.
PP 08-DEC-2000; 2000US-0251990.
PP 11-DEC-2000; 2000US-0254097.
PP 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM,
XX
DR WPI; 2001-465460/50.
DR P-PSDB; AAU17193.
XX
PT Novel polypeptides useful for diagnosing, treating, preventing and/or
PT prognosing disorders related to the proteins, including cancers, immune
PT disorders and neuronal disorders -
XX
PS Claim 1; SEQ ID No 145; 880pp; English.
XX
CC The invention relates to novel isolated polypeptides (I), and
CC polynucleotides (II). (I), (II) and the antibody to (I) are useful for
CC diagnosing, preventing and treating diseases including immune system
CC disorders (e.g. congenital and acquired immunodeficiencies, autoimmune
CC disorders (e.g. rheumatoid arthritis), inflammatory conditions, organ
CC transplant rejections and graft versus host disease, infectious diseases
CC (e.g. hepatitis C), bleeding disorders, haemoglobin abnormalities and
CC other blood-related disorders (sickle cell anaemia), myeloproliferative
CC disorders, primary haematopoietic disorders, hyperproliferative
CC disorders (e.g. Gaucher's disease and cancer), neurodegenerative
CC disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal
CC abnormalities (Down syndrome), ischaemic injury (e.g. stroke), renal
CC disorders (e.g. glomerulonephritis), cardiovascular disorders
CC (e.g. arrhythmia), respiratory disorders, dermatological disorders, in
CC wound healing, epithelial cell proliferation, endocrine disorders (e.g.
CC Addison's disease), reproductive system disorders, gastrointestinal
CC disorder (inflammatory disorders), liver disorders (cirrhosis),
CC as stimulators of B-cell responsiveness to pathogens, activators of
CC T cells, to induce higher affinity antibodies, and as a means to induce
CC tumour proliferation in pathologies e.g. acquired immune deficiency
CC syndrome (AIDS). AAS26976-AAS27850 represent novel signal transduction



RESULT 11
AR643864
ID AR643864 standard; cDNA; 1247 BP.
XX
AC AR643864;

XX
DT 05-JUN-2002 (first entry)
XX
DE DNA encoding novel central nervous system protein #444.
XX
KW Central nervous system; CNS; autoimmune disease, rheumatoid arthritis;
KW hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW cardiac arrest; cerebrovascular disorder; ischaemic angiopathy;
KW nervous system disorder; Alzheimer's disease; AIDS; ocular disorder;
KW acquired immunodeficiency virus; dysphagia; gastrointestinal disorder;
KW adenocarcinoma; reproductive system disorder; testicular feminisation;
KW endocrine disorder; diabetes; cancer; leukaemia; neovascularisation;
KW respiratory disorder; renal disorder; kidney failure; blood disorder;
KW myocardial infarction; wound healing; cell proliferation; skin graft;
KW food additive; food preservative; gene therapy; human.
XX
OS Homo sapiens.
XX
PN WO200155318 A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01332.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 26-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220983.
PR 26-JUL-2000; 2000US-0220984.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.

R 08-SEP-2000; 2000US-0232080.
P 08-SEP-2000; 2000US-0232081.
R 12-SEP-2000; 2000US-0231968.
R 14-SEP-2000; 2000US-0232397.
R 14-SEP-2000; 2000US-0232398.
R 14-SEP-2000; 2000US-0232399.
R 14-SEP-2000; 2000US-0232400.
R 14-SEP-2000; 2000US-0232401.
R 14-SEP-2000; 2000US-0233063.
R 14-SEP-2000; 2000US-0233064.
R 14-SEP-2000; 2000US-0233065.
R 21-SEP-2000; 2000US-0234223.
R 21-SEP-2000; 2000US-0234274.
R 25-SEP-2000; 2000US-0234997.
R 25-SEP-2000; 2000US-0234998.
R 26-SEP-2000; 2000US-0235484.
R 27-SEP-2000; 2000US-0235834.
R 27-SEP-2000; 2000US-0235836.
R 29-SEP-2000; 2000US-0236327.
R 29-SEP-2000; 2000US-0236367.
R 29-SEP-2000; 2000US-0236368.
R 29-SEP-2000; 2000US-0236369.
R 29-SEP-2000; 2000US-0236370.
R 02-OCT-2000; 2000US-0236802.
R 02-OCT-2000; 2000US-0237037.
R 02-OCT-2000; 2000US-0237038.
R 02-OCT-2000; 2000US-0237039.
R 02-OCT-2000; 2000US-0237040.
R 13-OCT-2000; 2000US-0239935.
R 13-OCT-2000; 2000US-0239937.
R 20-OCT-2000; 2000US-0240960.
R 20-OCT-2000; 2000US-0241221.
R 20-OCT-2000; 2000US-0241785.
R 20-OCT-2000; 2000US-0241786.
R 20-OCT-2000; 2000US-0241787.
R 20-OCT-2000; 2000US-0241808.
R 20-OCT-2000; 2000US-0241809.
R 20-OCT-2000; 2000US-0241826.
R 01-NOV-2000; 2000US-0244617.
R 08-NOV-2000; 2000US-0246474.
R 08-NOV-2000; 2000US-0246475.
R 08-NOV-2000; 2000US-0246476.
R 08-NOV-2000; 2000US-0246477.
R 08-NOV-2000; 2000US-0246478.
R 08-NOV-2000; 2000US-0246523.
R 08-NOV-2000; 2000US-0246524.
R 08-NOV-2000; 2000US-0246525.
R 08-NOV-2000; 2000US-0246526.
R 08-NOV-2000; 2000US-0246527.
R 08-NOV-2000; 2000US-0246528.
R 08-NOV-2000; 2000US-0246532.
R 08-NOV-2000; 2000US-0246609.
R 08-NOV-2000; 2000US-0246610.
R 08-NOV-2000; 2000US-0246611.
R 08-NOV-2000; 2000US-0246613.
R 17-NOV-2000; 2000US-0249207.
R 17-NOV-2000; 2000US-0249208.
R 17-NOV-2000; 2000US-0249209.
R 17-NOV-2000; 2000US-0249210.
R 17-NOV-2000; 2000US-0249211.
R 17-NOV-2000; 2000US-0249212.
R 17-NOV-2000; 2000US-0249213.
R 17-NOV-2000; 2000US-0249214.
R 17-NOV-2000; 2000US-0249215.
R 17-NOV-2000; 2000US-0249216.
R 17-NOV-2000; 2000US-0249217.
R 17-NOV-2000; 2000US-0249218.
R 17-NOV-2000; 2000US-0249244.
R 17-NOV-2000; 2000US-0249245.
R 17-NOV-2000; 2000US-0249264.
R 17-NOV-2000; 2000US-0249265.
R 17-NOV-2000; 2000US-0249297.
R 17-NOV-2000; 2000US-0249299.

PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-581633/65.
DR P-PSDB; AAU87523.
XX
PT New isolated nucleic acid encoding a protein for diagnosing,
PT preventing, treating or ameliorating medical conditions and used as
PT food additives or preservatives -
XX
PS Claim 1; SEQ ID No 443; 837pp; English.
XX
CC The invention describes an isolated nucleic acid molecule (I) encoding a
CC novel central nervous system protein (II) and polypeptides (III) encoded
CC by (I), are used to treat a medical conditions and in diagnosis of a
CC pathological condition. Disorders which are diagnosed or treated include
CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC angiogenesis, nervous system disorders e.g. Alzheimer's disease and
CC amylotrophic lateral sclerosis, infections caused by bacteria, viruses
CC e.g. Acquired immunodeficiency virus (AIDS) and fungi, ocular disorders
CC e.g. corneal infection, gastrointestinal disorders e.g. dysphagia,
CC adenocarcinomas and irritable bowel syndrome, reproductive system
CC disorders e.g. testicular feminisation, endocrine disorders e.g. diabetes
CC and pituitary dwarfism, cancers and disorders at the cellular level e.g.
CC leukaemia, disorders involving neovascularisation e.g. malignancies,
CC respiratory disorders e.g. nonallergic rhinitis, renal disorders e.g.
CC acute kidney failure and blood related disorders e.g. myocardial
CC infarction. The polypeptides can also be used to aid wound healing and
CC epithelial cell proliferation, to prevent skin aging due to sunburn, to
CC maintain organs before transplantation, for supporting cell culture of
CC primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content, lipid, protein,

Query Match 9.9%; Score 621.2; DB 23; Length 1247;
Best Local Similarity 80.6%; Pred. No. 6.4e-131;
Matches 725; Conservative 1; Mismatches 174; Indels 0; Gaps 0;

Qy 3181 ACGGCCTCTGTCTGGGGAGCCCAAGACCCCTTCAGTGGAGTCTCATGCCTTGACAGAGCC 3240
Db 1 ACTGCCTCTGCCCGAGGACCCAGGGACCCTTTCAGCAGAGCGTCGTTGCTTGACACAGCC 60

Qy 3241 CATGGAGGACAAGAACATCTCCACAAAGCTCCTTGTGCCCTCTGAAAGTGTGTGCTCTC 3300
Db 61 CGTGGAGGACCAGGGGCTCTCCACCCAGCTACTCGCGCCTCTGGCAGCGTGTGCTCTC 120

Qy 3301 CTATGCCAATGCACCCTGGAAGTTGTTCTTACGCAAGGAGGTGTTCTACCCCGGGAGAA 3360
Db 121 CTACACGGGCAGGCCCTGGAAGTTGTTCCTACGCAAGGAGGTGTTCTACCCCGGGAGAA 180

Qy 3361 CTTCAGTCATCCATACTGCCTCAGTCTCCTCTGCCAGCAGATCCTGCGGGACACCTTCAC 3420
Db 181 CTTCAGCCATCCCTACTACCTGAGGCTCCTCTGTGAGCAGATCCTACGGGACACCTTCTC 240

Qy 3421 AGAGTCCTGCAGCGGATCTCACAGGATGAGGGGCACAAAATGAAAGGCCTTCTGGGAGA 3480



RESULT 1
AAE07770
ID AAE07770 standard; cDNA; 826 BP.
XX
AC AAE07770;
XX
DT [1] ACS [2]-[3]-[4] (first entry)
XX
DE Human secreted protein encoding gene # cDNA #1 to AAE07795, SEQ ID NO 18
XX
KW Human; secreted protein; proliferative disorder; cancer; tumour;
KW foetal abnormality; developmental abnormality; haematopietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW inflammation; allergy; neurological disorder; Alzheimer's disease;
KW Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW cardiovascular disorder; angiogenic disorder; kidney disorder;
KW gastrointestinal disorder; pregnancy-related disorder;
KW endocrine disorder; infection; wound healing; vulnerary;
KW cell culture; chemotaxis; food additive; gene therapy;
KW binding partner identification; cc.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 171..653
FT /*tag= a
FT /product= "Human secreted protein precursor"
FT /transl_except= (pos:567..569, aa:Xaa)
FT /transl_except= (pos:636..638, aa:Xaa)
FT /note= "Xaa equals any of the naturally occurring
FT L-amino acids"
FT sig_peptide 171..293
FT /*tag= b
FT mat_peptide 294..650
FT /*tag= c
FT /product= "Mature human secreted protein"
XX
PN WO200132687-A1.
XX
PD 10-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US29364.
XX
PR 29-OCT-1999; 99US-0162238.
PR 30-JUN-2000; 2000US-0216134.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Komatsoulis GA, Duan RD, Fiscella M, Rieger R;
XX
DR WPI; 2001-308740/32.
DR P-PSDB; AAF03385.
XX
PT Isolated nucleic acid molecule encoding a human secreted protein, is
PT used in preventing, treating or ameliorating a medical condition.
XX
PS Claim 1; Page 351; 398pp; English.
XX
CC AAD07770-AAD07794 represent cDNAs corresponding to 25 human secreted
CC protein genes, and AAF03378-AAF03402 represent the proteins they encode.
CC AAE03403-AAE03415 represent human secreted protein fragments or variants.
CC The secreted proteins and their genes are useful for preventing,
CC treating or ameliorating medical conditions, e.g., by protein or gene
CC therapy. Pathological conditions can be diagnosed by determining the
CC amount of the new protein in a sample or by determining the presence of
CC mutations in the new genes. Specific uses are described for each of the
CC 10 genes, based on the tissues in which they are most highly expressed,
CC and include developing products for the diagnosis or treatment of
CC proliferative disorders, cancer, tumours, foetal and developmental
CC abnormalities, haematopietic disorders, diseases of the immune system,
CC AIDS, autoimmune diseases (e.g., rheumatoid arthritis, inflammation),
CC allergies, neurological disorders (e.g., Alzheimer's disease,
CC Parkinson's disease), cognitive disorders, schizophrenia, asthma,
CC skin disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis,
CC cardiovascular disorder, angiogenic disorders, kidney disorders,
CC gastrointestinal disorders, pregnancy related disorders, endocrine
CC disorders, and infections. The proteins can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin ageing due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues, to identify their
CC cognate ligands or binding partners, and in chromosome, and can be used
CC as a food additive or preservative to modify storage properties.
CC Antibodies specific for a protein of the invention can be used in
CC alleviating symptoms associated with the disease mentioned above, and
CC in diagnostic immunoassays e.g., radioimmunoassay, enzyme linked
CC immunosorbent assay (ELISA). The present sequence represents a human
CC secreted protein encoding cDNA of the invention.
XX
SQ Sequence 826 BP; 194 A; 191 C; 247 G; 193 T; 11 other;

Query Match 7.5%; Score 470.2; DB 2; Length 826;
Best Local Similarity 77.7%; Pred. No. 1e-90;
Matches 572; Conservative 0; Mismatches 56; Indels 1; Gaps 1;





RESULT 13
AAS27687/c
ID AAS27687 standard; DNA; 24757 BP.
XX
AC AAS27687;
XX
DT 07-NOV-2001 (first entry)
XX
DE DNA encoding novel signal transduction pathway protein, Seq ID 1347.
XX
KW Neuroprotective; cytostatic; dermatological; immunosuppressive, tumour;
KW antiinflammatory; anti HIV, antibacterial; antiinflammatory; cancer;
KW immune system disorder; rheumatoid arthritis; inflammatory condition;
KW organ transplant rejection; infection; hepatitis C; blood disorder;
KW sickle cell anaemia; hyperproliferative disorder; Gaucher's disease;
KW neurodegenerative disorder; Alzheimer's disease, Parkinson's disease;
KW chromosomal abnormality; Down syndrome, ischaemia; renal disorder;
KW cardiovascular; respiratory; wound healing; endocrine, Addison's disease;
KW reproductive system; gastrointestinal; liver disorder; AIDS; ds;
KW acquired immune deficiency syndrome.
XX
OS Homo sapiens.
XX
PN WO200154733-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01312.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 15-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 08-JUN-2000; 2000US-0210886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226079.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227192.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229087.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.

```
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   06-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA ) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM,
XX
DR   WPI; 2001-465460/50.
XX
PT   Novel polypeptides useful for diagnosing, treating, preventing and/or
PT   prognosing disorders related to the proteins, including cancers, immune
PT   disorders and neuronal disorders
XX
PS   Claim 1; SEQ ID No 1347; 880pp; English.
XX
CC   The invention relates to novel isolated polypeptides (I), and
CC   polynucleotides (II). (I), (II) and the antibody to (I) are useful for
CC   diagnosing, preventing and treating diseases including immune system
CC   disorders (e.g. congenital and acquired immunodeficiencies, autoimmune
CC   disorders (e.g rheumatoid arthritis), inflammatory conditions, organ
CC   transplant rejections and graft versus host disease, infectious diseases
CC   (e.g. hepatitis C), bleeding disorders, haemoglobin abnormalities and
CC   other blood-related disorders (sickle cell anaemia), myeloproliferative
CC   disorders, primary haematopoietic disorders, hyperproliferative
CC   disorders (e.g. Gaucher's disease and cancer), neurodegenerative
CC   disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal
CC   abnormalities (Down syndrome), ischaemic injury (e.g. stroke), renal
CC   disorders (e.g. glomerulonephritis), cardiovascular disorders
CC   (e.g. arrhythmia), respiratory disorders, dermatological disorders, in
CC   wound healing, epithelial cell proliferation, endocrine disorders (e.g.
CC   Addison's disease), reproductive system disorders, gastrointestinal
CC   disorder (inflammatory disorders), liver disorders (cirrhosis),
CC   as stimulators of B-cell responsiveness to pathogens, activators of
CC   T cells, to induce higher affinity antibodies, and as a means to inhibit
CC   tumour proliferation in pathologies e.g. acquired immune deficiency
CC   syndrome (AIDS). AAS26976-AAS27860 represent novel signal transduction
CC   pathway protein coding sequences and PCR primers of the invention.
XX
SQ   Sequence 24757 BP; 5183 A; 7437 C; 7328 G; 4809 T; 0 other;

  Query Match             2.6%;  Score 166.2;  DB [illegible];  Length 24757;
  Best Local Similarity   80.2%;  Pred. No. 4.2e-27;
  Matches  195;  Conservative    0;  Mismatches   48;  Indels    0;  Gaps    [illegible];

Qy    1119 GCGTGATCCTGCGGCTCCTGGGGGAAGGAT[illegible] 1178
Db   17652 GGCAGATGCTGCGGCTCCTGGGGGACGGAT[illegible] 17593

Qy    1179 GCACGTTCCTCGTGCAGCAGGC[illegible] 1238
Db   17592 GCGCATACCTGGTGCGGCAGGGGCAG[illegible] 17533

Qy    1239 AGCTGGTGGCCCAGC[illegible] 1298
Db   17532 AGCTGGTGGCCCAGCTATGGCAGAA[illegible] 17473

Qy    1299 [illegible] 1358
Db   17472 TCATGGCTGTTTTGCTCAGGCCTTT[illegible] 17413

Qy    1359 AAT 1361
           | |
Db   17412 AGT 17410


RESULT 14
AAS33481
ID   AAS33481 standard; DNA; 24757 BP.
XX
AC   AAS33481;
XX
DT   04-DEC-2001  (first entry)
XX
DE   DNA encoding human secreted protein, Seq ID No 764.
XX
KW   Immunomodulatory; human immunodeficiency virus; HIV; anaemia; asthma;
KW   rheumatoid arthritis; antiarteriosclerotic; cardiant; vasculat;
KW   cerebroprotective, thrombolytic; antimicrobial; ophthalmological;
KW   cytostatic, Alzheimer's disease, Parkinson's disease; human; cancer;
KW   multiple sclerosis, cancer; hyperproliferative disorder; infection;
KW   Gaucher's disease; neurological disease; cerebrovascular disorder;
KW   thrombosis; wound healing; ds.
XX
```

```
OS   Homo sapiens.
XX
PN   WO200155326-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01347.
XX
PR   31-JAN-2000; 2000US-0179065.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-451931/48.
XX
PT   New nucleic acids and polypeptides, useful for diagnosing, preventing
PT   or treating medical conditions
XX
PS   Disclosure; SEQ ID No 764; 753pp; English.
XX
CC   The invention relates to novel isolated nucleic acid molecules (I)
CC   encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC   treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC   goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC   the prevention, treatment and diagnosis of diseases associated with
CC   inappropriate expression of secreted proteins. (I) and complementary
CC   sequences may also be used as DNA probes in diagnostic assays (e.g.
CC   polymerase chain reactions (PCR)) to detect and quantitate the presence
CC   of similar nucleic acid sequences in samples, and so which patients may
CC   be in need of restorative therapy. (II) may also be used as antigens in
CC   the production of antibodies and in assays to identify modulators
CC   (agonists and antagonists) of the expression and activity of the secreted
CC   proteins. The anti-(II) antibodies and antagonists may also be used to
CC   down regulate expression and activity of (II). The anti-(II) antibodies
CC   may also be used as diagnostic agents for detecting the presence of (II)
CC   in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC   disorders include for example: immune/autoimmune diseases (e.g. HIV
CC   (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC   and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC   melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC   Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC   Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC   cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC   angina and thrombosis), infections caused by bacteria, viruses and
CC   fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC   agonists, antagonists and antibodies can also be used to promote wound
CC   healing, maintain organs before transplantation, and support cell culture
CC   of primary tissues. AAS33043-AAS33486 represent human secreted protein
CC   coding sequences, PCR primers, and related sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification but was obtained in electronic format directly from WIPO
CC   at: ftp wipo int/pub/published_pct_sequences.
XX
SQ   Sequence 24757 BP; 4809 A; 7229 C; 7437 G; 5183 T; 0 other;

 Query Match             2.6%;  Score 166.2;  DB 22;  Length 24757;
 Best Local Similarity   80.2%;  Pred. No. 4.2e-27;
 Matches  195;  Conservative    0;  Mismatches   48;  Indels    0;  Gaps    0;

Qy    1119 GGGTGATGCTGTGGGTCCTGTGGGGAAGGATCTGTGCAGTCCTGGCAAGAGCAGACCATGG 1178
           ||  |||||||||||||||||||||| ||||| ||| |||||||||   ||||| |||||
Db    7108 TGCAGATGCTGTGGGTCCTGTGGGGAAGGATCTGTGCAGTCCTGGCAGAGGCAGATCATGG 7167

Qy    1179 GCACGTTCCTCGTGCAGCAGGGCCAGGACGGCCCGGACTCCGAGATGAGCTCTTCAGCC 1238
           ||  | | ||| |||| |||||  ||| | ||||| || || ||  |||||||||| ||||
Db    7168 GCGCATACCTGGTGCGCAGGGGCAGGGCTGCGGAATGAGCTCTTTAGCC 7225

Qy    1239 AGCTGGTGGCCCAGCTGTGGCCCAACCCAGATGAGCAACAGAATCAGCGTGGCTGGGCCC 1298
           ||||||||||||||| |||| ||||||||| || |||  |||||||||||||||
Db    7226 AGCTGGTGGCCCAGCTATGGCAGAACCCAGATGAACAGCAGAGCCAGCGTGGCTGGGCCC 7285

Qy    1299 TAATGGTGATCCTGGTCAGTTCCTTTGATCCCAACCTGGCCTGGAGAAGCCACTGCTCA 1358
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    7286 TCATGGCTGTTTTGCTCAGCGCCTTTCCCCCACTGCCTGTCCTACAGAAGCCACTGCTCA 7345

Qy    1359 AAT 1361
           |||
Db    7346 AGT 7348


RESULT 15
AAS33480
ID   AAS33480 standard; DNA; 9703 BP.
XX
AC   AAS33480;
XX
DT   04-DEC-2001  (first entry)
XX
DE   DNA encoding human secreted protein, Seq ID No 763.
XX
KW   Immunomodulatory; human immunodeficiency virus; HIV; anaemia; angina;
KW   rheumatoid arthritis, antiarteriosclerotic; cardiant; vascular;
KW   cerebroprotective; thrombolytic; antimicrobial; ophthalmological;
KW   cytostatic, Alzheimer's disease; Parkinson's disease, human; cancer;
KW   multiple sclerosis; cancer; hyperproliferative disorder, infection;
KW   Gaucher's disease; neurological disease, cerebrovascular disorder;
KW   thrombosis; wound healing; ds.
XX
OS   Homo sapiens.
XX
PN   WO200155326-A2.
XX
PD   02 AUG-2001.
XX
PF   17-JAN 2001; 2001WO-US01347.
XX
PR   31 JAN 2000; 2000US-0179065.
XX
PA   (HUMA ) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI, 2001 451931/48.
XX
PT   New nucleic acids and polypeptides, useful for diagnosing, preventing
PT   or treating medical conditions -
XX
PS   Disclosure, SEQ ID No 763, 753pp; English.
XX
CC   The invention relates to novel isolated nucleic acid molecules (I)
CC   encoding human secreted proteins (II). (I) and (II) are used to prevent,
CC   treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC   goats, horses, cats, dogs, chickens or sheep. (I) and (II) may be used in
CC   the prevention, treatment and diagnosis of diseases associated with
CC   inappropriate expression of secreted proteins. (I) and complementary
CC   sequences may also be used as DNA probes in diagnostic assays (e.g.
CC   polymerase chain reactions (PCR)) to detect and quantitate the presence
CC   of similar nucleic acid sequences in samples, and so which patients may
CC   be in need of restorative therapy. (II) may also be used as antigens in
CC   the production of antibodies and in assays to identify modulators
CC   (agonists and antagonists) of the expression and activity of the secreted
CC   proteins. The anti-(II) antibodies and antagonists may also be used to
CC   down regulate expression and activity of (II). The anti-(II) antibodies
CC   may also be used as diagnostic agents for detecting the presence of (II)
CC   in samples (e.g. by enzyme linked immunosorbant assay (ELISA)). The
CC   disorders include for example: immune/autoimmune diseases (e.g. HIV
CC   (human immunodeficiency virus) infections, anaemia, rheumatoid arthritis
CC   and multiple sclerosis), cancers and hyperproliferative disorders (e.g.
CC   melanomas, neoplasms of the breast or liver, Sezary syndrome and
CC   Gaucher's disease), neurological diseases (e.g. Alzheimer's disease,
CC   Parkinson's disease and Charcot-Marie-Tooth disease), cardio-/
CC   cerebrovascular disorders (e.g. cardiac arrest, tachycardia,
CC   angina and thrombosis), infections caused by bacteria, viruses and
CC   fungi and ocular disorders (e.g. corneal infections). (I) and (II),
CC   agonists, antagonists and antibodies can also be used to promote wound
```

```
DE   Bovine, maintain organs before transplantation, and support cell culture
DE   of primary tissues. AAS33043-AAS33486 represent human secreted protein
CC   coding sequences, PCR primers, and related sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 9703 BP; 1950 A; 2842 C; 3079 G; 1832 T; 0 other;

  Query Match             1.6%;  Score 97.6;  DB 22;  Length 9703;
  Best Local Similarity   77.6%;  Pred. No. 1.1e-11;
  Matches  119;  Conservative    0;  Mismatches   34;  Indels    0;  Gaps    0;

Qy    5809 CAGCTCTCAGGAACTCTGCTGCTCTGTCATGCTAAAAGACCTGAAGCAGTTCCACCTGCT 5868
           :|| : |||   || | ||||    |     || ||   |||| ||| | ||||||||||
Db    5147 CTGCCCCCAGAGCCTGTACTGCCGCATTGCCCTGAAGAGCCTGCAGTGGCTCCACCTGCT 5206

Qy    5869 AACCCCAGGAGGACGGGCCCCTTGGCCTAGAACTCAACTATGGCTCTGTTGACAA 5928
           |:| |||| : ||||||||||||| || ||||||||||||| | ||||||
Db    5207 AACCCTTCTGGAGGAGAAGGGGCCCCCTGGCCTGGAAGTCAACTATGGCTCAGCTGACAA 5266

Qy    5929 TTTCAGACCATCTGGTTGGAGTTGCCACAGG 5960
           |.|||| |'|| |.| ||||.| ||
Db    5267 TTTTAGACCATCTGGTTTGAGCTGCCACAGG 5298


Search completed: January  9, 2003, 07:12:35
Job time : 147.91 secs
```